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Prostate cancer (PCa) is the most prevalent cancer in men worldwide. It is 
dependent on testosterone (T) and dihydrotestosterone (DHT) but estrogens 
seemed to play a role too. Androgen deprivation therapy (ADT) is the main 
treatment for advanced PCa but relapses into castration resistant prostate cancer 
(CRPC) are almost certain. PCa tumour consists of various cancer cells of 
different properties and they could survive under different mechanisms after 
ADT. Here, attempts were made to identify the types of mechanism for survival 
for the individual PCa cell line using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) and compared against results from stable human cell-
based AR- or ER-driven reporter gene assays. Thus far, the CRPC cells such as 
C4-2 and C4-2B were deduced to continue their proliferation mainly through 
overexpressed ARs while CWR22Rv1 sustain its growth mainly through 
intracrine production of potent androgens. In addition, promiscuity of the ARs in 
these PCa cells via using non-androgenic ligands such as estrogens for activation 
also seemed to play a role in maintaining proliferation of these cells. 
AKR1C3 is the critical enzyme to synthesise T and DHT in prostate. Through its 
inhibition, intracrine synthesis of these androgens was expected to be greatly 
hindered to lead to treatment of CRPC condition. Thus far, among the PCa cells 
studied, only CWR22Rv1 was verified to express high levels of AKR1C3 through 
western blot analysis. This further affirms the earlier deduction that CWR22Rv1 
can maintain through intracrine synthesis of androgens.   
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An androgen degradation enhancer, Dimethoxycurcumin is explored here for its 
potential as a selective AKR1C3 enzyme inhibitor. IC50 of dimethoxycurcumin on 
AKR1C3 and AKR1C2 were found to be 22.3 µM and 48.6 µM respectively via 
LC-MS/MS measurements on T and 5α-androstane-3α,17β-diol (3α-Diol). In 
addition, the IC50 of dimethoxycurcumin on AKR1C3 was approximately 10-fold 
smaller than the IC50 of AKR1C3 of indomethacin (a well-known selective 
inhibitor of AKR1C3). This suggested that dimethoxycurcumin is a more potent 
AKR1C3 inhibitor than indomethacin. Upon applying the saturating doses of 
dimethoxycurcumin, significant reductions in intracellular T and negligible DHT 
were observed. In turn, 5α-androstane-3β,17β-diol (3β-Diol), the metabolite of 
DHT was preferentially formed. It was reported to be a selective agonist towards 
ERβ receptors and is associated with anti-proliferation on PCa, a desired outcome 
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MRM Multiple Reaction Monitoring  
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SPE Solid-phase extraction  
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1.1 Common Occurrence of Prostate Cancer (PCa) in Men 
Prostate cancer (PCa) is the most widely diagnosed cancer in men worldwide 
(Antonarakis et al., 2010). According to World Health Organisation (WHO), the 
highest incidence rates occur in Australia and New Zealand, followed by Western 
and Northern Europe and North America and lowest in Asia. Approximately 1.1 
million cases of PCa were diagnosed in 2012, which accounted for 15 % of new 
cancer cases in men. The use of prostate specific antigen (PSA) screening for men 
could be one of the drivers in the sudden spike of the number of PCa cases 
diagnosed (Ferlay et al., 2014). 
Based on the Singapore Cancer Registry, PCa is ranked as the third most 
commonly diagnosed cancers in men but ranked sixth in cancer-causing deaths in 
Singapore between 2008 to 2012. In addition, the age-standardised incidence rate 
for PCa has increased by five-fold from 5.2 per 100,000 in 1973-1977 to 28.3 per 
100,000 in 2008-2012. (Lee et al., 2013)  
PCa is rarely found in men younger than 40 (“Prostate cancer”, 2012; “American 
Cancer Society Cancer Facts & Figures”, 2012.). In fact, as high as 70 % of the 
patients are aged 65 and above (Thompson et al., 2007; Shafi et al., 2013). In 
addition, it is also the most common cause of cancer deaths in men aged over 75 




1.2 Prostate and its Importance  
Prostate is a gland that is found below the bladder and in front of the rectum 
(Figure 1).  
 
Figure 1. Structure of the Male Reproductive System (Adapted from 
“Prostate cancer”, 2012) 
 
Prostate develops before birth and its growth is dependent on male hormones 
called androgens. It grows rapidly during puberty as there is a surge of androgens 
during this period. It is about the size of a walnut and remains approximately the 
same during adulthood but becomes slightly larger when older (“Prostate cancer”, 
2012). Prostate helps to generate part of the fluid that protects and nourishes 
sperm cells in semen and makes the semen less viscous. Behind the prostate are 
seminal vesicles that generate most of the fluid for semen. The urethra is the tube 
located through the center of the prostate where urine and semen is carried out of 
the body through the penis (Figure 1) (“Prostate cancer”, 2012). Thus, if tumour 











the urethra and restrict the flow of urine and semen from the penis (Figure 2, 
bottom) (Miller, 2013). 
 
                  
Figure 2. Top diagram showing the Normal Prostate. Bottom diagram 
showing the Enlarged Prostate with Cancerous Tumour that Presses onto the 
Urethra (Adapted from Miller, 2013) 
 
1.3 Signs & Symptoms and Detection of Advanced Prostate Cancers  
As men get old, prostate glands will normally be enlarged but may not necessarily 
be malignant. For benign growth, it is called Benign Prostatic Hyperplasia or 
BPH.  
At the early stage of PCa, there are hardly any signs and symptoms since it is 







enough to compress the urethra. At this point, if the tumour is malignant, it could 
probably be at its advanced stage.  
Advanced stage PCa can cause anemia, loss of bladder or bowel control, 
hematuria or blood in the urine or semen and impotence or painful ejaculations 
(Thompson et al., 2007). Worse of all, it could have metastasized, to the bones 
and can cause pain in the hips, pelvis, ribs and spine, which can lead to weakness 
or numbness to legs (Thompson et al., 2007). 
Since both benign and malignant prostate tumours share similar initial signs and 
symptoms, in order to obtain a more accurate diagnosis, there are two common 
types of screening tests (Thompson et al, 2007 & Schröder et al., 2009) that can 
be conducted before proceeding with a prostate biopsy to further affirm the 
condition.  
One of the screening tests is the Prostate Specific Antigen (PSA) blood test. PSA 
is produced by the prostate cells, and is found mostly in semen but trace amounts 
can also be found in the blood (Huang et al., 2014). Normal PSA concentration in 
blood is usually found to be below 4 ng/mL (Aslan et al., 2011; “Prostate cancer”, 
2012; Huang et al., 2014). Elevated PSA levels exceeding 4 ng/mL is associated 
with increased risk of having prostate cancer (Aslan et al., 2011; “Prostate 
cancer”, 2012; Huang et al., 2014). However, since an increase in PSA levels can 
also arise from other prostate problems, further confirmatory tests are needed to 
confirm the prognosis. 
Another type of screening test is the Digital Rectal Exam (DRE). Doctor will 
check by physically inserting a gloved, lubricated finger into the rectum to feel for 
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bumps or hard growths on the prostate. As the prostate is located just in front of 
the rectum, and cancer of the prostate usually originates at the back part of the 
gland, it can be felt during the rectal examination (Aslan et al., 2011; “Prostate 
cancer”, 2012). However, similar to PSA screening test, this screening test also 
requires further detailed assessments in order to confirm the diagnosis. 
If there is suspicion of PCa after the described screening tests, prostate biopsy is 
performed where samples of the prostate tissue are removed and examined under 
the microscope (Shariat & Roehrborn, 2008; “Prostate cancer”, 2012). A core 
needle biopsy is usually used coupled with the transrectal ultrasound (TRUS), 
where images of the prostate gland can be seen to facilitate the removal of cores 
of prostate tissues (Shariat & Roehrborn, 2008; “Prostate cancer”, 2012). 
Approximately 8 to 18 samples will be taken for examination by a pathologist. If 
cancer cells were found, then a grade would be assigned to the tumour. Gleason 
grade of 1 to 5 is first assigned to the cancerous tissue (Figure 3) (Humphrey, 
2004). For cancerous tissue which looked mostly like normal tissue, grade 1 is 
assigned. However, if the cancer cells and growth patterns are very abnormal, it 
will be assigned as grade 5. And those in between will be assigned as grades 2 to 
4 (Figure 3). Since different areas of the cancerous tissues may have varying 
degrees of abnormality, two areas of each tissue sample will be graded and the 
sum of these two areas will make up the Gleason score for the tumour. Thus, 
Gleason score is ranged from 2 to 10 and gives indications to the abnormality of 
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Figure 3. Assignment of Gleason Grades of 1-5 on Different Types of Cancerous 
Prostate Tissues (Adapted from Humphrey, 2004; “WebMD, Prostate Cancer 
Slideshows”, 2014) 
 
Table 1. Gleason Score and its Indications to Prostate Cancer 
Gleason Score Classification of  
Tumour 
Indications  
Less than 6 Well-differentiated or 
Low grade tumour 
Least chance of the cancer 
spreading and thus higher chances 
of survival 
7 Moderately differentiated 
or Intermediate grade 
tumour 
Moderate chance of the cancer 
spreading 
8 to 10 Poorly differentiated or 
High grade tumour 
Highest chance of the cancer 
spreading or becoming metastatic 
and thus poorer chances of survival 
 
Finally, staging is performed to describe the severity of the cancer. It often 
encapsulates information associated with size and growth of the primary tumor 
and spread (Compton et al., 2012) (Appendix I). Staging the disease helps the 
physician to plan a suitable treatment regime and predict possible outcomes for 




1.4 Treatment Options for Prostate Cancer  
PCa is a highly complex disease and different patients respond differently to each 
treatment. There are several treatment options available and they are often 
delivered alone or in combination depending on the patient’s condition (See 
Appendix II). The treatment options include active surveillance, surgery, 
radiation therapy, cryosurgery (cryotherapy), hormone therapy (or Androgen 
Deprivation Therapy), chemotherapy and immunotherapy.  
After the groundbreaking discovery by Hodges and Huggins in 1941 that PCa has 
high androgen dependency for its survival (Mostaghel & Nelson, 2008; 
Mostaghel et al., 2009; Shafi et al., 2013), androgen deprivation therapy (ADT) 
has become the most common treatment option for this disease at its advanced 
stage. 
 
1.4.1 Hormone or Androgen Deprivation Therapy (ADT) for Prostate 
Cancer  
Hormone therapy or more commonly known as Androgen Deprivation Therapy 
(ADT) acts to reduce the levels of male hormones, specifically T and DHT. These 
androgens come mainly from the testicles and aid in the growth of the PCa cells. 
Thus, by reducing the androgen levels helps to impede the growth of the cancer 
tumour, which will gradually enable it to shrink (Chuu et al, 2011). This therapy 
is used when surgery and radiation is not possible or when cancer recurs after 
these treatments and has advanced and spread beyond the prostate. Currently there 
are several types of hormone therapy in practice (Sharifi et al., 2005). 
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1.4.1.1 Orchiectomy or Surgical Castration 
Orchiectomy involves the surgical removal of the testicles, where most of the 
potent androgens, T and DHT are produced. This procedure effectively depletes 
these androgens and curbs the growth of PCa. However, as this involves a 
permanent change where their testicles have to be removed, many patients are not 
receptive to it (Sharifi et al., 2005; Rove & Crawford, 2013). Thus, this treatment 
is not a popular option among the patients. 
 
1.4.1.2 Luteinizing Hormone-releasing Hormone (LHRH) Agonists  
LHRH agonists help to reduce the amount of T produced by the testicles, typically 
to levels similar to that achieved by orchiectomy. This method is preferred over 
orchiectomy even though it is more costly and requires more frequent visits to 
doctors. With this, testicles can remain but will gradually shrink with time. Upon 
initial treatment, patients may experience “flare”, where T levels may increase 
and only decrease to low levels after some time (Sountoulides & Rountos, 2013). 
In order to reduce the likelihood of getting flare, especially for patients who has 
metastatic cancer, anti-androgens are given prior to treatment (Sharifi et al., 2005; 








1.4.1.3 Luteinizing Hormone-releasing Hormone (LHRH) Antagonists  
The LHRH antagonists are more effective in reducing the testosterone 
concentrations as compared to the agonists and do not cause tumour flare 
(Crawford & Hou, 2009) 
 
The general side effects that arise from ADT in all of the above mentioned 
treatments are similar. The commonly observed side effects include impotence, 
breast tenderness and growth of breast tissue, osteoporosis, anemia, reduction in 
mental sharpness, loss of muscle mass and depression (Sharifi et al., 2005; Rove 
& Crawford, 2013).  
 
1.4.1.4 Anti-androgens  
Despite orchiectomy or treatment with LHRH agonists, the adrenal glands can 
still supply some androgens to the PCa cells (Chen et al., 2009). This is where the 
use of anti-androgens becomes important as they are able to block the body’s 
ability to use androgens. Thus, they are often used concurrently with orchiectomy 
or LHRH agonists. This form of treatment is known as combined androgen 
blockade (CAB) (Sharifi et al., 2005; Chen et al., 2009; Rove & Crawford, 2013).  
Anti-androgens share similar side effects to orchiectomy and LHRH 
agonists/antagonists. The only difference is that the use of anti-androgens has 
lesser impact on sexual function and patients taking these drugs can maintain their 




1.4.1.5 Recently Developed Hormone Therapy Drugs 
More hormone therapy drugs have been developed and have been proven to be 
more effective than current ones. Abiraterone (ZYTIGA®), is an inhibitor to the 
the enzyme, CYP17A1, which is found in the steroidogenesis pathway, and leads 
to the decrease in synthesis of androgens in these cancerous cells (Hamid et al., 
2012; Adeniji et al., 2013). It can be used for patients with recurrent PCa even 
after androgen ablation. This drug has been proven effective in shrinking tumours, 
lowering PSA levels and increasing the overall survival period. However, there 
are side effects associated with this drug and has to be taken together with 
prednisone, a cortisone-like drug to reduce the side effects such as severe 
hypertension (Hamid et al., 2012; Adeniji et al., 2013).  
Other new drugs including Enzalutamide (XTANDI®) (Beer et al, 2014), will be 




1.5 Occurrence of Castration Resistant Prostate Cancer (CRPC) 
With the introduction of screening tests like PSA level screening, more men are 
diagnosed at the earlier stages of PCa (Stanbrough et al., 2006). However, there 
are still relatively large numbers of PCa patients who are diagnosed only at later 
stages due to a lack of signs and symptoms.  
Since the discovery by Hodges and Huggins that PCa growth is dependent on 
potent androgens such as T and DHT (Mostaghel & Nelson, 2008; Mostaghel et 
al., 2009; Koochekpour, 2010; Shafi et al, 2013), ADT has become the most 
frequently used therapy to treat advanced PCa. It is proven to be very effective for 
the first 1 to 3 years but subsequently, relapses are almost always certain for most 
patients despite their very low T levels in serum and their seemingly normal PSA 
levels (Mostaghel & Nelson, 2008; Mostaghel  et al., 2009; Knudsen & Penning, 
2010; Koochekpour, 2010; Acar et al., 2013; Karantanos et al., 2013). Following 
ADT, these cancer cells adapt and evolve to survive under the androgen-depleted 
environment. As a consequence, the cancer progresses to become hormone 
refractory or “androgen independent prostate cancer” (AIPC) as previously 
known (Feldman & Feldman, 2001). Currently, this condition is more accurately 
referred to as “castration resistant prostate cancer” (CRPC) to reflect a better 
understanding of the cancer progression (Montgomery et al., 2008; Attard et al., 




1.5.1 Androgens - Growth Factor for Prostate Cancer (PCa)  
As mentioned earlier, androgens are the main growth factors for normal prostate 
cells and inevitably, for PCa cells as well. However, PCa’s growth requires that 
the potent androgen levels meet the minimum threshold level (Feldman & 
Feldman, 2001). Testosterone (T) is the main potent androgen circulating in the 
body and is largely produced by the testes but small amounts are also produced by 
the adrenal glands. (Stanbrough et al., 2006; Mostaghel et al., 2009; Cai & Balk, 
2011; Cai et al., 2011; Shafi et al., 2013). In the blood, it is found in both the 
bound and free forms, where T is mainly bound to albumin and the sex hormone 
binding globulin (SHBG) (Hoimes & Kelly, 2010). Only a small fraction is 
unbounded. When the free T enters the prostate cells, most of it is converted to 
the more potent metabolite, dihydrotestosterone (DHT) by the 5-alpha reductase 
enzyme. DHT has about two to ten times higher affinity to the androgen receptors 
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Figure 5. Biological Events Triggered after Androgens Bind to AR (Adapted 
from Feldman & Feldman, 2001) 
 
Figure 5 summarises the cascades of biological events triggered after androgens 
are bound to the AR. The AR when at its basal state is bound to heat shock 
proteins and other proteins where DNA binding cannot occur (Hoimes & Kelly, 
2010). Androgens such as the newly converted DHT preferentially bind to AR, 
causing the initially bounded heat shock proteins to be dissociated (Hoimes & 
Kelly, 2010). Concurrently, phosphorylation of the receptors also occurs. As the 
androgens and AR bind to form the complex, this caused a conformation change 
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in AR, which makes it easier for dimerization of the AR-androgen complexes to 
be formed (Hoimes & Kelly, 2010). Homodimer AR complexes that are formed 
can subsequently bind to the androgen response elements (AREs) in the promoter 
regions of target genes (Hoimes & Kelly, 2010). These activated DNA-bound AR 
homodimer complexes will be able to recruit co-regulatory proteins, co-activators 
or co-repressors to the AR complexes. These co-activators can either promote or 
prevent the interactions of these AR complexes with the general transcription 
apparatus (GTA), which is a group of proteins with the potential to facilitate 
transcription of genes so as to stimulate or inhibit target gene transcription. The 
activation or repression of target genes can result in biological responses such as 
growth of prostate cells or production of prostate specific antigens, PSA.  
 
1.5.2 Possible Mechanisms behind Occurrence of Castration Resistant 
Prostate Cancer (CRPC) 
PCa can recur despite ADT when the potent androgens are reduced to 
physiologically minimal levels in serum. There are five broadly categorized 







1.5.2.1 Hypersensitive AR 
The first mechanism via which the PCa cells progresses despite ADT is by 
increasing its sensitivity to androgens. In doing so, it can continue to proliferate 
and survive despite extremely low levels of androgens.  
There are three routes through which PCa cells can increase their sensitivities to 
low levels of androgens, and they act by modulating ARs. First mechanism is via 
AR amplification, which leads to an increased likelihood of ligand binding with 
the ARs, even when there is reduction of androgens’ concentrations (Montgomery 
et al., 2008). In fact, it has been reported that approximately 20-30 % of cancer 
tumours have been found to have increased in AR gene expression (Edwards et al, 
2003; Merson et al., 2014).  
The second mechanism employed by these cancer cells is through enhancing the 
sensitivity of ARs, which will result in greater stability and enhanced nuclear 
localization of ARs in these hormone refractory cells (Lonergan & Tindall, 2011). 
Indeed, in these hormone refractory PCa cells, the AR was activated at DHT 
concentration which was fours orders of magnitude lower than needed in the 
androgen dependent cells, LNCap (Mao et al., 2009). Thus, despite the low 
circulating androgen levels in men after ADT, cancer cell proliferation is still 
viable. 
Third mechanism is through increased production of the more potent androgens 
within the PCa cells (Locke et al., 2008; Montgomery et al., 2008; Knudsen & 
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Penning, 2010; Cai & Balk, 2011; Cai et al., 2011; Shafi et al., 2013)  to 
compensate for the decrease in circulating T levels. In this scenario, an increase in 
5α-reductase enzyme activity is observed in the PCa cells, resulting in an increase 
in the rate of conversion of T to the more potent DHT (Kosaka et al., 2014). In 
fact, studies have shown that even when serum T levels were decreased by 95 %, 
the DHT levels in the prostate tissue is only reduced by 60 % (Li et al, 2011), 
implying that DHT was being replenished in the prostate tumour. Alternatively, 
there could also be an increase conversion of the precursors, the adrenal steroids 
into the potent androgens (Kosaka et al., 2014), so as to sustain the activation of 
AR for cancer to survive even after ADT.  
 
Figure 6. Five Possible Routes to Castration Resistant Prostate Cancer (Adapted 
from Feldman & Feldman, 2001) 
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1.5.2.2 Promiscuous AR 
PCa cells could have mutations where the AR gene has reduced specificity for the 
types of ligand that can bind to the AR (Mao et al., 2009; Hoimes & Kelly, 2010; 
Knudsen & Penning, 2010; Amaral et al, 2012). This opens up an avenue for 
permitting other non-androgenic steroids such as progestins, estrogens, adrenal 
androgens and metabolites of DHT (Mao et al., 2009; Karantanos et al., 2015) to 
activate the ARs to maintain the androgen signal. Consequently, it enables these 
malignant cells to continue to proliferate. 
The range of ligands that can bind AR could be further extended to drugs, which 
were initially used for ADT treatment including antagonists to ARs (Mao et al., 
2009; Amaral et al, 2012). A typical example is flutamide, which is a well-known 
and effective ADT drug for treatment of PCa (Barqawi et al., 2003). It serves as 
an antagonist to the wild-type (non-mutated) ARs, where it binds to the receptors 
to block off or lower the biological responses from the agonists. However, there 
have been reports of patients suffering from the “flutamide withdrawal syndrome” 
(Sartor et al., 2008; Knudsen & Penning, 2010), where treatment with flutamide 
not only did not improve their existing conditions and instead, worsened and 
caused a rapid spike in the PSA levels (Sartor et al., 2008). Once they are taken 
off this drug, the patients’ conditions improved. This is the result of the drug 
acting as a non-specific agonist or substitute ligand to the mutated ARs, instead of 







































5α-Androstane-3α,17β-diol (3α-Diol) 5α-Androstane-3β,17β-diol (3β-Diol) 
Figure 7. Structurally Similar Steroids to Testosterone and Dihydrotestosterone 
that can potentially act as alternative ligands to activate ARs 
 
1.5.2.3 Outlaw AR 
Theoretically, outlaw AR would refer to mutated AR that can be activated even in 
the absence of androgens. However, outlaw ARs like these have yet to be 




First is through growth factor-activated outlaw route, where certain growth factors 
like insulin-like-growth-factor-1 (IGF-1), keratinocyte growth factor (KGF) and 
epidermal growth factor (EGF), can activate the ARs by creating outlaw receptors 
and therefore induce AR genes in the absence of androgens (Dutt & Gao, 2009; 
Mao et al., 2009; Knudsen & Penning, 2010). Among these growth factors, IGF-1 
is the most potent and able to induce a 5-fold increase in PSA levels in LNCap 
(Tan et al., 2015). It was discovered that these growth factors are overexpressed in 
some PCa, which supported that these growth factors could have activated the 
outlaw mechanism. Furthermore, the well-known drug, casodex, which is an AR 
antagonist, can fully block the activation of the AR by IGF-1, KGF and EGF (Ha 
et al., 2013). This suggested that although presence of androgens is unnecessary 
here, the AR ligand binding domain remains necessary for the activation of this 
outlaw path. 
Another is through receptor tyrosine kinase activated outlaw path (Mao et al., 
2009). AR in PCa can also become an outlaw receptor through binding to HER-
2/neu (or ERBB2), which is a member of the EGF receptor family. It is found to 
be overexpressed in hormone refractory PCa cells generated from xenografts 
implanted on castrated mice (Scher et al., 2004). HER-2/neu activation can lead to 
phosphorylation and activation of the AR despite the absence of androgens 
(Berger et al., 2006). However, unlike IGF-1, the outlaw AR via HER-2/neu 
overexpression could not be blocked by casodex and suggests that this path works 




1.5.2.4 Bypass AR 
The three mechanisms mentioned earlier all required the presence of ARs for the 
development of hormone refractory PCa. However, there are also mechanisms 
that bypass the activation of ARs and work to maintain cell proliferation and 
inhibit apoptotic cell death (Pienta & Bradley, 2006; Knudsen & Penning, 2010; 
Amaral et al., 2012). For instance, BCL2 is a bypass candidate gene that can 
block apoptosis. So, by up-regulation of BCL-2 in these hormone refractory PCa 
cells, it prevents them from apoptosis when there is a shortage of potent 
androgens (Pienta & Bradley, 2006).  
Another alternative pathway the PCa cells adopt is via the activation of ERs with 
estrogens (Harkonen & Makela, 2004; Singh et al., 2008). Estrogens have been 
widely recognized by many studies as a crucial factor, apart from androgens to 
initiate prostate tumorigenesis (Harkonen & Makela, 2004; Singh et al., 2008). In 
fact, PCa has been frequently associated with the activation of ERα with the 
estrogens (Risbridger et al., 2007; Ellem & Risbridger, 2009; Yeh et al., 2014) as 
this could lead to inflammation and gradually to PCa development. Therefore, it is 
not surprising that the occurrence of CRPC after ablation can possibly go through 






1.5.2.5 Lurker Cells 
Another postulated reason for relapse of PCa after ADT is the presence of cells 
that are independent of androgens for growth even before therapy. These cells 
begin to dominate after ADT, enabling the tumour to continue growth without 
androgens (Pienta & Bradley, 2006; Amaral et al., 2012; Li et al., 2014). 
Epithelial stem cells of the prostate are believed to be the origins of hormone 
refractory PCa as they are androgen independent and their proliferation and death 
are unaffected by ADT (Li et al., 2014). They were believed to first transform into 
the androgen dependent cancer cells when there were abundant androgens. After 
ADT, the androgen dependent cells are eliminated, leaving behind only the 
androgen independent malignant epithelial stem cells (Li et al., 2014). These cells 











Table 2. Mechanisms Behind Development of Castration Resistant Prostate 
Cancer (Pienta & Bradley, 2006 ) 











 Sensitive AR 
 Amplified AR 
 Increased DHT 








 Dependent on 


















 Mutant PTEN 
 Amplified Her-
2/neu 
 Activated P13K 
 Mutant co-
regulator  
 Activated  
MAPK  










 Activation of 
other oncogenes 
 Inactivation of 
tumour 
suppressor genes 








Based on the possible mechanisms mentioned, PCa after ADT may not be entirely 
independent of androgens. Thus, a more apt term to reflect the relapse of PCa 
after ADT is “Castration Resistant Prostate Cancer”, CRPC (Montgomery et al., 




1.6 AKR1C3 Enzyme Involvement in CRPC 
A commonly prescribed explanation for the development of CRPC is self-
synthesis of potent androgens within the PCa cells to sustain its needs after ADT 
(Adeniji et al., 2013). As such, targeting the steroidogenesis pathway in these 
cells would act to further reduce the availability of androgens to the ARs, which 
can therefore abrogate the AR signaling axis after ADT.  
Currently, there are four postulated pathways in the prostate via which androgen 
synthesis occurs (Adeniji et al, 2013; Ishizaki et al., 2013). From the 
steroidogenesis map (Figure 8), three out of four of these postulated pathways to 
synthesize DHT coincidentally involves 17β-hydroxysteroid dehydrogenase type 
3 (17β-HSD3) and/or aldo-keto reductase 1C3, (AKR1C3) (also known as 17β-
hydroxysteroid dehydrogenase type 5, 17β-HSD5) (Dufort et al., 1999). However, 
AKR1C3 is more readily available in the prostate than 17β-HSD3 (Day et al., 
2008) and thus, is the main enzyme in these three pathways for the conversion to 
DHT in prostate. 
The better known pathway involves the conversion from DHEA to A4 to T then 
to DHT, where AKR1C3 catalyzes the conversion of A4 to T (Stanbrough et al., 
2006; Dozmorov et al., 2010; Byrns et al., 2011; Cai et al., 2011; Hamid et al., 
2012; Adeniji et al., 2013; Liedtke et al., 2013). Another possible pathway 
bypasses T altogether and involves the conversion from DHEA to A4 to 5α-
Adione then to DHT (Adeniji et al., 2013), in which AKR1C3 catalyzes the 
conversion of 5α-Adione to DHT. And lastly, the proposed “backdoor” pathway, 
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which involves the conversion from progesterone to 5α-dihydroprogesterone to 
allopregnanolone to androsterone to 3α-Diol and finally back to DHT (Mohler et 
al., 2011; Adeniji et al., 2013), where AKR1C3 converts androsterone into 3α-
Diol. This shows the crucial role that AKR1C3 enzyme plays in the biosynthesis 
of the potent androgens in the prostate.  
In fact, based on some of the reported in vitro studies, it was found that AKR1C3 
is up-regulated in these CRPC cells (Pfeiffer et al., 2011; Tian et al., 2014). When 
there is excess androgen supply in culture media, AKR1C3 expression was 
suppressed in different types of PCa cell lines. However, upon culture in 
androgen-depleted conditions such as with charcoal dextran-stripped fetal bovine 
serum, a significant increase in the AKR1C3 expression was observed (Hofland et 
al, 2010; Pfeiffer et al., 2011). In addition, there was an increased in the AKR1C3 
gene expression by 5.3-fold, the highest among other steroidogenic enzymes in 
the CRPC tissues samples compared to the primary PCa tissues samples 
(Stanbrough et al., 2006). All these results indicated that upregulation of AKR1C3 
enzymes is a mechanism for these PCa cells to adapt and survive during 




Figure 8. Steroidogenesis Pathway into T & DHT and Drugs that Inhibit Specific Enzymes to Prevent 
Downstream Conversion to T and DHT (Adapted from Mostaghel et al., 2009) 
  
1.7 Dimethoxycurcumin  
Given the critical role the AR plays in the development and progression of PCa, 
identifying novel compounds that can specifically target AR in PCa is of 
paramount importance to combatting the disease. Besides this, there is growing 
trend in PCa therapeutics to identify novel drug candidates that can demonstrate a 
dual mechanism of action (Adeniji et al., 2013). This ideal drug would preferably 
be able to degrade AR and concurrently selectively inhibit AKR1C3 (Adeniji et 
al., 2013). If this is possible, by degrading the ARs, it can greatly minimize the 
possibility of activation of the ARs and therefore, prevent the further progression 
of PCa. Additionally, if combined with the selective inhibition of AKR1C3, it can 
also impede the intracrine production of the potent androgens in the prostate 
tumour, which could prevent patients from developing CRPC or even treat 
patients with existing CRPC conditions. 
Curcumin is the major active constituent of turmeric (Curcuma Longa Linn) 
(Anand et al., 2007; Anand et al., 2008; Vareed et al., 2008; Soh et al., 2014). 
This compound has generated tremendous interest as it was found to be able to 
exhibit potential as an anti-cancer drug through perturbation of several molecular 
targets (Deeb et al., 2004; Ravindran et al., 2009; Saradhi et al., 2010; Killian et 
al., 2012). Furthermore, it does not exhibit any harmful effects even when given 
at high doses during clinical trials (Vareed et al., 2008; Singh & Jain, 2010; Li et 
al., 2011). Unfortunately, there are two major drawbacks to this compound that 
prevented its use for clinical applications. These included its poor oral 
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bioavailability and its rapid in vivo metabolic rate (Anand et al., 2007; Vareed et 
al., 2008; Saradhi et al., 2010; Singh & Jain, 2010; Wei et al., 2012).  
In order to overcome these limitations, extensive research was conducted to find 
suitable curcumin derivatives and analogues that offer therapeutic benefits with 
minimal side effects. In fact, some of these compounds were reportedly able to 
inhibit proliferation and invasion of tumor cells (Adams et al., 2004; 
Tamvakopoulos et al., 2007). Furthermore, there were also reports of curcumin 
derivatives being able to effectively inhibit some members of the AKR family of 
enzymes (Matsunaga et al., 2012). With these factors, it indicated that curcumin 
derivatives or analogues could be a class of drug targets worth considering as PCa 
drugs. Among the numerous curcumin derivatives, dimethoxycurcumin (ASC-















Figure 9. Structural Similarity of Dimethoxycurcumin to Curcumin. 
 
Dimethoxycurcumin has been reported to be able to act as an effective AR 
degradation enhancer (Lai et al., 2013; Yamashita et al., 2012), which fits into the 
first criteria of the dual-mechanism PCa drug. For this, it has been used for 
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treatment of AR-related diseases such as spinal and bulbar muscular atrophy 
(SBMA) (Yang et al., 2007) and acne, where its effectiveness for acne treatment 
has been tested in clinical phase 2B (Wang et al., 2011). It promotes AR 
degradation by interrupting the interactions between ARs and selective co-
regulators (Yamashita et al., 2012). In addition, dimethoxycurcumin-mediated AR 
degradation, leads to a series of other actions which includes interfering AR 
binding to androgens, disrupting AR N-C interactions, AR nuclear translocation, 
and AR recruitment to targeted gene promoter regions (Lai et al., 2013). 
Cumulatively, these can lead to the inhibition of AR transcriptional activity. 
Besides these, dimethoxycurcumin-mediated AR degradation might reduce the 
chances of development into CRPC by altering several signaling pathways. 
Studies have shown that AR splice variants, especially the most dominant variant 
AR-V7/AR3, which lacks the androgen-binding domain might also contribute to 
CRPC (Guo & Qiu, 2011; Ryan & Tindall, 2011; Yamashita et al., 2012; Jernberg 
et al., 2013). It has been suggested that the constitutively active AR3 relies on 
full-length AR to exert the AR transcriptional activity and cell growth in LNCap-
AR cells (Yamashita et al., 2012). However, another study also demonstrated that 
AR3 itself might contribute to promoting cell growth (Yamashita et al., 2012). 
Therefore, it would be better to target both full-length AR and AR3 to achieve the 
best therapeutic efficacy in CRPC. So far, it has been suggested that 




Moreover unlike some of the currently used drugs like enzalutamide or 
bicalutamide, dimethoxycurcumin does not promote metastasis (Lin et al., 2013; 
Lin et al., 2013) and display minimal side effects (Lai et al., 2013).  
To date however, the impact of dimethoxycurcumin on the AKR1C3 enzyme has 
not been explored, though curcumin derivatives could serve as good inhibitors to 
AKR family of enzymes (Matsunaga et al., 2012). Thus, given the known 
beneficial anti-cancer properties of dimethoxycurcumin, it was of interest to 
assess if this compound can also act as an inhibitor of AKR1C3, so that it can act 
as an effective CRPC drug and possibly even on other steroidogenesis-dependent 
diseases, including breast cancers (Byrns et al., 2010) and ovarian endometriosis 
(Day et al., 2008) in future.  
 
1.8 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)  
Liquid chromatography tandem mass spectrometry (LC–MS/MS) is gaining wide 
acceptance as a diagnostic tool in the clinical laboratories apart from the basic 
research laboratories (Pitt, 2009). In fact, both chromatography and mass 
spectrometry (MS) were commonly used as separation and detection tools long 







1.8.1 Brief History behind Development of Chromatographic-Mass 
Spectrometric Techniques 
Gas chromatography (GC) coupled mass spectrometry (GC–MS) was the first to 
be introduced about 50 years ago (Kang, 2012). It is suitable for volatile 
compounds as they can be readily converted to gaseous state to be separated and 
detected (Shushan, 2010; Ouweland & Kema, 2012). As for polar analytes which 
are non-volatile by nature, they have to be chemically derivatised prior to GC-MS 
detection so that they can be converted to gaseous state more readily (Shushan, 
2010; Ouweland & Kema, 2012). Before being able to leverage on this technique, 
it requires specialised training and knowledge of mass spectrometry (MS) as well 
as performing tedious but necessary sample preparation. However, since it 
provides high sensitivity and specificity, specialized diagnostic laboratories would 
prefer to use this technique (Ouweland & Kema, 2012).  
With the introduction of a series of soft ionization techniques collectively known 
as atmospheric pressure ionisation (API), it enables the marriage of liquid 
chromatography to mass spectrometry (Gao et al., 2005; Kang, 2012). This brings 
the technique to a whole new level. It enables a more widespread usage with the 
added convenience of samples being able to be introduced directly in solution 
form. As a result of this, thermally labile analytes which used to be unsuitable for 
GC-MS detection can now be detected with this LC-MS technique (Shushan, 
2010). For quantitation purposes, triple quadrupole mass spectrometry in multiple 
reaction monitoring (MRM) mode is suitable for detection of multiple analytes.  
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LC–MS/MS has undergone massive transformation over the past ten years, 
becoming a highly accessible analytical technique (Shushan, 2010; Kang, 2012; 
Ouweland & Kema, 2012). Sensitivity used to be an issue, especially for detection 
of particularly low levels of endogenous steroids in biological samples. However, 
with the advancement in technology, realization of high sensitivity using LC–
MS/MS detection is no longer a big concern. This makes it possible to investigate 
the trace amounts of steroid sex hormones in complicated biological samples. In 
fact, the American Endocrine Society has actually recommended LC-MS/MS as 
the technique for quantitation of endogenous trace levels of hormones over 
traditional immunoassays (Rosner et al., 2007; Shushan, 2010; Methlie et al., 
2013).  
 
1.8.2 Pros and Cons of Liquid Chromatography Tandem Mass Spectrometry 
(LC-MS/MS) and Method of Choice for Detection for Steroids 
As an analytical technique, there are several associated pros and cons to LC–
MS/MS over immunoassays for the measurement of steroids. 
Besides the high sensitivity on the measurement of steroids that can be achieved 
by the advanced LC-MS/MS systems nowadays, it also offers superior specificity 
as compared to immunoassays (Rosner et al., 2007; Ouweland & Kema, 2012). 
This is an essential characteristic as it helps to detect and quantify with greater 
confidence on specific steroids, in this case, the androgens and estrogens of 
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interest in this project. With this, it reduces the likelihood of false positive 
detection on the samples. 
Another major advantage to this technique is it can enable simultaneous detection 
of many different types of steroids within a single run (Shushan, 2010; Ouweland 
& Kema, 2012). This is very crucial as some biological samples are very hard to 
collect or are very little and thus, are extremely precious. Apart from requiring 
lesser sample for analysis, simultaneous detection also helps to save costs, time 
and effort in sample preparation and detection. Most importantly, it enables a 
more reliable comparison and correlation for the inter-related steroids in the 
steroidogenesis pathway within the same samples, which is very essential for this 
study.  
Though there are several advantages to the techniques, there are still associated 
problems using this analytical technique. One such problem is the detection of 
extremely trace levels of steroids such as estrogens in postmenopausal women 
and androgens in females or males with hypogonadism (Ouweland & Kema, 
2012). This could be overcome by simple chemical derivatisation of the steroidal 
structures, so as to enhance the detection signals or through the use of more 
efficient sample preparation.  
Though LC-MS/MS is a much more specific technique than immunoassays, there 
are still challenges with the multi-steroid analysis. In the biological samples, it 
contains many endogenous steroids with highly similar structures. Therefore, they 
are likely to share similar or even the same MRM transitions, where chances of 
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cross-talk could be high. To overcome this problem, good separation prior to MS 
detection is necessary so as to ensure the signal comes from the analyte itself and 
not from interferences. Other pros and cons of the LC-MS/MS technique are 
listed in Table 3. 
Despite the issues faced by this technique, LC–MS/MS is still a far more superior 
analytical and quantitation technique compared to other analytical or biological 
techniques with its higher sensitivity and specificity with reduced sample 
preparation and analysis time. With the more sophisticated and highly sensitive 
LC–MS/MS instruments, coupled with better sample preparation, trace levels of 
analytes can now be accurately measured in body fluids that were unsuitable 
previously. As such, this is the main method of choice for quantitation of 
androgens and estrogens of interest involved in PCa progression for this study.  
 
Table 3. Analysis of LC-MS/MS Pros and Cons in Clinical Diagnostics. 
(Shushan, 2010; Ouweland & Kema, 2012) 
Pros Cons 
 High sensitivity 
 High specificity 
 Affordable and relatively fast 
development for new assays 
compared to immunoassays. 
 Simultaneous measurement of 
multiple analytes in the same 
sample 
 Versatility 
 Matrix independency (serum, 
saliva, urine, etc.) 
 High instrument costs 
 Required well-trained personnel 
for doing method development, 
validation, operation and 
troubleshooting. 
 No well-established quality 
regulations yet. 
 Absence of approved 






1.9 Sensitive Cell-based Bioassay for Hormone Measurements  
Chemical assays such as LC-MS/MS can provide information regarding the 
chemical structures, the physical and chemical properties and the specific 
concentrations of the known and/or suspected compounds present in the samples. 
However, it cannot provide information on their respective biological activities. 
Thus, bioassays play complementary roles by providing information on the 
cumulative androgenic or estrogenic activities of the whole cell lysates. AR and 
ER-mediated hormonal activities of these whole cell lysates can be measured 
using individual cell-based bioassays respectively. There are many types of 
bioassays available and among which reporter genes AR- or ER-transfected 
human cell lines offer better quantitation ability with their better specificity, 
sensitivity, accuracy and precision (Paris, et al. 2002; Wong et al., 2007). A group 
has reported of successfully using stably transfected AR-deficient PC-3 cells with 
a human AR expression vector and the reporter gene MMTV-luciferase (Roy et 
al., 2004). The cell line was characterized by its response to androgens and anti-
androgens as reflected by the luciferase activity. In addition, ER-driven reporter 
gene assays have already been widely used and validated for measuring 
estrogenic activity of serum samples with low levels of estrogens from 
postmenopausal women (Wang, et al. 2005) and pre-pubertal children (Paris et al. 
2002).  
Thus, for the convenience of our future applications, HeLa cells were stably 
transfected with androgen- and estrogen-responsive reporter genes so that they 
can be used for more reliable measurements of the biological responses from both 
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estrogenic and androgenic ligands (Wong et al. 2007). HeLa cell, a human 
cervical cell line was chosen to serve as a neutral party cell line that possesses 
negligible AR and ERβ. This allows for fair comparison among the biological 
responses elicited from the cell lysates of the different cell lines. Apart from this, 
stable transfection was preferred as it would have less variability in the data 
obtained. Furthermore, though transient transfection is simpler but it can only last 
for a very short period (Roy et al., 2004).  
A simple calibration curve can be established using known concentrations of 
DHT or 17β-estradiol (E2) respectively, spiked into media with charcoal dextran 
stripped fetal bovine serum (CD-FBS). The respective luciferase responses 
elicited from the cell lysates samples can then be semi-quantified against the 
calibration curves established concurrently.  
Nevertheless, this method can only be used to measure the activation of androgen 
and estrogen receptors through the classical pathways. Besides these, endogenous 
growth factors present in the media may also activate the receptors which may 










1.10 Hypotheses and Objectives 
1.10.1 Hypotheses 
1) Highly specific and ultrasensitive chemical and biological assays can provide 
reliable tools to investigate the effects and responses of trace levels of sex 
hormone receptor active compounds in prostate cancer-related biological 
samples.   
2) Combination of ultrasensitive LC-MS/MS analysis and relevant bioassays can 
confirm the potential AKR1C3 inhibitory effects of Dimethoxycurcumin and 
can investigate whether specific PCa cells in the tumour can adapt to the low 
androgen environment after ADT via self-synthesis of potent androgens to 
develop into CRPC. 
 
1.10.2 Objectives 
1) To develop specific and ultrasensitive LC-MS/MS methods for determination 
of trace amounts androgens and estrogens so as to establish these intracellular 
androgens and estrogens to provide insights to the respective mechanisms that 
each CRPC cell line in this study survives under androgen-depleted conditions 
(Schematic Plan for Achieving Objective 1).  
2) To investigate the pharmacokinetic (PK) and pharmacodistribution (PD) 
profiles of Dimethoxycurcumin and its inhibitory property on AKR1C3 by 
ultrasensitive LC-MS/MS analysis and a series of relevant bioassays 
(Schematic Plan for Achieving Objective 2). 
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In vitro experiments conducted on seven types of prostate cell 
lines (normal to benign to androgen sensitive and insensitive 
PCa cells) under six types of treatment conditions for both 
intracellular androgens and estrogens measurements  
1. 10 % FBS 
2. 10 % FBS with 1 nM DHT 
3. 10 % FBS with 10 nM E2 
4. 10 % CD-FBS 
5. 10% CD-FBS with 1 nM DHT 
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In vitro experiment for 
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used in this study 
Western Blot Analysis to find out 
which of the PCa cell line used in this 
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Establishment of Reference Levels of Three Main Intracellular Androgens in 
Prostate Cells through LC-MS/MS Analysis and Human Cell-based 
Androgen-driven Reporter Gene Bioassay 
2. Introduction 
Based on the several suggested pathways that CRPC can develop after ADT, ARs 
play a crucial role in this aggravation. AR can be weakly stimulated by high 
levels of various types of steroids such as the weak androgens, androestenedione 
(A4) and dehydroepiandrosterone (DHEA) from the adrenal glands (Cai & Balk, 
2011). However, AR has a much greater affinity for potent androgens like 
testosterone (T) and dihydrotestosterone (DHT). The main source of T of healthy 
men comes from testes and only the minority of 5-10 % comes from the adrenal 
glands (Cai & Balk, 2011). On the other hand, the major source of weak 
androgens like A4 or DHEA comes from the adrenal glands. They are present in 
much higher concentrations than T. These weak adrenal androgens can undergo 
reduction to form T in some peripheral tissues including prostate (Cai & Balk, 
2011). In the prostate cells, DHEAS-S is first converted to DHEA, which is then 
reduced to A4 by 3β-hydroxysteroid dehydrogenase 1 (HSD3B1). A4 in prostate 
can then be converted to T by enzyme aldo-keto reductase family 1, member C3 
(AKR1C3) or 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) (Byrns et 
al., 2011; Adeniji et al., 2012; Byrns et al., 2012; Adeniji et al., 2013; Tian et al., 
2014). However, this avenue of conversion to T is insignificant in males with 
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intact, functional testes but becomes significant during CRPC as it is the 
classically recognized path to make up for the low T and DHT levels. 
In this chapter, the reference levels of A4, T, and DHT in prostate cells are being 
investigated more comprehensively for the first time by using LC-MS/MS 
analysis and human cell-based androgen-driven reporter gene bioassays. In 
addition, plausible intracrine mechanisms to sustain the levels of potent androgens 
are also discussed. 
 
2.1 LC-MS/MS Method Development and Validation for Simultaneous 
Detection and Quantitation of A4, T and DHT 
2.1.1 Materials 
 
Dihydrotestosterone (DHT), Hydroxylamine hydrochloride and 17β-Estradiol 
(E2) of purity 97 % were all obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Androstenedione (A4) and Testosterone (T) were from Toronto Research 
Chemicals (New York, ON, Canada). Internal standard, deuterated-testosterone 
(d3-T) of purity 98% was obtained from CDN isotopes. 
Solvents used for LC-MS/MS measurement were all of HPLC grade, unless 
otherwise stated. Formic acid, methyl tert butyl ether (MTBE) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), Acetonitrile (ACN), and methanol 
(MeOH) were purchased from Merck (Darmstadt, Germany). Ultra-pure water 




Cell lines RWPE-1 (normal, epithelial), WPMY-1 (normal, stroma), LNCap 
(androgen sensitive PCa) and CWR22Rv1 (androgen insensitive PCa) were 
obtained from American Type Culture Collection (ATCC). BPH-1 (benign 
prostate hyperplasia tumour cells) was purchased from Leibniz Institute DSMZ- 
German Collection of Microorganisms and Cell Cultures. C4-2 (androgen 
insensitive PCa), C4-2B (androgen insensitive PCa) and stably AR-transfected 
HeLa were from gifts from Prof Yong Eu Leong’s lab. These different types of 
prostate cell lines were chosen to provide comparison of the intracellular sex 
hormone levels from the normal to benign to androgen sensitive and androgen 
insentive PCa cell types. 
Phosphate Buffered Saline (PBS) from Vivantis Inc, US, Bovine Albumin Serum 
(BSA), Phenol red free RPMI-1640 and Phenol red free Eagle’s MEM were from 
Sigma-Aldrich (St. Louis, MO, USA). Phenol red free, high glucose DMEM and 
KSFM serum free media were from Life technologies (Green Island, NY, USA), 
Fetal Bovine Serum (FBS) from Thermo Scientific (Rockford, IL, USA), 
Charcoal Dextran Stripped Fetal Bovine Serum (CD-FBS) was treated with 
charcoal to remove most of the endogenous steroids. Hygromycin B in PBS 50 
mg/ml, sodium pyruvate (NaCO2COCH3) and L-glutamine were from Invitrogen 
(Carlsbad, CA, USA). Geneticin® was from Life technologies (Green Island, NY, 
USA). MPer lysis buffer was from Thermo Scientific (Rockford, IL, USA) and 
Cell Titer 96® Aqueous non-radioactive cell proliferation assay (MTS reagent) 





2.1.2.1 Preparation and Extraction of Calibration Standards and Quality 
Controls  
All the stock and standards of A4, T and DHT were stored at -20 oC and wrapped 
with foil. Calibration standards were prepared by spiking 20 µL of each standard 
mixture of A4, T and DHT in methanol into 80 µL of 1g/L of PBS/BSA solution 
to make up 100 µL of final solution. As such, the final calibration levels for both 
A4 and T ranged from 0.01 to 100 nM and 0.1 to 1000 nM for DHT. 10 µL of 25 
nM internal standard, d3-T was spiked into each of the 100 µL sample. Three 
quality controls (QC) with concentrations 0.2 nM, 2 nM and 10 nM for A4 & T 
and 2 nM, 20 nM and 100 nM for DHT were also prepared. 1 mL of MTBE was 
added to each sample and vortexed vigorously for 2 mins. It was then centrifuged 
at 13,000 rpm for 3 mins at room temperature. Supernatants were transferred into 
clean eppendorf tubes. Extraction was repeated once more and extracts were 
combined and dried under nitrogen gas at 40 oC. The dried residue was 
reconstituted with 60 µL of 0.1 M hydroxylamine hydrochloride prepared in 3:7 
methanol:water and reacted at 70 oC for 15 mins. It was allowed to cool and 
centrifuged at 14,000 rpm for 1 min. 20 µL of the reconstituted solution was 







2.1.2.2 Preparation of Stability Tests Samples 
Triplicates of the three QCs mentioned in section 2.1.2.1 were prepared in 1g/L 
PBS/BSA. For determination of freeze-thaw stability, they were subjected to three 
freeze-thaw cycles of -80 oC (freeze) and 24 oC (thaw), with 24-hr span between 
each cycle. Another set of triplicates was left at room temperature of 24 oC for 4, 
6, 8 and 24 hrs respectively, before analysis to study the short term stabilities of 
the three androgens in PBS/BSA under room temperature. For both freeze-thaw 
and short term stability samples, the responses were compared against responses 
from triplicates of a reference set, freshly prepared on the day of extraction and 
detection with the same concentrations of the respective androgens. 10 µL of 25 
nM internal standard, d3-T was spiked into each of the sample and reference set 
prior to extraction. 
 
2.1.2.3 Cell Culture under Different Treatments 
Seven types of prostate cell lines were cultured at 37 oC at 5% CO2 in humid 
conditions. All the cell lines were treated under the same set of conditions for 
comparison purposes. These included normal prostate epithelial cell line, RWPE-
1, normal prostate stromal cell line, WPMY-1, benign prostate cell line, BPH-1, 
androgen dependent prostate cancer cell line, LNCap and androgen independent 
PCa cell lines, C4-2, C4-2B and CWR22Rv1. The cell lines were subjected to six 
different types of conditions for 48 hrs before collection and out of which four 
treatments were relevant for androgen levels comparison. These conditions 
include treatment 1 (T1): culture in respective phenol-red free media with 10% 
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FBS; treatment 2 (T2): culture in respective phenol-red free media with 10% FBS 
and supplemented with 1 nM DHT; treatment 3 (T3): culture in respective phenol-
red free media with 10% FBS and supplemented with 10 nM E2 (for estrogen 
levels comparison in Chapter 3); treatment 4 (T4): culture in respective phenol-
red free media with 10% CD-FBS; treatment 5 (T5): culture in respective phenol-
red free media with 10% CD-FBS and supplemented with 1 nM DHT and 
treatment 6 (T6): culture in respective phenol-red free media with 10% CD-FBS 
and supplemented with 10 nM E2 (for estrogen levels comparison in Chapter 3). 
For each treatment of each cell line, cells were cultured in two T175 flasks. After 
48 hrs of treatment, the cells were passaged. During the passage, the collected 
cells were kept in 15 mL centrifuge tubes and centrifuged under 4 oC at 1000 rpm 
so as to enable the aspiration of the media. These tubes were then kept in ice 
during the entire process. Each tube of collected cells was rinsed twice with 10 
mL of cold 1x PBS each time. The cells were counted using a hemocytometer. 
The collected cells were then suspended in PBS solution to obtain approximately 
1 million cells per 100 µL of 1x PBS solution. The volume of cold 1x PBS to be 
added to the collected cells was based on the number of cells counted earlier and 
calculated using the following equation: 
Vol of 1x PBS to be added to collected cells = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑖𝑛 4 𝑠𝑚𝑎𝑙𝑙 𝑐𝑜𝑟𝑛𝑒𝑟 𝑠𝑞.÷ 4 ×10000 × 𝑉𝑜𝑙.𝑜𝑓 𝑠𝑢𝑠𝑝𝑒𝑛𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
10000000
 
The cells in the added volume of 1x PBS was re-suspended and vortexed at slow 
speed to ensure that the cells were evenly suspended and yet not to break the cells. 
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100 µL of the suspended cells (approx. 1 million cells) was transferred quickly 
into each of the 1.5 mL microcentrifuge tubes. For each set of treatment for the 4 
different types of treatment for each cell line, at least 8 x 3 = 24 tubes of cells in 
PBS was collected for different assays. Triplicates of the cells for each treatment 
were used for each assay. All the results were performed for the subsequent 
passage of each cell line to see if the results were of similar trend. Cells collected 
and measured were kept within narrow passages to ensure repeatability of results. 
All the tubes of cells collected were immediately stored at -80 ºC before 
extraction and LC-MS/MS analysis.  
(Note: Each batch of collected cells was used for LC-MS/MS measurements of 
androgens and estrogens, for stably AR-, ERα- and ERβ-transfected HeLa 
reporter gene bioassays and MTS cell proliferation bioassays so that the results 
for these different assays can be better correlated to each other.) 
 
2.1.2.4 Preparation and Extraction from Cell Samples  
Each tube of sample contains approximately 1 million cells in 100 µL of 1x PBS 
was thawed at room temperature. A 10 µL of 25 nM d3-T was spiked as internal 
standard into each of the sample. 1 mL of MTBE was added to each tube of 
sample and sonicated in waterbath sonicator filled with ice for 10 mins to ensure 
complete extraction. Similar extraction procedure for the standards and quality 
controls as mentioned in section 2.1.2.1 was performed. However, instead of 
centrifuging at 13,000 rpm, the cell samples were centrifuged at a slower speed 
6000 rpm for 5 mins for the first round of extraction and only increased the speed 
46 
 
to 13,000 rpm at the last round of extraction. The supernatants were transferred to 
individual 2 mL eppendorf tubes. The extraction process was repeated again. The 
supernatants were combined and dried under nitrogen gas at 40 oC and similar 
derivatisation with 0.1 M hydroxylamine hydrochloride as mentioned in section 
2.1.2.1 was adhered before injection for LC-MS/MS detection. Triplicates of each 
cell line under each treatment were measured.  
 
2.1.2.5 LC-MS/MS Analysis  
UPLC was carried out on an Agilent 1290 Infinity liquid chromatography system 
with a binary pump. An Agilent Eclipse Plus C18 RRHD (2.1 mm × 50 mm, 1.8 
µm particle size) column was used for separation. The mobile phase consisted of 
two eluents, solvent A (ultrapure water with 0.1 % formic acid) and solvent B 
(acetonitrile) delivered at a flow rate of 0.5 ml/min and at column temperature at 
40 oC. 20 µL of each sample was injected into the LC-MS/MS, after which the 
injector needle was washed with flush port with washing liquid (acetonitrile). The 
column was equilibrated at 20 % B and it was increased to 40 % B within 0.5 
mins. After which, it was further increased to 60 % B within 1 min. At 1.5 min, 
60 % B was maintained for 1 min and subsequently increased to 100 % B at the 
3rd min of the sample run. This was maintained for another min and decreased to 
20 % during 1 min duration and was maintained at this condition for another 2 
mins. During the run, the first 0.8 mins was diverted to waste and the next 0.8 to 5 
mins was diverted to MS detector and subsequently diverted to waste again after 
the 5th min. This was to done to divert any interferences from the actual peaks of 
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interest as well as to prolong the lifetime of the MS detector. Total runtime was 7 
mins and the flow rate was kept constant at 0.5 mL/min throughout. During the 
detection, the samples were kept in the autosampler at 6 oC. 
The separated analytes was analyzed by an Agilent 6490 Triple Quadrupole 
(ifunnel) mass spectrometer equipped with Agilent Jet Stream (AJS) ESI source 
operated under ESI positive ion mode. Multiple reaction monitoring (MRM) was 
used for the quantification. The optimized MS parameters used were delta EMV: 
+250 V; cell accelerator voltage: 3 V and source parameters used were gas 
temperature: 200 oC; gas flow: 12 L/min; Neubuliser: 20 psi; Sheath gas 
temperature: 350 oC; Sheath gas flow: 12 L/min; capillary (+): 4000 V; nozzle 
voltage: 1000 V(+); ifunnel high pressure RF: 190 V and low pressure RF: 160 V. 
The MRM transitions used were m/z 306 → 105 (quantifier) with optimised 
collision energy of 38 and m/z 306 → 107 (qualifier) with optimised collision 
energy of 28 for DHT-oxime, m/z 304 → 124 (quantifier) with optimised collision 
energy of 25 and m/z 304 → 112 (qualifier) with optimised collision energy of 29 
for T-oxime, m/z 317 → 112 (quantifier) with optimised collision energy of 25 
and m/z 317 → 124 (qualifier) with optimised collision energy of 29 for A4-
oxime, and internal standard d3-T-oxime m/z 307 → 124 (quantifier) with 
optimised collision energy of 25 and m/z 307 → 112 (qualifier) with optimised 
collision energy of 29. Nitrogen gas was used as the curtain and collision gas. All 
data were recorded and processed by using the Agilent MassHunter B06.00 
(Agilent, Foster City, CA). Retention times for A4-oxime, T-oxime and DHT-
oxime were 1.43 min, 1.48 min and 1.58 min respectively. Internal standard, d3-T-
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oxime shared the same retention time as T-oxime at 1.48 min. The concentrations 
of the androgens were quantified using a 12-point calibration curve of peak area 
ratio against the concentration ratio of the analyte to internal standard.  Two-way 
Anova with Bonferroni post-test correction from Graphpad prism version 5 was 
used for the statistical analysis for p-values. 
 
2.1.2.6 Method Validation 
Accuracy and coefficient of variation (CV %) of the quantitation method was 
validated using interday (n = 9) and intraday (n = 6) assays performed on the 
calibration standards in PBS/BSA solution. Limit of quantification (LOQ) was 
based on signal-to-noise (S/N) ratio of 10:1. Matrix effects were investigated by 
analyzing the blank PBS/BSA solution containing internal standard only.  
 
2.2 Correlation of Intracellular A4, T and DHT under Different Treatments 
using Stable Human Cell-based AR-Driven Reporter Gene Assay 
Stably AR-transfected HeLa cell line developed from our lab was used for this 
luciferase reporter gene assay. This AR-transfected HeLa cells were cultured in 
phenol red-free Eagle’s MEM selection media containing 100X NaCO2COCH3, 
0.292 g/L L-glutamine, 1.5 g/L of NaHCO3, 120 µg/mL hygromycin and 300 
µg/mL of geneticin®. It was then changed to phenol red-free Eagle’s MEM 




These AR-transfected HeLa cells were seeded into 96-well plate. 10000 of these 
cells were seeded into each well with 100 µL of the 7 % CD-FBS MEM media. It 
was cultured at 37 oC with 5 % CO2 under humid conditions and allowed to 
adhere for 24 hrs.  
After 24 hrs, the media was aspirated and replaced with media dissolved with 
extracts from the cells cultured under the 4 different treatments that were 
collected previously in section 2.1.2.3. Extracts from the cells were prepared in 
similar fashion as mentioned in section 2.1.2.4, except that no internal standard 
was spiked and no chemical derivatisation was performed on the samples. After 
the extraction, the combined supernatant was dried and re-dissolved in 2 µL of 
methanol and 98 µL of 7 % CD-FBS MEM media to make up 100 µL of media 
for the treatment to the AR transfected HeLa cells in each well. In addition, 2 µL 
of methanol is added to 98 µL of 7 % CD-FBS MEM media as the negative 
control and 2 µL of 5, 50 and 500 nM of DHT dissolved in methanol were each 
dissolved in 98 µL of the media that eventually resulted in 0.1, 1 and 10 nM of 
DHT (50 x dilution) as the positive controls to be used for comparison with the 
androgen levels in the cell samples extracts. 
After 24 hrs of this treatment with the cell extracts, the media was aspirated. 150 
µL of 1x PBS was added to each well to rinse the wells containing the cells and 
aspirated. 25 µL of the MPer cell lysis buffer was added to each well and shaken 
vigorously for 5 mins. The 96-well plate was placed into the Glomax microplate 
luminometer and readout. Triplicates of each treatment of each cell line lysates 
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were analysed. Two-way Anova with Bonferroni post-test correction from 
Graphpad prism version 5 was used for the statistical analysis for p-values. 
 
2.3 MTS Cell Proliferation Assay with Cell Lysates after Treatment 
Approximately 10,000 of each type of prostate cell, namely RWPE-1, WPMY-1, 
LNCap, C4-2, C4-2B and CWR22Rv1 were seeded into each well of the 96-well 
plate with 100 µL of their respective 5 % CD-FBS phenol-red free media. It was 
cultured at 37 oC with 5 % CO2 under humid conditions and allowed to adhere for 
24 hrs.  
After 24 hrs, the media was aspirated and replaced with their respective media 
dissolved with extracts from the cells prepared as mentioned in luciferase assay in 
section 2.2. Cells were treated with its own cell lysates under the 4 types of 
treatment dissolved in their respective media. Triplicates of the respective blank 
media were added and measured for background subtraction. 2 µL of methanol is 
added to 98 µL of the respective media as the negative control for fold-induction 
calculation. After 24 hrs of this treatment with the cell extracts, 25 µL of the MTS 
reagent was added to each well and incubated for 1, 2, 3 and 4 hrs respectively 
and analysed using Tecan, Magellan version 6.5 software. Triplicates of each 
treatment of each cell line lysates were analysed. Graphpad prism version 5 was 





2.4 Results and Discussions 
2.4.1 LC-MS/MS Method Development for Simultaneous Detection of A4, T 
and DHT 
These three androgens were chosen as the analytes of interest here as based on the 
steroidogenesis map on Figure 8, A4 lies at the junction for most of the suggested 
synthetic paths which eventually lead to formation of T and is in turn converted to 
DHT. However, it is rather challenging as quantitation method has to be sensitive 
enough to detect these androgens in minimal amount of cells, in this case, 
approximately one million cells per sample. 
As such, chemical derivatisation is employed here to enhance the signals from the 
analytes for LC-MS/MS detection and quantitation. Hydroxylamine hydrochloride 
is used here as the derivatisation agent as the structures of these three androgens 
contained the carbonyl functional group, C=O. This reagent is well-known for its 
efficacy and simplicity of reaction with the compounds containing C=O groups 




















Figure 10. General Reaction Scheme of Carbonyl Compounds with 
Hydroxylamine Hydrochloride.  
 
Besides, this reagent is also commonly available. As such, through this reaction 
the carbonyl group of these androgens can react with the amine group of 
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hydroxylamine through an initial nucleophilic addition reaction, followed by an 














































Figure 11. Reaction Mechanism of Carbonyl Compound with Hydroxylamine 
Hydrochloride.  
 
Through the introduction of an amine group to these androgens, this functional 
group which is basic in nature can now react readily with the protons in the acidic 
mobile phase to form the protonated derivatised analytes. These cations can be 
easily detected under the positive ESI mode, which will help to improve the 
sensitivity of detection.  
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2.4.2 Validation of LC-MS/MS Method 
Linear regression with 1/y weighting was obtained for all A4, T and DHT in the 1 
g/L PBS/BSA matrix. The acceptable ranges for measurements of A4 and T were 
from 0.05 to 100 nM and DHT was from 0.5 to 1000 nM, with all the regression 
coefficients, r2 close to 0.99. For A4, the typical calibration curves equations 
using PBS/BSA was y = 4.644191x + 0.004781. For T, the typical calibration 
curves equations using PBS/BSA was y = 12.382492x + 0.001325. For DHT, the 
typical calibration curves equations using PBS/BSA was y = 1.303989x + 
0.006094.   
Recoveries and matrix effect were determined using the QCs prepared in the 
matrix. From the chromatograms of the blank matrix, there were no peaks 
observed at the same retention times for all the three analytes (refer to Appendix 
III). So, this implied that the method was selective and specific for detecting A4, 
T and DHT. All the validated values for accuracies and coefficient of variation 
(CV%) were within acceptable requirements according to Guidance for Industry 
Bioanalytical Method Validation ("Guidance for Industry Bioanalytical Method 
Validation," 2001) for A4, T and DHT as shown in Tables 4 to 6. The LOQ 
values of A4 and T were experimentally determined to be 0.05 nM and DHT to be 
0.5 nM with S/N ratio of at least 10:1 as analyzed with the Agilent MassHunter 
Quantitative Analysis B.05.02 software. The results showed that this current 
method was sensitive, robust and reproducible for the measurement of the three 








Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(µM) 
Stdev CV % Accuracy % 
0.05 0.052 0.042 0.048 0.047 0.005 10.74 94.44 
0.1 0.097 0.083 0.085 0.088 0.008 8.64 88.38 
0.2 0.191 0.196 0.186 0.191 0.005 2.76 95.46 
0.5 0.446 0.473 0.483 0.467 0.019 4.10 93.43 
1 0.868 0.949 0.978 0.932 0.057 6.10 93.17 
2 1.835 1.993 2.015 1.948 0.098 5.05 97.40 
5 4.675 5.046 4.947 4.889 0.192 3.94 97.79 
10 9.482 10.712 9.589 9.928 0.681 6.86 99.28 
50 50.804 49.660 51.498 50.654 0.928 1.83 101.31 
100 100.776 99.796 99.585 100.052 0.636 0.64 100.05 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(µM) 
Stdev CV % Accuracy % 
0.2 0.208 0.180 0.181 0.190 0.016 8.30 94.85 
2 1.757 2.143 1.863 1.921 0.200 10.40 96.06 
10 8.958 11.018 8.593 9.523 1.307 13.73 95.23 




Estimated Intraday Concentration (nM)       Intraday Validation Summary 







0.05 0.069 0.069 0.075 0.072 0.071 0.068 0.071 0.002 3.43 141.37 
0.1 0.114 0.113 0.116 0.116 0.116 0.115 0.115 0.001 1.14 114.90 
0.2 0.222 0.224 0.209 0.227 0.041 0.340 0.210 0.096 45.52 105.20 
0.5 0.470 0.433 0.452 0.436 0.445 0.489 0.454 0.022 4.75 90.88 
1 0.823 0.821 0.843 0.835 0.847 0.844 0.836 0.011 1.34 83.55 
2 1.681 1.779 1.834 1.922 1.774 1.959 1.825 0.103 5.64 91.27 
5 4.223 5.074 4.637 4.518 4.554 4.626 4.605 0.275 5.97 92.12 
10 10.144 8.768 10.587 8.679 9.173 9.333 9.447 0.765 8.10 94.47 
50 44.675 51.858 49.550 44.975 59.116 50.210 50.064 5.299 10.58 100.10 
100 86.723 92.541 111.923 98.683 94.373 115.000 99.874 11.246 11.26 99.87 




Estimated Intraday Concentration (nM)        Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.192 0.229 0.213 0.210 0.219 0.201 0.210 0.013 6.20 105.20 
2 1.967 1.759 1.778 1.678 1.714 1.754 1.775 0.101 5.66 88.73 











Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.050 0.046 0.042 0.046 0.004 8.65 92.24 
0.1 0.098 0.094 0.091 0.094 0.004 3.85 96.16 
0.2 0.197 0.202 0.182 0.194 0.010 5.40 98.17 
0.5 0.463 0.493 0.505 0.487 0.021 4.37 105.11 
1 0.915 0.984 0.985 0.961 0.040 4.14 105.02 
2 2.020 2.109 2.143 2.091 0.064 3.04 103.50 
5 4.869 5.087 5.090 5.015 0.127 2.53 103.01 
10 9.716 11.086 10.114 10.305 0.705 6.84 106.06 
50 51.178 51.916 52.079 51.724 0.480 0.93 101.07 
100 99.843 97.348 98.069 98.420 1.284 1.30 98.57 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.203 0.199 0.194 0.199 0.005 2.30 97.88 
2 1.888 2.273 2.059 2.074 0.193 9.30 109.80 
10 9.746 11.442 9.243 10.144 1.152 11.36 104.08 




Estimated Intraday Concentration (nM)        Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.095 0.095 0.093 0.096 0.098 0.093 0.095 0.002 2.07 189.87 
0.1 0.124 0.123 0.124 0.124 0.123 0.131 0.125 0.003 2.42 124.72 
0.2 0.224 0.230 0.221 0.229 0.059 0.383 0.224 0.102 45.63 112.18 
0.5 0.552 0.513 0.520 0.493 0.524 0.564 0.528 0.026 4.97 105.53 
1 0.946 0.987 0.977 0.948 0.984 0.999 0.973 0.022 2.25 97.33 
2 1.840 1.973 2.109 2.109 2.038 2.026 2.016 0.101 5.00 100.78 
5 4.690 5.675 5.277 5.274 5.032 5.146 5.182 0.325 6.26 103.63 
10 11.051 9.486 11.434 9.782 10.080 9.791 10.271 0.785 7.65 102.70 
50 45.996 54.614 50.935 47.273 59.441 48.732 51.165 5.064 9.90 102.33 
100 84.457 91.786 118.280 92.915 98.734 112.465 99.773 13.039 13.07 99.78 




Estimated Intraday Concentration (nM) Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.228 0.228 0.219 0.223 0.213 0.228 0.223 0.006 2.70 111.43 
2 1.965 1.751 1.762 1.812 1.843 1.844 1.830 0.077 4.22 91.48 









Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. (nM) Stdev CV % Accuracy % 
0.5 0.465 0.312 0.444 0.407 0.083 20.39 81.37 
1 0.958 1.039 0.875 0.957 0.082 8.56 95.73 
2 2.006 2.127 1.904 2.012 0.112 5.55 100.62 
5 4.947 5.182 5.454 5.194 0.254 4.88 103.88 
10 9.624 11.172 10.981 10.592 0.844 7.97 105.92 
20 21.951 23.416 22.252 22.540 0.774 3.43 112.70 
50 52.733 58.356 54.302 55.130 2.902 5.26 110.26 
100 105.439 116.208 107.987 109.878 5.628 5.12 109.88 
500 522.587 521.633 523.525 522.581 0.946 0.18 104.52 
1000 973.977 953.526 966.478 964.660 10.346 1.07 96.47 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. (nM) Stdev CV % Accuracy % 
2 2.109 2.140 1.955 2.068 0.099 4.77 103.39 
20 20.625 22.903 22.280 21.936 1.177 5.37 109.68 
100 104.242 114.749 99.064 106.018 7.992 7.54 106.02 




                          Estimated Intraday Concentration (nM)       Intraday Validation Summary 







0.5 0.493 0.421 0.459 0.481 0.467 0.421 0.457 0.030 6.60 91.38 
1 1.098 1.147 0.963 1.123 1.136 1.050 1.086 0.070 6.41 108.60 
2 2.317 2.318 2.213 2.328 0.209 4.254 2.273 1.280 56.33 113.65 
5 5.124 5.180 5.224 4.997 4.982 5.535 5.173 0.202 3.90 103.47 
10 10.288 10.454 10.125 9.899 10.651 10.420 10.306 0.265 2.58 103.05 
20 20.716 21.973 22.460 22.475 21.233 23.060 21.986 0.871 3.96 109.95 
50 51.356 55.818 55.626 56.457 55.332 56.344 55.156 1.910 3.46 110.32 
100 117.515 101.556 108.596 99.861 107.424 107.658 107.102 6.233 5.82 107.12 
500 492.028 528.875 479.876 467.004 538.189 465.809 495.297 31.259 6.31 99.07 
1000 832.787 925.922 1166.424 899.438 963.251 1122.982 985.134 131.458 13.34 98.50 




Estimated Intraday Concentration (nM)        Intraday Validation Summary 







2 1.945 2.025 1.987 1.905 2.006 1.958 1.971 0.044 2.22 98.53 
20 23.046 19.195 18.633 19.558 19.710 19.969 20.018 1.554 7.76 100.10 





2.4.3 Stabilities of A4, T and DHT in PBS/BSA  
It is necessary to investigate the stabilities of these androgens in the respective 
matrices to elicit information on the rate of degradation during storage and sample 
preparation, which can then be avoided. Here, freeze-thaw and short term stability 
tests were performed.  
 
Table 7. Recoveries of A4, T and DHT at Low, Mid and High Concentrations 
for Freeze-Thaw and Short Term Stability Tests 
Analyte Range of Recoveries (%) 
At 4 hrs At 6 hrs At 8 hrs At 24 hrs Freeze-
Thaw 
















89.7 to 95.5 97.5 to 
97.8 











For the freeze-thaw samples prepared in 1g/L of PBS/BSA matrix, the mean 
recoveries for the three QCs (low, mid and high) for A4 were from 115.8 to 120.9 
%, T were from 97.5 to 97.8 % and DHT were from 78.2 to 86.1 % when 
compared to the freshly prepared reference samples (Table 7 and Figures 12a-c).  
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% Recovery of A4 in PBS/BSA matrix








































% Recovery of T in PBS/BSA matrix












































% Recovery of DHT in PBS/BSA matrix







































Figure 12. Graphs showing the Recoveries of (a) A4, (b) T and (c) DHT in 1g/L 
of PBS/BSA matrix for Freeze-Thaw and Short Term Stability tests. 
 
As for the short term stability tests samples, recoveries fell within the same ranges 
as compared to the freeze-thaw samples for all the three analytes (Table 7 and 
Figures 12a-c).  
A4, T and DHT were quite stable in PBS/BSA matrix and were able to keep its 
degradation to within 10 % under both short term and freeze-thaw stability test 
conditions. However, DHT seemed to undergo a larger extent of degradation or 
about 20 % under freeze-thaw condition. So, careful operation and storage at -80 
oC without any freeze-thaw actions is required in order to maintain the cell sample 




2.4.4 Measurement of Intracellular A4, T and DHT in Prostate Cells under  
Different Treatments and Correlation with Stable Human Cell-based 
AR-Driven Reporter Gene Assay 
Each prostate cell line was cultured under six different treatments and out of 
which, four treatments were relevant for the various androgens levels comparison 
here. The treatments relevant for androgen levels comparison were treatment 1 
(T1): phenol red free media with 10 % FBS; treatment 2 (T2): phenol red free 
media with 10 % FBS and 1 nM DHT; treatment 4 (T4): phenol red free media 
with 10 % CD-FBS and treatment 5 (T5): phenol red free media with 10 % CD-
FBS and 1 nM DHT. Cell lines were cultured and collected within narrow 
passages in case of mutations to cell lines that will cause deviation to 
measurements. Triplicates of cell samples under each treatment were used for LC-
MS/MS measurements of A4, T and DHT, as well as for measurements of 
biological responses using AR-transfected HeLa luciferase reporter gene assay for 
comparison. Measurements were repeated for at least two passages for each cell 
line, except for LNCap due to its extremely slow growth. 
From the data shown in Table 8, intracellular A4 concentrations ranged from 
0.00171 to 0.00684 pmole/million cells. Interestingly, intracellular levels of A4 
was found to have similar trends throughout all the 4 sets of treatment, regardless 
of addition of 1 nM DHT as shown in Figures 13a and b. In addition, there was 
no vast differences in intracellular levels of A4 across the normal, benign and 
cancerous (androgen sensitive and insensitive) prostate cells (p-values > 0.05), 
except for C4-2 with higher intracellular levels of A4 across the treatments (p-
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values < 0.001). The intracellular levels of A4 for all types of prostate cells were 
mostly kept within 0.01 pmole/million cells, which was of similar magnitude to 
the intracellular levels of T found in the prostate cells.  
Average A4 conc. in Prostate  Cells















































































































































Trtment 2-10% FBS w 1nM DHT
Trtment 4 -10%CD-FBS
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Trtment 2-10% FBS w 1nM DHT
Trtment 4-10%CD-FBS
Trtment 5-10%CD-FBS w 1nM DHT





























Figures 13 (a) Average of Intracellular Measurements of A4 between the two 
passages. Using two-way Annova with Bonferoni post-test corrections, most cell 
lines have insignificant differences in intracellular levels of A4 (p-values >0.05), 
except for C4-2 (p-values <0.0001). (b) Individual Intracellular Measurements of 








Type of Cell 
Line 
Av. Conc. Of Androgens in Different Treatments  
nM  
pmole/ million cells 
Std Dev 
 
  (1) 
10 % FBS 
(2) 
10 % FBS + 1 nM 
DHT 
(3) 
10 % CD-FBS 
(4)  
10 % CD-FBS + 1 
nM DHT 
RWPE-1 








































































































































































































































































































Average Conc. of T in Prostate  Cells








































Trtment 2-10% FBS w 1nM DHT
Trtment 4 - 10%CD-FBS
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Trtment 2-10% FBS w 1nM DHT
Trtment 4 - 10%CD-FBS
Trtment 5-10%CD-FBS w 1nM DHT




























Figures 14 (a) Average of Intracellular Measurements of T between the two 
passages. Using two-way Annova with Bonferoni post-test corrections, only 
WPMY-1 and all the PCa cell lines have significant differences in intracellular 
levels of T (p-values <0.001) between Treatments with 10 % FBS media and 10% 






From the data obtained in Table 8, the intracellular levels of T ranged from 
0.0003 to 0.0095 pmole/million cells and were kept within 0.01 pmole/million 
cells of similar magnitude to intracellular A4 as mentioned earlier. Intracellular T 
has an obvious trend across the different types of prostate cell lines as reflected in 
Figures 14 a and b. 
Intracellular levels of T are much higher in PCa cell lines (p-value < 0.0001), 
regardless of androgen sensitive or insensitive types under all the four treatments 
when compared to normal and benign tumour cells. This could be due to a more 
ready uptake of T from the exogenous surroundings into the cells as the PCa cells 
are reported to express higher levels of ARs (Stanbrough et al., 2006; Mostaghel 
et al., 2009; Koochekpour, 2010). Alternatively, these PCa cells may have 
mutations or mechanisms such as overexpression of AKR1C3 for intracrine 
synthesis to supply more T for proliferation (Hamid et al, 2012) in such PCa 
systems.  
Another further observation is between the treatments of media supplemented 
with 10 % FBS (treatments 1 & 2) to those with 10 % CD-FBS media (treatments 
4 & 5), PCa cells under media with 10 % FBS has higher intracellular T (p-values 
< 0.001). These results were repeatable during an earlier data collection. This is 
possible as there might be higher endogenous T contents from 10 % FBS media 
than 10 % CD-FBS media. Thus, these PCa cells could expressed higher levels of 
AR (Mostaghel et al., 2009; Koochekpour, 2010), enabling them to be able to take 
in the T more actively from the media, resulting in slightly higher intracellular T 
for the cell lines for the PCa cells when cultured in 10 % FBS media.  
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Figures 15(a) Average of Intracellular Measurements of DHT between the two 
passages. Using two-way Annova with Bonferoni post-test corrections, all the 
PCa cell lines have significant differences in intracellular levels of DHT (p-values 
<0.001) between treatments with and without excess DHT added in media. (b) 





The measured intracellular levels of DHT under the 4 different treatments ranged 
from 0.0013 to 0.1832 pmole/ million cells and were much higher as compared to 
intracellular T and A4 in PCa cells (Table 8). This is a reasonable result as 
intracellular DHT could be more than 10-fold higher in concentration than 
intracellular T due to its predominant nuclear localization and also higher affinity 
to the androgen receptors in the cells (Feldman & Feldman, 2001).  
The range of the intracellular levels of DHT do not have significant differences 
for all the four types of treatments, except for PCa cells like LNCap, C4-2 and 
C4-2B. They have much higher intracellular levels of DHT than the normal, 
benign and even the CWR22Rv1 prostate cells under treatments that contained 
additional 1 nM DHT (Treatments 2 and 5) (p-values < 0.001). Likewise in the 
case of T, this implied that the DHT was spontaneously taken in from the external 
source from the media for these PCa cells like LNCap, C4-2 and C4-2B (Liu et 
al., 2004). This could further verified that PCa cells like LNCap, C4-2 and C4-2B 
functions through hypersensitivity of AR, where levels of AR are overexpressed 
for such cells (Stanbrough et al., 2006; Mostaghel et al., 2009; Koochekpour, 
2010), which enables the ease of taking in DHT into the cells. However, not all 
PCa cells behave in the similar manner. Intracellular DHT in CWR22Rv1 were 
about the same across the 4 treatments, with just slight increase when there were 
additional 1 nM DHT supplemented. This indicated that this cell does not seem to 
have overexpressed AR like C4-2 and C4-2B. Rather, it is able to maintain 
comparable levels of DHT even under androgen-depleted condition (under 10% 
CD-FBS only). This could mean that CWR22Rv1 might be able to supply its own 
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androgens for sustenance, despite under the androgens-depleted culture 
conditions. 
Fold Response of Prostate Cells Extracts on
AR-Transfected HeLa Luciferase Reporter Gene Assay









T2: 10%FBS with 1nM DHT
T4: 10% CD-FBS































Figure 16. Biological Responses of the Cell Lysates from Different Treatments 
using AR-Transfected HeLa Luciferase Reporter Gene Assay. Using two-way 
Annova with Bonferoni post-test corrections, most of the PCa cell lysates from 
treatments with and without excess DHT displayed significant differences in AR 
responses (p < 0.0001). 
 
Stably AR-transfected HeLa cells were chosen for this assay to measure 
androgenic response in a common ground for comparison of the biological 
responses elicited from the different cell extracts across the different cell lines 
collected under different treatment conditions. The negative control used was 
methanol dissolved in CD-FBS MEM media and the positive controls prepared in 
media were 0.1, 1 and 10 nM DHT to serve as a basic calibration curve here. DHT 
was used to establish the calibration curve as it is the most potent androgen, 
which can elicit the highest biological response upon activation of AR. Therefore, 
though other androgens including T can also bind and activate AR, their 
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biological responses produced would be comparatively less significant. Therefore, 
based on the AR-transfected HeLa luciferase reporter gene bioassay responses 
(Figure 16), the normal prostate cell extracts and the benign prostate hyperplasia 
cell extracts have shown indications that they contained minimal or negligible 
levels of intracellular DHT. As for the PCa cells cell extracts (under four 
treatments), they were mostly estimated to contain 0.1 to 1 nM of intracellular 
DHT (equivalent to 0.01 to 0.1 pmole/million cells) by comparison to the positive 
controls responses. These results closely correlated to the earlier LC-MS/MS data. 
As observed, the cell extracts of all the PCa cells had much higher biological 
responses when cultured under additional 1 nM DHT, just like the LC-MS/MS 
data. CRPC representative cells like C4-2 and C4-2B produced relatively higher 
biological responses when higher intracellular levels of DHT were detected in 
them using LC-MS/MS. This further indicated that there could be overexpressed 
ARs in C4-2 and C4-2B, which allows for more efficient intake of the androgenic 
ligands and translates to higher androgenic responses as observed here from these 
cell lysates. 
On the other hand, CWR22Rv1 produced higher biological responses when the 
cell extracts were detected to have slightly higher intracellular DHT using LC-
MS/MS (treatments T2 and T5). Despite the lower intracellular DHT in 
CWR22RV1 under treatments T1 and T4 compared to T2 and T5, these levels 
were still higher compared to the normal and benign prostate cells. Hence, these 
extracts were able to produce relatively higher responses on the AR-transfected 
cells than the normal and benign prostate cells. These suggested CWR22Rv1 
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could probably survive through intracrine synthesis to produce the potent 
androgens.  
In conclusion, the LC-MS/MS measurements for the intracellular androgen levels 
correlated quite well to the luciferase bioassay results obtained. These data 
provided valuable insights on the various probable mechanisms that enabled the 
sustenance of the different types of CRPC cells.  
 
2.4.5 MTS Proliferation Assay using the PCa Cell Extracts under Different 
Treatments  
Proliferation of Prostate Cells using its











































































































































































































T2: 10%FBS with 1nM DHT
T4: 10% CD-FBS































Figure 17. Proliferation of Prostate Cells after Treatment with Cell Extracts 
subjected to Different Culture Conditions 
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The respective cell extracts under different treatments were used and treated on 
their own type of cells for this MTS assay for 48 hrs before readout. MTS reagent 
was then added and incubated. Readings reached saturation at the first hour of 
incubation. 
As compared to the negative control, methanol and positive control, 1 nM DHT, 
the normal epithelial RWPE-1 and PCa cell extracts were able to induce its own 
cell proliferation, regardless of the types of conditions those cell extracts 
originated. And this is even more apparent from the cell extracts from the normal 
epithelial RWPE-1 and the androgen insensitive or CRPC representative cell type, 
CWR22Rv1. The cell extracts from CWR22Rv1 under most types of treatments 
can induce proliferation of its own type of cells as well as elicit high biological 












2.5 Summary of Results 
For the seven prostate cell lines tested so far, intracellular levels of A4, precursor 
to T were about the same across the four treatments for all the prostate cells. On 
the other hand, the intracellular levels of T were much higher in the PCa cells, 
which may indicate the ability of these cells to self-synthesise for survival and 
growth, especially for the CRPC or androgen insensitive type of PCa cells. 
Besides, when these cells were cultured in 10 % FBS media than in CD-FBS 
media, higher levels of intracellular T were detected. Thus, there is also a more 
ready uptake of T from the media into the cells and this could be suggestion that 
there could be overexpressed AR, enabling faster rate of absorption of T.  
Intracellular levels of DHT were found to be much higher than intracellular T and 
A4. It has no major differences in magnitude for all the cells when compared 
between FBS or CD-FBS media. This is indication that the circulating DHT 
absorbed into all types of the prostate cells from either FBS or CD-FBS media 
does not have significant difference. Intracellular DHT in normal, benign and 
even CRPC cell like CWR22Rv1 are similar across the four treatments despite 
addition of 1 nM DHT. However, LNCap, and the other two CRPC cells, C4-2 
and C4-2B experienced much higher increments in the intracellular DHT when 1 
nM DHT was added.  
When LC-MS/MS data were compared to results from the AR-transfected HeLa 
luciferase reporter gene assay, the data corresponded well. Similar to LC-MS/MS 
data, PCa cell extracts generally displayed much higher biological responses 
when cultured under additional 1 nM DHT. Thus, from the combined information, 
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there is strong implication that CRPC cells like C4-2 and C4-2B were able to 
grow under ablation conditions through overexpressed AR to aid in their 
absorption of DHT from exogenous sources. And coupled with the enhanced 
sensitive AR, even despite lower intracellular DHT, the amount is still sufficient 
to elicit high biological responses.  
In contrast, the remaining CRPC cell, CWR22Rv1 seems to depend more on self-
synthesis mechanism to provide enough potent androgens for sustenance. 
Valuable insights were gained from the combined investigations using LC-
MS/MS and the bioassays as possible mechanisms were inferred that enabled the 





Establishment of Reference Levels of Two Intracellular Estrogens in Prostate 
Cells through LC-MS/MS and Human Cell-based Estrogen-driven Reporter 
Gene Bioassay 
3. Introduction 
Androgens are required for the growth and maintenance of prostate. However in 
the same capacity, they are also the risk factors for the development and 
progression of BPH and PCa. Despite this, it seems that androgens are not the 
only factor that induces prostate diseases. There is a growing body of evidence 
pointing to the crucial role that estrogens play for the development of prostate 
diseases (Aggarwal et al., 2009; Risbridger et al., 2007; Ellem & Risbridger, 
2009). One stark observation is that PCa normally occurs to men age above 65, 
where the levels of T in serum would have decreased significantly (Stanworth & 
Jones, 2008). So, if PCa were solely dependent on androgens, then there should 
be higher incidence rates in younger men than in older men. In contrast, these 
older patients have E2 levels that remain relatively unchanged or have slight 
increments (Yao et al., 2011). E2 is maintained in these elderly men through 
increase in aromatase activity (Ellem & Risbridger, 2010), the enzyme that is 
responsible to convert the adrenal androgens within peripheral adipose tissue to 
estrogens. As a result, the ratio of T to E2 is significantly decreased (Yao et al., 
2011), that could possibly lead to the initiation of prostate disease such as PCa. 
Moreover, in vivo studies also showed that androgens alone are insufficient for 
tumorigenesis but required the combined action of estrogens (Bosland & 
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Mahmoud, 2011). Consistent evidence has also indicated the essential role ERα 
played in the induction of malignancy (Risbridger et al., 2007; Ellem & 
Risbridger, 2009; Nelles et al., 2011; Yeh et al., 2014). New insights were gained 
on the induction of carcinogenesis through the use of combined hormone therapy 
to mature mice and provided evidence that ERα is responsible for the undesirable 
effects (Nelles et al., 2011; Yeh et al., 2014).  
In contrast, there has been substantial evidence that estrogens, through activation 
of another estrogen receptor, ERβ has an entirely differing effect in comparison 
than to the activation of ERα (Risbridger et al., 2007; Ellem & Risbridger, 2009). 
ERβ is highly expressed in the prostate (Horvath et al., 2001; Guerini et al., 
2005), even though this organ is supposedly an androgenic environment. 
Activation of ERβ has been attributed to many beneficial effects such as anti-
proliferative, anti-inflammatory, and, even anti-carcinogenic as opposed to 
activation of ERα (Risbridger et al., 2007; Ellem & Risbridger, 2009). In the 
absence of ERβ, the prostate will eventually develop focal lesions of epithelial 
hyperplasia and would display three times higher proliferative activity than in 
normal mice (Imamov et al., 2004). However, it is still unclear what are the 
mechanisms behind the beneficial action of ERβ and would require further 
investigations.  
In this study, we would like to investigate the reference levels of E1 and E2 in 
prostate cells using LC-MS/MS analysis and human cell-based androgen-driven 




3.1 LC-MS/MS Method Development and Validation for Simultaneous 
Detection and Quantitation of E1 and E2 
3.1.1 Materials 
 
Estrone (E1), estradiol (E2), dansyl chloride (Dns-Cl) [5-(dimethylamino)-1-
naphthalenesulfonyl chloride] with >98 % purity and internals standard, 
deuterated-estradiol (d5-E2) of purity 97 % were all obtained from Sigma-Aldrich 
(St. Louis, MO, USA).  
Anhydrous sodium bicarbonate (NaHCO3) was used for preparation of buffers of 
pH 11.4 was obtained from Sigma-Aldrich (St. Louis, MO, USA). Sodium sulfate 
(NaSO4) used as drying agent for acetone in preparation of Dns-Cl were 
purchased from Merck (Darmstadt, Germany). 
Solvents used for LC-MS/MS measurement were all of HPLC grade, unless 
otherwise stated. Formic acid, methyl tert butyl ether (MTBE) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), Acetone, Acetonitrile (ACN), and 
methanol (MeOH) were purchased from Merck (Darmstadt, Germany). Ultra-pure 
water was obtained using Milli-Q water purification system (Millipore, Bedford, 
MA, USA).  
Cell lines RWPE-1, WPMY-1, LNCap and CWR22Rv1 were obtained from 
American Type Culture Collection (ATCC). BPH-1 was purchased from Leibniz 
Institute DSMZ- German Collection of Microorganisms and Cell Cultures. C4-2, 
C4-2B and Stably ERα- and ERβ-Transfected HeLa were from gifts from Prof 
Yong Eu Leong’s lab.   
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Phosphate Buffered Saline (PBS) from Vivantis Inc, US, Bovine Albumin Serum 
(BSA), Phenol red free RPMI-1640 and Phenol red free Eagle’s MEM were from 
Sigma-Aldrich (St. Louis, MO, USA). Phenol red free, high glucose DMEM and 
KSFM serum free media were from Life technologies (Green Island, NY, USA), 
Fetal Bovine Serum (FBS) from Thermo Scientific (Rockford, IL, USA), 
Charcoal Dextran Stripped Fetal Bovine Serum (CD-FBS) was treated with 
charcoal to remove most of the endogenous steroids. Hygromycin B in PBS 50 
mg/ml, sodium pyruvate (NaCO2COCH3) and L-glutamine were from Invitrogen 
(Carlsbad, CA, USA). Geneticin® was from Life technologies (Green Island, NY, 
USA). MPer lysis buffer was from Thermo Scientific (Rockford, IL, USA) and 
Cell Titer 96® Aqueous non-radioactive cell proliferation assay (MTS reagent) 
from Promega (Madison, WI, USA). 
3.1.3 Experimental 
3.1.2.1 Preparation and Extraction of Calibration Standards and Quality 
Controls  
Stock and standards of E1 and E2 were stored at -20 oC and wrapped with foil. 
Calibration standards for the estrogens were prepared differently from the 
androgen standards in Chapter 2. The required concentrations of E1 and E2 were 
prepared into PBS/BSA solution and stored at -20 oC and wrapped in foil. As 
such, the final prepared calibration standards for both E1 and E2 were ranged 
from 0.01 to 10 nM. 10 µL of 2 nM internal standard, d5-E2 was spiked into each 
of the 100 µL sample. Three QCs with concentrations 0.05 nM, 0.2 nM and 5 nM 
were also prepared in matrix. Liquid–liquid extraction with 1 mL of MTBE per 
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sample was used. Samples were vortexed vigorously for 2 mins. They were then 
centrifuged at 13,000 rpm for 3 mins at room temperature. The supernatants were 
transferred into clean eppendorf tubes and extraction was repeated thrice in all. 
Extracts were combined and dried under nitrogen gas at 40 oC. The dried residue 
was reconstituted with 25 µL of 100 mM NaHCO3 at pH 11.4 and vortexed for 1 
min before adding another 25 µL of 1 g/L of danysl chloride (Dns-Cl) in acetone 
and vortexed for another min. It was reacted at 60 oC for 5 mins and allowed to 
cool before centrifuging at 14,000 rpm for 1 min. 20 µL of the reconstituted 
solution was injected for the analysis. 
 
3.1.2.2 Preparation of Stability Tests Samples  
Triplicates of the three QCs as mentioned in section 3.1.2.1 were prepared in 1g/L 
of PBS/BSA. In addition, similar preparation procedure for the two sets of 
stability samples: freez-thaw and short term stability samples were prepared as 
according to section 2.1.2.2. These stability and reference samples were spiked 
with 10 µL of 2 nM d5-E2 internal standard before extraction. 
 
3.1.2.3 Cell Culture under Different Treatments 
Same cell culture conditions and collection procedure were adhered as mentioned 
in Chapter 2. In fact, for each batch of culture, cells were cultured under six 
different conditions and collected concurrently for study of intracellular 
androgens (Chapter 2) and intracellular estrogens (Chapter 3) in the prostate 
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cells. This is done so that comparison of results can be done between data from 
androgen and estrogens detection for certain sets of treatment conditions.  
 
3.1.2.4 Preparation and Extraction from Cell Samples  
Each tube of cell sample contained approximately 1 million cells in 100 µL of 1x 
PBS was thawed at room temperature. 10 µL of 2 nM d5-E2 was spiked as 
internal standard into each of the sample. Similar extraction procedure for the 
standards and quality controls as mentioned in section 3.1.2.1 was performed. 
However, upon addition of 1 mL MTBE, the samples were subjected to sonication 
at 4 oC for 10 mins. In addition, prior to extraction, centrifuging of the cell 
samples were performed at a slower speed 6,000 rpm for 5 mins for the first round 
of extraction and only increase the speed to 13,000 rpm during the last round of 
extraction. Supernatants were transferred to 2 mL eppendorf tubes. The entire 
extraction process was repeated again and extracts were combined and dried 
under nitrogen gas at 40 oC. Similar derivatisation process as mentioned in 
section 3.1.2.1 was adhered here before injection for LC-MS/MS detection. 
Triplicates of each cell line under each treatment were measured.  
 
3.1.2.5 LC-MS/MS Analysis  
UPLC was carried out on an Agilent 1290 Infinity liquid chromatography system 
with a binary pump. An Agilent Eclipse Plus C18 RRHD (2.1 mm × 50 mm, 1.8 
µm particle size) column was used for separation. The mobile phase consisted of 
two eluents, solvent A (ultrapure water with 0.1 % formic acid) and solvent B 
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(acetonitrile) delivered at a flow rate of 0.5 ml/min and at column temperature at 
40 oC. 20 µL of each sample was injected into the LC-MS/MS, after which the 
injector needle was washed with flush port with washing liquid (acetonitrile). The 
column was equilibrated at 20 % B and was increased to 40 % B within the next 1 
min duration. It was subsequently increased to 85 % B within the next. At 2 mins, 
this 85 % B was maintained for 3 mins and then increased to 100 % B at the 5th 
min of the sample run. This was maintained for 1 min and decreased to 20 % at 
8th min and was maintained for another minute before ending the run. Total 
runtime was 9 mins and the flow rate was kept constant at 0.5 mL/min 
throughout. During the run, the first 2 mins was diverted to waste and from 2 to 6 
mins, it was diverted to MS for detection. Then the last 3 mins, it was diverted to 
waste again to help to better maintain the MS detector. During the detection, the 
samples were kept in the autosampler at 6 oC. 
The separated derivatised analytes was analyzed by an Agilent 6490 Triple 
Quadrupole (ifunnel) mass spectrometer equipped with Agilent Jet Stream (AJS) 
ESI source operated under ESI positive ion mode. Multiple reaction monitoring 
(MRM) was used for the quantification. The optimized MS parameters used were 
delta EMV: +250 V; cell accelerator voltage: 5 and source parameters used were 
gas temperature: 200 oC; gas flow: 12 L/min; Neubuliser: 20 psi; Sheath gas 
temperature: 350 oC; Sheath gas flow: 12 L/min; capillary (+): 4000V and nozzle 
voltage: 1000 V(+). The MRM transitions used were m/z 504 → 171 with 
optimised collision energy of 37 for danysl-E1, m/z 506 → 171 with optimised 
collision energy of 41 for danysl-E2, and internal standard danysl d5-E2 m/z 511 
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→ 171 with optimised collision energy of 41. Nitrogen gas was used as the 
curtain and collision gas. All data were recorded and processed by using the 
Masshunter (Agilent, Foster City, CA). Retention times for danysl-E1 and danysl-
E2 were 2.95 min and 2.83 min respectively. Internal standard, d5- danysl-E2 
shared the same retention time as dansyl-E2 at 2.83 min. The concentrations of 
the estrogens were quantified using a 10-point calibration curve of peak area ratio 
against the concentration ratio of the analyte to internal standard. Two-way Anova 
with Bonferroni post-test correction from Graphpad prism version 5 was used for 
the statistical analysis for p-values. 
 
3.1.2.6 Method Validation 
Validation of the experimental method was performed using interday (n = 9) and 
intraday (n = 6) assays on calibration standards in PBS/BSA so as to determine 
the accuracy and the coefficient of variation (CV %). Limit of quantification 
(LOQ) was determined based on signal-to-noise (S/N) ratio of 10:1. Matrix 
effects were also investigated by analyzing the blank PBS/BSA solution with 
internal standard only.  
 
3.2 Correlation of Intracellular E1 and E2 under Different Treatments using 
Stable Human Cell-based ERα- and ERβ-Driven Reporter Gene Assay 
Stably ERα- and ERβ-transfected HeLa cell lines developed from our lab were 
used for the luciferase reporter gene assays. These two transfected cell lines were 
cultured in phenol red-free Eagle’s MEM complete selection media with 100 
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µg/mL of hygromycin and 300 µg/mL of geneticin®. It was then changed to 
phenol red-free Eagle’s MEM supplemented with 7 % CD-FBS media and 
cultured for at least 48 hrs before seeding.  
10000 of these cells were seeded into each well of 96-well plate, with 100 µL of 
the 7 % CD-FBS MEM media per well. It was cultured at 37 oC with 5 % CO2 
under humid conditions and allowed to adhere for 24 hrs.  
After 24 hrs, the media was aspirated and replaced with media dissolved with 
extracts from the cells cultured under the four different treatments that were 
collected previously in section 3.1.2.3. The extracts from the cells were prepared 
in similar fashion as mentioned in section 3.1.2.4, except that no internal standard 
was spiked and no chemical derivatisation was performed on the samples. 
Subsequent steps for this procedure were the same as those described on section 
2.2. Triplicates of each treatment of each cell line lysates were analysed. Two-
way Anova with Bonferroni post-test correction from Graphpad prism version 5 
was used for the statistical analysis for p-values. 
 
3.3 MTS Cell Proliferation Assay with Cell Lysates after Treatment 
Approximately 10,000 of each type of prostate cell, namely RWPE-1, WPMY-1, 
LNCap, C4-2, C4-2B and CWR22Rv1 were seeded into each well of the 96-well 
plate with 100 µL of their respective 5 % CD-FBS phenol-red free media. It was 
cultured at 37 oC with 5 % CO2 under humidified conditions and allowed to 
adhere for 24 hrs.  
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The media was aspirated after 24 hrs and replaced with their respective media 
dissolved with cell extracts prepared in similar fashion as in luciferase assay in 
section 3.2. Subsequent steps for this procedure were the same as those described 
on section 2.3. Triplicates of each treatment of each cell line lysates were 
analysed. Graphpad prism version 5 was used to analyse the data. 
 
3.4 Results and Discussions 
3.4.1 LC-MS/MS Method Development for Simultaneous Detection of E1 and 
E2 
Estrogens are often perceived as the “female hormones” simply due to its 
predominance in the female reproductive organs. Prostate is part of the male 
reproductive organs. Though there were reports that indicated that male 
reproductive organs such as prostate also requires the existence of estrogens for 
their maintenance and well-being as well as for malignancies to occur, there is 
uncertainty as to how much of estrogens that can be found in prostate cells. So, to 
develop a sensitive LC-MS/MS method for detection and quantification of E1 and 
E2 becomes necessary.  
Unfortunately, since sensitivity is an issue for consideration here, it is not possible 
currently that a highly sensitive method be developed for simultaneous detection 
for both androgens (Chapter 2) and estrogens here as the attempt to develop such 
a method fared poorly in terms of sensitivity. Thus, a separate LC-MS/MS 
method was developed here to quantify E1 and E2 simultaneously in the cell 
samples containing approximately one million cells each. 
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To enhance the sensitivity of detection of E1 and E2, derivatisation was used here 
too. This time dansyl chloride (Dns-Cl) was used here as the derivatisation agent. 
Dns-Cl is a very commonly used derivatising agent as it is very simple and 
convenient to use. It has been reported to be able to provide a signal enhancement 
for detection of estrogens (Nelson et al., 2004; Xia et al., 2004; Kushnir et al., 
2008). Dns-Cl can be used to react with the phenolic functional groups of E1 and 
E2 through a nucleophilic substitution reaction by replacing the –Cl on Dns-Cl 
with the phenoxide ions generated from E1 and E2 to form the dansylated 
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Figure 18. General Reaction Scheme of Phenolic Compounds with Dansyl 
Chloride (Dns-Cl) under commonly reported conditions marked with *(Gao et al., 






















Figure 19. Reaction Mechanism of Phenolic Compounds with Danysl Chloride 
(Dns-Cl).  
 
From the mechanism (Figure 19), it can be seen that with appropriate use of 
alkaline buffers to help to generate phenoxide ions from E1 and E2, it will allow a 
fast and more efficient substitution reaction to occur. With the introduction of 
tertiary amine group which is basic in nature via attaching Dns-Cl moiety, it 
enables ease of protonation to the target analytes under the acidic mobile phase 
(Gong et al., 2007). Thus, it allows ease of formation of positive ions that can be 





3.4.2 Validation of LC-MS/MS Method 
Linear regression with 1/y weighting was obtained for both E1 and E2 in 1g/L of 
PBS/BSA matrix. The acceptable ranges for measurements of E1 and E2 were 
from 0.02 to 5 nM, with all the regression coefficients, r2 close to 0.99. For E1, 
the typical calibration curves equations using PBS/BSA was y = 21.669138x -
0.103386. For E2, the typical calibration curves equations using PBS/BSA was y 
= 5.805517x + 0.049215.   
QCs in matrix were used to determine the recoveries and matrix effect. There 
were peaks with the same retention times for both the identification of E1 at m/z 
504 → 171 and for E2 at m/z 506 → 171 from the blank PBS/BSA matrix (refer 
to Appendix VIII). However, the peak for E1 was very small and insignificant 
whereas for E2, it is relatively more prominent. This is inevitable since BSA 
would most probably contain some endogenous estrogens. In addition, chemical 
derivatisation has improved the detection limits of the two estrogens, making the 
method very sensitive even to the small amounts present. Fortunately, these 
background peaks were still comparatively small and can be subtracted before 
calculation of the actual detection from the samples.  
All the validated values for accuracies and coefficient of variation (CV%) were 
within acceptable requirements according to the Guidance for Industry 
Bioanalytical Method Validation ("Guidance for Industry Bioanalytical Method 
Validation," 2001) for E1 and E2 as shown in Tables 9 to 10. The LOQ values of 
E1 and E2 were experimentally determined to be 0.02 nM with S/N ratio of at 
least 10:1 as analyzed with the Agilent MassHunter Quantitative Analysis B.05.02 
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software. The results showed that this current method was more sensitive and 
robust and reproducible for the measurement of E1 and E2 in PBS/BSA matrix.  




Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.02 0.022 0.021 0.022 0.022 0.000 1.54 108.61 
0.05 0.056 0.053 0.053 0.054 0.002 3.15 108.24 
0.1 0.087 0.090 0.091 0.089 0.002 2.40 89.30 
0.2 0.178 0.170 0.177 0.175 0.004 2.38 87.57 
0.5 0.523 0.415 0.489 0.476 0.055 11.62 95.12 
1 0.870 0.920 0.945 0.911 0.038 4.18 91.15 
5 5.168 5.210 5.056 5.145 0.080 1.55 102.89 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.054 0.050 0.053 0.052 0.002 4.44 104.27 
0.2 0.175 0.195 0.168 0.179 0.014 7.86 89.51 
5 5.139 5.325 5.127 5.197 0.111 2.14 103.94 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.02 0.021 0.023 0.022 0.020 0.021 0.021 0.021 0.001 3.36 106.72 
0.05 0.056 0.048 0.056 0.056 0.056 0.055 0.055 0.003 5.74 109.02 
0.1 0.093 0.091 0.090 0.086 0.088 0.088 0.089 0.003 2.92 89.20 
0.2 0.166 0.171 0.193 0.162 0.166 0.187 0.174 0.013 7.35 87.02 
0.5 0.493 0.510 0.464 0.510 0.508 0.484 0.495 0.018 3.74 98.95 
1 0.988 0.977 0.870 0.948 0.832 0.856 0.912 0.067 7.36 91.18 
5 4.987 5.081 5.100 5.164 5.231 5.351 5.152 0.127 2.47 103.03 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.055 0.054 0.049 0.059 0.049 0.045 0.052 0.005 9.97 104.08 
0.2 0.167 0.174 0.162 0.185 0.186 0.179 0.175 0.010 5.42 87.63 










Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.02 0.021 0.019 0.018 0.019 0.002 9.33 95.67 
0.05 0.058 0.054 0.056 0.056 0.002 3.46 111.76 
0.1 0.102 0.108 0.103 0.104 0.003 3.04 104.40 
0.2 0.225 0.228 0.217 0.223 0.006 2.58 111.55 
0.5 0.507 0.481 0.508 0.499 0.015 3.07 99.77 
1 1.068 1.082 1.112 1.087 0.023 2.08 108.70 
5 4.915 4.924 4.729 4.856 0.110 2.27 97.12 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.055 0.052 0.054 0.053 0.002 2.92 106.91 
0.2 0.205 0.232 0.210 0.216 0.015 6.74 107.82 
5 4.442 4.814 5.065 4.773 0.314 6.57 95.47 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.02 0.016 0.020 0.016 0.019 0.019 0.019 0.018 0.002 8.57 90.73 
0.05 0.057 0.055 0.056 0.053 0.056 0.048 0.054 0.003 6.34 107.97 
0.1 0.104 0.103 0.104 0.093 0.096 0.098 0.100 0.005 4.56 99.55 
0.2 0.204 0.214 0.233 0.203 0.226 0.232 0.218 0.013 6.13 109.17 
0.5 0.462 0.539 0.523 0.470 0.464 0.518 0.496 0.034 6.94 99.13 
1 1.135 1.153 1.048 1.081 0.975 1.049 1.074 0.065 6.03 107.35 
5 4.785 4.656 4.746 4.684 5.060 5.808 4.956 0.441 8.90 99.12 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.055 0.053 0.055 0.060 0.056 0.056 0.056 0.002 4.19 111.20 
0.2 0.205 0.218 0.206 0.233 0.205 0.222 0.215 0.012 5.40 107.38 








3.4.3 Stabilities of E1 and E2 in PBS/BSA  
In order to ensure these estrogens do not undergo much degradation during 
sample preparation and storage, there is need to study the stabilities of these 
estrogens in the matrix. For the freeze-thaw samples in PBS/BSA, the mean 
recoveries for the three QCs (low, mid and high) for E1 were from 78.9 to 108.1 
% and E2 were from 63.6 to 78.7 % when compared to the same concentrations of 
the freshly-spiked samples (Table 11 and Figures 20a-b).  






































   








































Figures 20. Graphs showing the Recoveries of (a) E1 and (b) E2 in 1g/L of 





As for the short-term stability samples, recoveries for E1 for the short term 
stability samples ranged from 81.3 to 123.7 % on the average and does not suffer 
much degradation. As for E2, the recoveries for the short term samples were 
much lower and can fall to as low as 57.1 % (Table 11 and Figures 20a-b). So, 
E2 degraded more extensively after 6 hrs under room temperature as compared to 
E1.  So, it required faster and more careful preparation. 
Table 11. Recoveries of E1 and E2 at Low, Mid and High Concentrations for 
Freeze-Thaw and Short Term Stability Tests 
Analyte Range of Recoveries (%) 
At 4 hrs At 6 hrs At 8 hrs At 24 hrs Freeze-
Thaw 









On the whole, E2 suffered a more extensive degradation of about 40 % under both 
freeze-thaw or short term conditions under room temperature beyond 6 hrs. As for 
E1, it also degraded by about 20 % under freeze-thaw and short term conditions 
under room temperature beyond 6 hrs. So, it is necessary to ensure sample 
preparation be as fast as possible and store the samples at -80 oC without any 






3.4.4 Measurement of Intracellular E1 and E2 levels in Prostate Cells under 
Different Treatments and Correlation with Stable Human Cell-based 
ERα- and ERβ-Driven Reporter Gene Assay 
The prostate cell lines were subjected to four different treatments as mentioned in 
section 3.1.2.3 and were collected within narrow passages to avoid mutations to 
cell lines. Triplicates of cell samples under each treatment were used for LC-
MS/MS measurements of E1 and E2 and for biological responses using ERα- and 
ERβ-transfected HeLa luciferase reporter gene assay and MTS assay. 
Measurements were repeated for at least two passages for each cell line, except 
for LNCap due to its extremely slow growth. 
Intracellular levels of E1 in the PCa cells were found to be just slightly higher 
than the normal and benign prostate cells across the four treatments. The 
intracellular E1 for all the cell lines under the 4 different treatments ranged from 
0.00236 to 0.00743 pmole/ million cells (Table 12). This is approximately a 
magnitude lower compared to the reported E1 levels found for PCa cells like PC-
3 and DU-145, which were 0.0282 pmole/million cells and 0.0183 pmole/million 
cells respectively (Xu & Veenstra, 2012). As observed, there were similar 
intracellular E1 trends across all treatments (p-values > 0.05) with the PCa cells 
containing slightly higher intracellular E1 than the normal and benign tumour 
prostate cells (Figures 21a & b). 
93 
 
Average Conc. of E1 in Prostate  Cells










































Trtment3-10%FBS w 10nM E2
Trtment 4-10%CD-FBS
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Trtment3-10%FBS w 10nM E2
Trtment 4-10%CD-FBS
Trtment 6-10%CD-FBS w 10nM E2





























Figures 21(a) Average Intracellular Measurements of E1 between the two 
passages Using two-way Annova with Bonferoni post-test corrections, all cell 
lines have insignificant differences in intracellular levels of E1 across all 
treatments with p-values >0.05 (b) Individual Intracellular Measurements of E1 in 








Type of Cell 
Line 
Av. Conc. Of Estrogens in Different Treatments  
nM  
pmole/ million cells 
Std Dev 
 
  (1) 
10 % FBS 
(2) 
10 % FBS + 10 
nM E2 
(3) 
10 % CD-FBS 
(4)  
10 % CD-FBS + 10 
nM E2 
RWPE-1 
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Trtment3-10%FBS w 10nM E2
Trtment 4-10%CD-FBS
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Trtment 3-10%FBS w 10nM E2
Trtment 4-10%CD-FBS
Trtment 6-10%CD-FBS w 10nM E2





























Figures 22(a) Average Intracellular Measurements of E2 between the two 
passages Using two-way Annova with Bonferoni post-test corrections, all the PCa 
cell lines have significant diffences in intracellular levels of E2 (p-values <0.001) 
between treatments with and without excess E2 added in media. (b) Individual 





Intracellular levels of E2 under the 4 different treatments ranged from 0.002715 to 
0.07898 pmole/ million cells (Table 12). This goes in line with the observations to 
the detected E1 values mentioned earlier. The detected intracellular E2 values 
here as compared against the reported intracellular E2 values for PCa cells like 
PC-3 (0.154 pmole/million cells) and DU-145 (0.102 pmole/million cells) (Xu & 
Veenstra, 2012) were also approximately a magnitude lower. When cultured under 
conditions that contain additional 10 nM E2 (treatments 3 and 6), there were 
much higher intracellular E2 detected in all the PCa cells than in the normal and 
benign tumour prostate cells (p-values < 0.001) (Figures 22a & b). Even though 
prostate cells contained high levels of ERs, it could not explain the significant 
differences in the intracellular E2 observed between the PCa cells and the normal 
and benign prostate cells when cultured under excess E2. A plausible explanation 
behind this is due to the mutated ARs in these PCa cells that could cause them to 
be promiscuous (Mao et al., 2009; Amaral et al, 2012; Karantanos et al., 2015) 
and enable structurally similar steroids such as E2 to be taken and bind and 
activate these mutated ARs. Hence, a much higher intracellular E2 was detected in 
these PCa cells, especially under excess E2 as it can be more readily taken in by 
these PCa cells not only to bind and activate the ERs but also to bind and activate 
the promiscuous ARs, causing the large difference. 
  
Fold Response of Prostate Cells Extracts on
ER-Transfected HeLa Luciferase Reporter Gene Assay










T3: 10% FBS with 10 nM E2
T4: 10% CD-FBS






























Fold Response of Prostate Cells Extracts on
ER-Transfected HeLa Luciferase Reporter Gene Assay













T3: 10% FBS with 10 nM E2
T4: 10% CD-FBS






























Figures 23. (a) Biological Responses of the Cell Lysates from Different 
Treatments using ERα- and (b) ERβ-Transfected HeLa Luciferase Reporter Gene 
Assay. Using two-way Annova with Bonferoni post-test corrections, all the PCa 
cell lysates from treatments with and without excess E2 displayed significant 
differences in ERβ (p < 0.0001), whereas only C4-2 and C4-2B lysates from 






Stably ERα- and ERβ-transfected HeLa cells were used for the luciferase assays 
where the use of the common HeLa cell line can serve as a common ground for 
fair comparison to elicit ERα and ERβ biological responses respectively from 
across the whole cell extracts of the different cell lines.  
Normal and benign tumour prostate cell extracts under all the different conditions 
displayed minimal or negligible ERα and ERβ responses respectively from both 
ERα and ERβ luciferase assays (Figures 23a & b). On the other hand, PCa cell 
extracts from androgen sensitive, LNCap, and CRPC cells like C4-2, C4-2B 
displayed relatively higher ERα responses equivalent to 0.1 to 1 nM E2 
(equivalent to 0.01 to 0.1 pmole/million cells) when these cells were cultured 
under additional 10 nM E2 (Figure 23a). In addition, all the PCa cells extracts 
cultured under excess E2 exhibited significantly higher ERβ responses, equivalent 
to responses from 0.01 to 0.1 nM E2 (Figure 23b). These correlated well with the 










3.4.5 MTS Proliferation Assay using the PCa Cell Extracts under Different 
Treatments  
Proliferation of Prostate Cells using its












































































































































































































T3: 10% FBS with 10 nM E2
T4: 10% CD-FBS































Figure 24. Proliferation of Prostate Cells after Treatment with Cell Extracts 
subjected to Different Culture Conditions 
 
As mentioned in Chapter 2, the respective cell extracts under different treatments 
were treated on their own type of cells for 48 hrs before readout. MTS reagent 
was added and incubated for 1 to 4 hrs and readout was performed at every hour. 
The cell extracts readout reached saturation at the first hour of incubation.   
As compared to the negative control, methanol and positive control, 10 nM E2, 
only the normal epithelial RWPE-1 and the CRPC representative cell type, 
CWR22Rv1 can induce much higher proliferation on its own type of cells under 




3.5 Summary of Results 
Among the prostate cells tested, intracellular E1 ranged from 0.00236 to 0.006963 
pmole/ million cells and intracellular E2 ranged from 0.002715 to 0.06385 pmole/ 
million cells. There were similar intracellular E1 trends across all treatments with 
the PCa cells, with slightly higher intracellular E1 than the normal and benign 
tumour prostate cells.  
When cultured under conditions that contained additional 10 nM E2, there were 
relatively higher intracellular E2 detected only in the PCa cells but not the normal 
and benign tumour prostate cells. These LC-MS/MS results were well-correlated 
to the biological responses of the ERα- and ERβ-transfected HeLa luciferase 
assays. A plausible explanation for this is apart from the abundance of ER that 
allows for estrogens to bind in prostate, PCa cells can also contain promiscuous 
AR allowing for more estrogens with highly similar structures to androgens to 





Dimethoxycurcumin as a potential AKR1C3 Enzyme Inhibitor for 
Treatment of Castration Resistant Prostate Cancer (CRPC) 
4.  Introduction 
Castration resistant prostate cancer (CRPC) patients have been associated with 
poor median survival rate of approximately 30 months (Hamid et al., 2012). 
Intracrine synthesis of the potent androgens such as T and DHT has been reported 
as one of the main causes of CRPC (Hamid et al, 2012). Apparently at this stage 
of the disease, it is still androgen dependent as patients responded to anti-
androgen treatments such as Enzalutamide (XTANDI®), and Abiraterone 
(ZYTIGA®) (Sternberg, 2012; Adeniji et al., 2013).  
Abiraterone (ZYTIGA®) is a CYP17A1 inhibitor that blocks the conversion of 
pregnenolone and progesterone into their 17-hydroxylated forms of pregnenolone 
and progesterone (Hamid et al., 2012; Sternberg, 2012; Adeniji et al., 2013). This 
in turn results in a reduction in the downstream androgens. It seemed quite 
effective as a CRPC treatment as it was found to be able to improve the median 
survival duration for up to another 4 months (Acar et al., 2013; Karantanos et al., 
2013). As such, it was approved by the FDA for CRPC treatment. Unfortunately, 
this drug alone can lead to serious side effects. It can prevent the metabolism of 
glucocorticoid, which will lead to the accumulation of desoxycorticosterone 
(DOC) resulting in hypokalemia, fluid retention and/or serious hypertension 
(Attard et al., 2009; Hamid et al., 2012; Adeniji et al., 2013). Thus, this drug is 
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normally co-administered with prednisone to suppress the hypothalamic–
pituitary–adrenal axis (Richards et al., 2012). However, despite this drug 
combination, more than half of the patients continue to develop a secondary 
mineralocorticoid excess (Richards et al., 2012), which will require the further 
addition of an aldosterone antagonist. Moreover, recent findings suggest that 
prednisone has the potential to activate AR, which might eventually lead to 
resistance against Abiraterone treatment for CRPC (Richards et al., 2012).  
Another promising drug that was also recently approved for CRPC treatment for 
patients who do not respond to docetaxel treatment is Enzalutamide (XTANDI®). 
Enzalutamide is an AR antagonist where it inhibits androgen-AR binding and 
nuclear translocation and also prevents the AR complex DNA binding (Sternberg, 
2012; Golshayan & Antonarakis, 2013). As a result, it can prevent AR signaling 
that will eventually lead to AR degradation (Acar et al., 2013; Karantanos et al., 
2013). Nevertheless, this drug has limitations as well since it has been associated 
with dose-limiting central nervous system (CNS) seizures (Adeniji et al., 2013). 
With the severe associated side effects to these currently approved CRPC 
treatment drugs, tremendous interest continues in search for a better treatment 
strategy. Evidence has shown that AKR1C3, an enzyme involved in the 
conversion of adrenal androgens into T, is often upregulated in CRPC patients 
(Adeniji et al., 2013; Yepuru et al., 2013). There were also reports that AKR1C3 
is often low or negligible in normal prostate epithelia but highly expressed in 
localized, advanced, and recurrent PCa and CRPC (Dozmorov et al., 2010). In 
addition, since AKR1C3 acts downstream of CYP17A1-hydroxylase and 
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CYP17A1-lyase, its inhibition will not interfere with the glucocorticoid 
metabolism (Adeniji et al., 2013). As such, since AKR1C3 plays a pivotal role in 
androgen biosynthesis and is highly localised and does not interfere with 
glucocorticoid metabolism, it is expected that selective inhibition of AKR1C3 
will have less side effects and inevitably becomes a reasonable target for CRPC 
treatment (Adeniji et al., 2013; Liedtke, 2013).  
In recent years, there has been huge interest in the scientific arena to identify 
novel compounds that not only degrade ARs, but also act as inhibitors to 
AKR1C3 enzyme (Adeniji, et al., 2013). Dimethoxycurcumin (ASC-J9®) is a 
novel, synthetic derivative of curcumin, which has been reported to be an 
effective AR degradation enhancer (Yamashita et al., 2012; Lai, et al., 2013). 
More importantly, there have been minimal side effects with its use and it has not 
shown any effects on weight and sexual libido in in vivo mice models (Lai, et al., 
2013). In addition, reports have also shown that curcumin and its derivatives can 
act as effective inhibitors to some members of the AKR family of enzymes 
(Matsunaga et al., 2012). Thus, it is of immense interest in this study to 
investigate if this AR degradation enhancer, dimethoxycurcumin could also act as 
an AKR1C3 enzyme inhibitor. To the best of our knowledge, no studies have 
been conducted to investigate if this drug can act as an AKR1C3 enzyme 
inhibitor. If this is possible, then this drug would not only hold great potential for 
CRPC treatment, but also for other steroid-driven AKR1C3 dependent diseases 




Currently, there are three known isoforms to the AKR1C3 enzyme, namely 
AKR1C1, AKR1C2 and AKR1C4 (Dozmorov et al., 2010; Byrns et al., 2011). 
Thus, is it is imperative to ensure that the drug is selective towards AKR1C3 and 
not the other isoforms, so that side effects can be minimised. Fortunately, one of 
the isoforms, AKR1C4 is present only in liver (Byrns et al., 2011) and not in 
prostate. As such, greater emphasis was placed on AKR1C1 and AKR1C2, with 
more than 86 % sequence similarity to AKR1C3 in the prostate (Dozmorov et al., 
2010). AKR1C1 and AKR1C2 are critical for catalyzing the conversion of DHT 
to 5α-androstane-3β,17β-diol (3β-Diol) and 5α-androstane-3α,17β-diol (3α-Diol) 
respectively (Byrns et al., 2011). These processes help to catabolize and 
deactivate DHT within the prostate, which are crucial for the treatment of CRPC. 
3α-Diol is an inactive androgen to AR (Dondi et al., 2010; Adeniji et al., 2012) 
when kept under the maximum threshold level, while 3β-diol is a selective ligand 
for ERβ (Guerini et al., 2005; Picciarelli-Lima et al., 2006; Dondi et al., 2010). 
Thus, selectivity of inhibition towards AKR1C3 is imperative for the effective 
reduction in the levels of T and DHT and to prevent interferences to the 
deactivation processes of DHT. In this study, an attempt was made to investigate 
dimethoxycurcumin’s ability to show inhibition towards AKR1C3 and more 
specifically, to show selective inhibition of AKR1C3 over AKR1C1 and 






Cell lines HepG2, MCF-7, LNCap and CWR22Rv1 were obtained from American 
Type Culture Collection (ATCC). C4-2 and C4-2B were from gifts from Prof 
Yong Eu Leong’s lab.   
Dihydroepiandrosterone (DHEA), Dihydrotestosterone (DHT), internal standard, 
deuterated-estradiol (d5-E2), hydroxylamine hydrochloride and indomethacin of 
purity 97 % were all obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Androstenedione (A4) and Testosterone (T) were purchased from Toronto 
Research Chemicals (New York, ON, Canada). 5α-androstane-3β,17β-diol (3β-
Diol) and 5α-androstane-3α,17β-diol (3α-Diol) were purchased from Steraloids 
(Newport, RI, USA). Dimethoxycurcumin (ASC-J9®) was obtained from 
Invitrogen (Shanghai, China). Internal standard, deuterated-testosterone (d3-T) of 
purity 98 % was obtained from CDN isotopes Inc (Pointe-Claire, Quebec, 
Canada). 
Solvents used for LC-MS/MS measurement were all of HPLC grade, unless 
otherwise stated. Formic acid, methyl tert butyl ether (MTBE) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), Acetonitrile (ACN), and methanol 
(MeOH) were purchased from Merck (Darmstadt, Germany). Ultra-pure water 
was obtained using Milli-Q water purification system (Millipore, Bedford, MA, 
USA).  
Cell Titer 96® Aqueous non-radioactive cell proliferation assay (MTS reagent) 
was purchased from Promega (Madison, WI, USA). Phosphate Buffered Saline 
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(PBS) and Tris buffer were from Vivantis Technologies Sdn Bhd (Selangor Darul 
Ehsan, Malaysia). Primary antibody of β-actin, Bovine Albumin Serum (BSA), 
Phenol red free RPMI-1640, Phenol red free Eagle’s MEM media, 
Tetramethylethylenediamine (TEMED), β-mecaptoethanol, sodium fluoride 
(NaF), sodium vanadate (Na3VO4) and non-fat dry skim milk were from Sigma-
Aldrich (St. Louis, MO, USA). Phenol red free, high glucose Dulbecco Modified 
MEM was from Life technologies (Green Island, NY, USA). AKR1C3 Primary 
antibody, Fetal Bovine Serum (FBS), RIPA lysis buffer, ECL plusTM 
luminescence kit and protein ladder were obtained from Thermo Scientific 
(Rockford, IL, USA). Charcoal Dextran stripped Fetal Bovine Serum (CD-FBS) 
was treated with charcoal to remove most of the endogenous steroids. Protesase 
Inhibitor Cocktail (PI) and Phenylmethylsulfonyl fluoride (PMSF) were from 
Roche (Indianapolis, IN, USA). Bradford dye and Acrylamide were from BioRad 
Laboratories (Hercules, CA, USA). Sodium Dodecyl Sulfate (SDS) was from TCI 
(Tokyo, Japan). Ammonium Persulphate (APS) was from USB Corporation 
(Cleaveland, OH, USA). AKR1C2 primary antibody was obtained from Cell 
Signaling Technology (Beverly, MA, USA). ECL select™ was purchased from 
GE Healthcare (Buckinghamshire, UK) and secondary antibody of rabbit origin 







4.2.1 Determination of the Presence of AKR1C3 Enzyme in Various PCa 
Cells Lines using Western Blot Analysis 
4.2.1.1 Cell culture for Western Blot Analysis 
Five types of cell lines were cultured. HepG2, a liver cancer cell line, was used as 
the positive control as it is known to express AKR1C3 enzyme. The other 4 cell 
lines were the same PCa cell lines mentioned earlier in Chapters 2 and 3. They 
are androgen-dependent PCa cell line, LNCap and androgen-independent (or 
CRPC type) PCa cell lines, C4-2, C4-2B and CWR22Rv1. All the PCa cell lines 
were cultured in phenol-red free RPMI media with 10 % FBS and 1 % L-
glutamine under the usual culture conditions at 37 oC at 5% CO2 in humidified 
conditions. Only HepG2 was cultured in phenol-red free MEM media with 10 % 
FBS and 1 % L-glutamine. Each type of cells were cultured in T75 flask and 
collected when they reached 90 % confluency. The collected cells were washed 
with cold 1x PBS followed by centrifugation at 1000 rpm for 3 mins and the 
supernatant was aspirated off. This process was repeated and the cell pellets were 
kept immediately at -80 oC before cell lysis.  
 
4.2.1.2 Cell Lysis  
Sufficient volume of RIPA lysis buffer was prepared prior to cell lysis. For 1 mL 
of the buffer, 5 µL of 200 mM of NaF, 5 µL of 200 mM Na3VO4, 100 µL of 10x 
PI and 10 µL of 100 mM PMSF was added into 880 µl of RIPA solution. PMSF 
was added last among the reagents as the buffer will start to degrade within half 
109 
 
hour upon its addition. After preparation, the lysis buffer was placed on ice. The 
volume of 1 x RIPA lysis buffer added was 5 times the volume of the cell pellet in 
the tube. Cell pellets were re-suspended by vortexing vigorously. The re-
suspended cells in lysis buffer was placed back on ice and incubated for another 
30 mins. During the incubation on ice, cells were vortexed vigourously for four 
times to ensure complete lysis. The tubes with the lysates were centrifuged at the 
highest speed of 14100 rpm for 15 min at 4 oC. Supernatants were transferred into 
clean eppendorf tubes on ice. The protein concentrations were measured 
immediately after the collection using the Bradford protein measurement assay. 
All the collected cell lysates were appropriately aliquoted into tubes for ease of 
use later and were stored at -80 oC. 
 
4.2.1.3 Bradford Protein Measurement Assay  
The protein concentrations of the respective cell lysates were determined by 
quantifying against a 10-point calibration curve using the bovine serum albumin 
(BSA) as the standard. Using a 96-well plate, appropriate volumes of BSA and 
ultrapure water was added into each well as shown in the table to make up a total 
volume of 80 µL.  
 1 2 3 4 5 6 7 8 9 10 
Conc. Of protein 
(µg/ml) 
0 5 10 20 30 40 50 60 70 80 
Vol. of BSA added 
(µL/100 µg/ml) 
0 5 10 20 30 40 50 60 70 80 




Afterwhich, 20 µL of Bradford dye was added to each well to make up a final 
volume of 100 µL mixture. Triplicates of each concentration of the BSA standards 
were determined. For the cell lysates, 1 µL of each cell lysate was added to 79 µL 
of ultrapure water, followed by 20 µL of the Bradford dye. The 96-well plate was 
shaken gently to ensure uniformity in each well before measurements using the 
Tecan, Magellan version 6.5 software. The calibration curve and concentrations of 
the proteins in the samples were analysed using Microsoft Excel 2010. The final 
concentrations of the measured proteins were multiplied by 100 times in this case 
before dilution.  
After obtaining the protein concentrations of the samples, the loading volumes of 
each protein and their respective volumes of 4x SDS loading buffer were 
calculated. Loading volume was calculated in µL by dividing the desired loading 
mass to the respective concentration (µg/µl) of each of the protein that was 
measured earlier on. Usually, approximately 30 µg of each protein from each cell 
lysates was loaded initially before further adjustments.  
 
4.2.1.4 Western Blot Analysis 
4.2.1.4.1 Gel Casting 
Running gel mixture was prepared first. 10 % of 1.5 mm thick gel was casted 
here. Depending on the percentage of the running gel desired and the number of 
gels to be casted, appropriate volumes of the gel mixture was prepared (refer to 
Appendix XIII). For 20 ml of 10 % gel, 10 mL of water, 5 mL of acrylamide, 5 
mL of 1.5 M tris buffer of pH 8.8, 0.2 mL of SDS, 0.2 mL of APS and 60 µL of 
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TEMED was added into a 50 mL falcon tube and gently mixed. APS and TEMED 
was added last as TEMED will cause the mixture to coagulate. The running gel 
mixture was loaded into the slits of the glass plates until appropriate height. Water 
was added immediately to help to smoothen edges and compress the gel mixture. 
This was allowed to stand for 10 to 15 mins for complete gelling. While waiting, 
appropriate volume of stacking gel mixture was prepared by adding similar 
reagents as in the running gel mixture (refer to Appendix XIII). However, tris 
buffer of pH 6.8 was used instead of pH 8.8. Water that was added earlier was 
decanted and the stacking gel mixture was loaded into the slits of the glass plates 
to the brim of the plates. A clean comb with the desired number of wells was 
inserted to create the wells for loading the proteins. The mixture was allowed to 
stand to gel.  
After the gels are casted, they were placed together with the glass plates into the 
chamber and 1x running buffer was poured into the hollow spaces between and 
outside the two plates containing the gels.  
 
4.2.1.4.2 Denaturation of Proteins and Sample Loading 
A 4X loading buffer (or 4x SDS Protein Sample Buffer) was used, so, for every 
three parts of proteins, one part of loading buffer was added. For 40 µL of 4x SDS 
loading buffer, 4 µL β-mercaptoethanol was added to 36 µL of bromophenol blue 
mixture (refer to Appendix XIV) prepared earlier. Suitable volume of each 
protein was transferred to clean PCR tube and appropriate loading buffer was 
added to each tube and vortexed. These tubes of proteins were heated and 
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denatured for 5 mins using the heating block that was pre-heated to 95 oC. They 
were allowed to cool and centrifuge briefly to be ready for loading.  
The previously calculated total volume of the samples with their loading buffers, 
together with a 5 µL of the protein ladder were loaded into each well of the casted 
gel. Gel electrophoresis was used to run the loaded samples with an initial voltage 
at 80V for a slow but better separation. This was maintained for 2 hrs before 
increasing the voltage to 120 V for another hr. The run was stopped when the 25 
kDa line of the ladder ran out of the gel. 
 
4.2.1.4.3 Transfer of Bands from Gel to Membrane and Addition of AKR1C3 
Antibody 
The filter papers were pre-soaked in 1x transfer buffer. Membrane for transfer 
was marked at the corner to indicate the front surface. It was activated by soaking 
the membrane with methanol. A piece of soaked filter paper was placed on the 
blotting machine, followed by the activated membrane with the marked corner 
facing upwards, then the gel and lastly, another piece of soaked filter paper. With 
each step of stacking, air bubbles were carefully squeezed out using the roller. 
Excess transfer buffer was poured over the stack and covered with the compressor 
lid and the cover of the blotting machine. The transfer process was conducted at 
23 V for 70 mins. After the bands were transferred to membrane, unwanted 
proteins were blocked with 5% w/v non-fat dry milk in 1x PBS by gentle shaking 
for 1 hr. The milk was rinsed off with 1x PBST twice before transferring the 
membrane into 50 mL falcon tube, containing 5 µL of AKR1C3 primary antibody 
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to 5 mL (1000X dilution) of  5% w/v non-fat milk in 1x PBS and rotated 
overnight at 4 oC in cold room.  
 
4.2.1.4.4 Addition of Secondary Antibody for AKR1C3 
After rotating overnight, the membrane was rinsed and shaken vigorously at 115 
rpm for 5 mins with 1xPBST to remove as much of the unwanted proteins as 
possible. This process was repeated thrice. The membrane was then transferred to 
another 50 mL falcon tube containing 10 mL of 5% w/v non-fat dry milk with 1 
µL (10000X dilution) of secondary antibody of rabbit origin and rotated for 1 hr. 
Afterwhich, the rinsing process was repeated thrice with 1x PBST at 115 rpm for 
5 mins each.  
 
4.2.1.4.5 Film Development 
The luminescence reagent, ECL plusTM was prepared by mixing 1 mL of 
luminescence buffer and 25 µL of the luminescence enhancer reagent. The 
membrane was placed on the developer with attached plastic sheet and about 100 
µL of luminescence reagent was added onto the surface of the membrane and 
spread across the desired band locations and covered with the plastic sheet and 
closed. For AKR1C3, the molecular weight is at 37 kDa. In the dark room, the 
film was then placed onto the membrane covered with the plastic sheet. Once 





4.2.1.4.6 Standardisation via checking on β-actin  
β-actin was developed from the same membrane to check for standardization of 
the loaded proteins. The membrane was rinsed with 1xPBST and shaken at 115 
rpm for 5 mins to remove the luminescence reagent. It was then shaken with 
stripping buffer at pH 2 at 115 rpm for 5 mins. The membrane was transferred to 
50 mL falcon tube containing 5 µL of primary antibody for β-actin was added to 5 
mL of milk (1000X dilution) and rotated for 1 hr at room temperature. Rinsing 
with 1x PBST was performed thrice as mentioned previously. Membrane was 
then transferred to 50 mL falcon tube containing 1 µL of secondary antibody of 
mouse origin into 10 mL 5 % w/v of non-fat dry milk (10000X dilution) and 
rotated for 1 hr. Rinsing was performed thrice with 1x PBST. Film development 
was done and ECL plus was used as the luminescence reagent here. For β-actin, 
the molecular weight is 42 kDa. 
 
4.2.2 Determination of Saturating Doses of Known AKR1C3 Inhibitor and 
Dimethoxycurcumin and its Potential as AKR1C3 Enzyme Inhibitor 
4.2.2.1 Preparation of Drugs in Different Concentrations 
Indomethacin, an NSAID drug and also a known AKR1C3 selective inhibitor was 
chosen as the positive control. Both indomethacin and dimethoxycurcumin was 
prepared in acetonitrile (ACN) as they can dissolve very well in this solvent. 
Thus, ACN was used as the negative control here. The two drugs were each 
prepared with 9 concentrations of 0.05 µM, 0.5 µM, 5 µM, 50 µM, 0.5 mM, 1.25 
mM, 2.5 mM, 5 mM and 50 mM in ACN and stored at -20 oC, wrapped in foil. 
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4.2.2.2 Preparation of Drugs in Different Doses in Media 
The drugs prepared in ACN were vortexed to ensure that the drugs were 
completely dissolved before spiking into the media. 50x dilution was performed 
for each dose of the drug where 2 µL of each dose of drug in ACN was spiked 
into 98 µL of 10 % CD-FBS phenol-red free RPMI media for each well in the 96-
well plate. This resulted in final drug doses of 1 nM, 10 nM, 100 nM, 1 µM, 10 
µM, 25 µM, 50 µM, 100 µM and 1 mM in media. Triplicates for each dose of 
each drug were performed. ACN was spiked into the media with the same dilution 
factor as the negative control. These drugs in media were prepared a day prior to 
treatment and kept at 4 oC.  
 
4.2.2.3 MTS Cell Proliferation Assay on CRPC Cell containing AKR1C3 
enzyme  
Approximately 10,000 of the verified AKR1C3-positive CRPC cells were seeded 
into each well of the 96-well plate with 100 µL of 10 % CD-FBS phenol-red free 
RPMI media. It was cultured at 37 oC with 5 % CO2 under humidified conditions 
and allowed to adhere for 24 hrs.  
After 24 hrs, the media was aspirated and replaced with the media spiked with the 
doses of drugs as mentioned in section 4.2.2.2. Triplicates of the respective blank 
media were added and measured for background subtraction. 2 µL of ACN was 
spiked into 98 µL of media as the negative control for fold-induction calculation. 
The treatment of the different doses of drugs on the cells was tested separately for 
24-hr and 48-hr periods respectively for the optimal treatment duration. After the 
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intended treatment duration, 25 µL of the MTS reagent was added to each well 
and incubated till saturation. The 96-well plate was analysed using the Tecan, 
Magellan version 6.5 software after the 1st, 2nd, 3rd and 4th hour of incubation after 
addition of the MTS reagent. Experiments were repeated twice and each time 
triplicates of each dose of each drug were analysed. Graphpad prism version 5 
was used to analyse the data. 
 
4.2.3 Investigation of Dimethoxycurcumin using LC-MS/MS as a Potential 
Drug Treatment for CRPC via Multiple Enzymatic Pathways  
4.2.3.1 Preparation of Different Doses of Drugs  
The doses of drugs in the media for dose dependent curve were prepared similarly 
as in section 4.2.2.2 for MTS assay. However, 10 mL for each dose of each drug 
was prepared here, so 0.2 ml of drug of each dose in ACN was spiked into 9.8 mL 
of media instead.  
 
4.2.3.2 Culture of CWR22Rv1 for Dose Dependent Curve 
Among the PCa cell lines tested, only CWR22Rv1 was identified to endogenously 
express AKR1C3 enzyme strongly. Based on western blot analysis, a total of 
nineteen 100 mm culture dishes seeded with CWR22Rv1 were cultured. It was 
cultured initially in phenol red free RPMI media, supplemented with 10 % FBS at 
37 oC at 5% CO2 in humidified conditions. After 24 hrs, the media was changed 
to media with 10 % CD-FBS. When the cells reached 70 to 80 % confluency, 
each dish of cells were treated individually with the different doses of drugs 
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prepared in media as mentioned in section 4.2.3.1.  All the dishes of cells were 
treated for 48 hrs based on the optimal treatment duration and passaged.  During 
the passage, the collected cells were kept in 15 mL centrifuge tubes and 
centrifuged under 4 oC at 1000 rpm so as to enable the aspiration of the media. 
These tubes were then kept in ice during the entire working process. Each tube of 
collected cells was rinsed twice with 10 mL of cold 1x PBS each time. The cells 
were counted using a hemocytometer. In order for division of the collected cells 
into approximately 1 million cells per 100 µL of 1x PBS solution, 1 mL of 1x 
PBS solution was added for every 10 million cells. Thus, the volume of cold 1x 
PBS to be added to the collected cells was based on the number of cells counted 
earlier and calculated using the following equation: 
Vol of 1x PBS to be added to collected cells = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑖𝑛 4 𝑠𝑚𝑎𝑙𝑙 𝑐𝑜𝑟𝑛𝑒𝑟 𝑠𝑞.÷ 4 ×10000 × 𝑉𝑜𝑙.𝑜𝑓 𝑠𝑢𝑠𝑝𝑒𝑛𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
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The cells in the added volume of 1x PBS was re-suspended and vortexed at slow 
speed to ensure that the cells were evenly suspended. 100 µL of the suspended 
cells was transferred quickly into each of the 1.5 mL microcentrifuge tubes. For 
each treatment, at least 2 x 3 = 6 tubes of cells in PBS were collected for different 
assays. Triplicates of the cells for each treatment were used for each assay. 
Experiment was repeated for the subsequent passage to see if the results were of 
similar trend. Cells collected and measured were kept within narrow passages to 
ensure repeatability of results. All the tubes of cells collected were immediately 
stored at -80 ºC before extraction and LC-MS/MS analysis.  
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4.2.3.3 Culture of CWR22Rv1 under Saturating Doses of Drugs 
A total of eighteen 100 mm culture dishes of CWR22RV1 cells were cultured. 
Culture conditions in these dishes of cells were the same as mentioned in section 
4.2.3.2, prior to treatment. The final saturating doses of indomethacin and 
dimethoxycurcumin were 1 mM and 50 µM respectively, spiked into the culture 
media. The 6 culture conditions were T1: 10 % CD-FBS (To simulate condition 
after castration) (Negative control); T2: 10 % CD-FBS + 1 mM indomethacin 
(Positive Control); T3: 10 % CD-FBS + 50 µM dimethoxycurcumin; T4: 10 % 
CD-FBS + 0.1 µM A4 (Negative control); T5: 10 % CD-FBS + 0.1 µM A4 + 1 
mM indomethacin (Positive Control); T6: 10 % CD-FBS + 0.1 µM A4 + 50 µM 
dimethoxycurcumin. For each culture condition, 3 dishes of cells were treated for 
48 hrs based on the optimal treatment duration and passaged. During the passage, 
the collected cells were kept in 15 mL centrifuge tubes and centrifuged under 4 oC 
at 1000 rpm so as to enable the aspiration of the media. 1 dish of each treatment 
was kept for western blot analysis. The other two dishes of each treatment were 
used for LC-MS/MS analysis and were counted and aliquoted as described in 






4.2.3.4 Preparation and Extraction of Calibration Standards and Quality 
Controls 
All the stock and standards of dihydroepiandrosterone (DHEA), androstenedione 
(A4), testosterone (T), dihydrotestosterone (DHT), 5α-Androstane-3α,17β-diol 
(3α-Diol) and 5α-Androstane-3β,17β-diol (3β-Diol) were stored at -20 oC and 
wrapped with foil. Calibration curves were established with each of the 
compounds in 1g/L of PBS/BSA. The calibration standards were prepared by 
spiking 20 µL of each of the standard mixture of DHEA, A4, T, DHT, 3α-Diol 
and 3β-Diol in methanol into 80 µL of PBS/BSA to make up 100 µL of final 
sample. As such, the final calibration standards prepared for the six analytes, 
DHEA, A4, T, DHT, 3α-Diol and 3β-Diol ranged from 0.01 to 20 nM in the 
PBS/BSA. 10 µL of internal standard mixture of 5 nM, d3-T and 500 nM of d5-E2 
was spiked into each of the 100 µL sample. Four QCs with concentrations 0.05 
nM, 0.5 nM, 2 nM and 10 nM were also prepared in the 1g/L PBS/BSA matrix. 
These samples were extracted using liquid–liquid extraction with 1 mL MTBE 
each and vortexed vigorously for 2 mins. They were centrifuged at 13,000 rpm for 
3 mins at room temperature. Supernatants were transferred into clean eppendorf 
tubes. Extraction was repeated twice in all and extracts were combined and dried 
under nitrogen gas at 40 oC. The dried residue was reconstituted with 60 µL of 0.1 
M hydroxylamine hydrochloride in 3:7 methanol:water and reacted at 70 oC for 
15 mins. Samples were cooled and centrifuged at 14,000 rpm for 1 min. 20 µL of 




4.2.3.5 Preparation of Stability Tests Samples 
Triplicates of the four QCs mentioned in section 4.3.2.4 in 1g/L of PBS/BSA 
were prepared. For determination of freeze-thaw stability of the androgens, one 
set of triplicates of these four QCs were stored at -80 oC after preparation and 
subsequently subjected to three freeze-thaw cycles over three days. For long term 
stability test, one set of triplicates of these four QCs samples were stored at -80 oC 
for a month till day of analysis. Lastly, for short term stability tests, triplicates of 
the four QCs were left at room temperature of 24 oC for 4, 6, 8 and 24 hrs 
respectively before analysis. For all the stability samples, the measurements were 
compared against measurements from triplicates of a reference set with the same 
concentrations of the respective androgens but freshly prepared on the day of 
extraction and analysis. All these samples, including the reference set, were 
spiked with 10 µL of internal standard mixture of 5 nM of d3-T and 500 nM of d5-
E2 on the day of analysis before extraction. 
 
4.2.3.6 Preparation and Extraction from Cell Samples  
Each tube of cell sample containing approximately 1 million cells in 100 µL of 1x 
PBS were thawed at room temperature. A 10 µL of internal standard mixture of 5 
nM d3-T and 500 nM d5-E2 was spiked into each of the sample. 1 mL of MTBE 
was added to each tube of sample and sonicated in water bath sonicator at 4 oC for 
10 mins to ensure complete extraction. Similar extraction procedure for the 
standards and quality controls as mentioned in section 4.2.3.4 was performed. 
Instead of centrifuging at 13,000 rpm, the cell samples were centrifuged at a 
121 
 
slower speed 6,000 rpm for 5 mins for the first round of extraction and only 
increased to 13,000 rpm during the last round of extraction. Supernatant for each 
sample was transferred to 2 mL eppendorf tubes. The entire extraction process 
was repeated again from the addition of MTBE. The supernatants were combined 
and dried under nitrogen gas at 40 oC and similar derivatisation process as 
mentioned in section 4.2.3.4 was adhered here before injection for LC-MS/MS 
detection. Triplicates of each cell line under each treatment were measured. 
 
4.2.3.7 LC-MS/MS Analysis  
UPLC was carried out on an Agilent 1290 Infinity liquid chromatography system 
with a binary pump. An Agilent Eclipse Plus C18 RRHD (2.1 mm × 50 mm, 1.8 
µm particle size) column was used for separation. The mobile phase consisted of 
two eluents, solvent A (ultrapure water with 0.1 % formic acid) and solvent B 
(acetonitrile) delivered at a flow rate of 0.5 ml/min and at column temperature at 
40 oC. 20 µL of each sample was injected into the LC-MS/MS, after which the 
injector needle was washed with flush port with washing liquid (acetonitrile). The 
column was equilibrated at 20 % B and it was increased to 40 % B within 0.5 
mins and maintained at this condition up till 1.5 min. Afterwhich, B was increased 
to 60 % within 0.1 mins and maintained for another 0.9 mins. Subsequently, B 
was increased to 90 % at the 3rd min of the sample run. This was maintained for 
another min and decreased to 20 % during 1 min duration and maintained at this 
condition for another minute. During the run, the first 0.8 mins was diverted to 
waste and the next 0.8 to 3.5 mins was diverted to MS detector and subsequently 
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diverted to waste again till end of run. Total runtime was 6 mins and the flow rate 
was kept constant at 0.5 mL/min throughout. During the detection, the samples 
were kept in the autosampler at 6 oC. 
The separated analytes was analyzed by an Agilent 6490 Triple Quadrupole 
(ifunnel) mass spectrometer equipped with Agilent Jet Stream (AJS) ESI source 
operated under ESI positive ion mode. Multiple reaction monitoring (MRM) was 
used for the quantification. The optimized MS parameters used were delta EMV: 
+250 V; and source parameters used were gas temperature: 200 oC; gas flow: 14 
L/min; Neubuliser: 20 psi; Sheath gas temperature: 250 oC; Sheath gas flow: 11 
L/min; capillary (+): 3000 V; nozzle voltage: 1500 V(+); ifunnel high pressure 
RF: 200 V and low pressure RF: 110 V. The following table shows the MRM 
transitions and their respective optimized collision energies, optimized cell 
accelerator voltage and the retention times for the analytes detected. 















m/z 304 → 253(quantifier) 







m/z 317 → 112(quantifier) 







m/z 304 → 124(quantifier) 








m/z 306 → 105(quantifier) 










m/z 307 → 124(quantifier) 








m/z 257 → 161(quantifier) 









m/z 257 → 161(quantifier) 









m/z 260 → 161(quantifier) 







For the two analytes, 3α-Diol and 3β-Diol, based on their chemical structures, 
they cannot undergo similar derivatisation as the other analytes under the same set 
of conditions. Furthermore, both shared the same MRM transitions as they are 
stereoisomers of each other with only difference in one of their chiral centers. The 
internal standard used for the two diols was d5-E2. Nitrogen gas was used as the 
curtain and collision gas. All data were recorded and processed by using the 
Agilent MassHunter B06.00 (Agilent, Foster City, CA). Concentrations of the 
androgens were quantified using an 11-point calibration curve of peak area ratio 
against the concentration ratio of the analyte to internal standard. One-way Anova 
with Bonferroni post-test correction from Graphpad prism version 5 was used for 
the statistical analysis for p-values. 
 
4.2.3.8 Method Validation 
To determine the accuracy and the coefficient of variation (CV %) of the 
experimental method, interday (n = 9) and intraday (n = 6) assays were performed 
for the androgens in the calibration standards in PBS/BSA. The limit of 
quantification (LOQ) was of signal-to-noise (S/N) ratio of 10:1. Matrix effect was 




4.2.4 Western Blot Analysis for Detection of Changes to AKR1C3 and 
AKR1C2 after Drug Treatment 
Similar procedure was applied here as mentioned in the entire section 4.2.1.4 for 
western blot analysis. The cell lysates analysed here were from cells cultured 
under the three sets of culture conditions, T1: 10 % CD-FBS media; T2: 10 % 
CD-FBS with 1 mM indomethacin and T3: 10 % CD-FBS with 50 µM 
dimethoxycurcumin. Same procedure was adhered for adding primary AKR1C3 
antibody but for adding the primary antibody for AKR1C2, instead of adding 5 
µL of the primary antibody to non-fat milk, it was added to 5 mL of 5 % w/v BSA 
in 1xPBS and rotated overnight at 4 oC in cold room. In this case, ECL select™ 















4.3 Results and Discussions 
4.3.1 Determination of the Presence of AKR1C3 Enzyme in Various PCa Cell 
Lines using Western Blot Analysis  
 
Figure 25. Endogenous Expression of AKR1C3 enzyme found only in 
CWR22Rv1 cell lysate, one of the CRPC cell lines used in this study when 
compared against the postitive control cell line, HepG2. 
 
From the Western blot analysis, among the PCa cell lines used for the current 
study, only the CRPC representative cell line, CWR22Rv1 endogenously 
expressed AKR1C3 enzyme at high levels. This result was in tandem with 
reported findings, where CWR22Rv1 indeed expressed high levels of AKR1C3 
(Byrns et al., 2012; Hamid et al., 2012). As such, this cell line was chosen for this 
study to see if dimethoxycurcumin can act as selective inhibitor towards AKR1C3 











4.3.2 Preliminary Investigation of Known AKR1C3 Inhibitor and 
Dimethoxycurcumin on Proliferation of AKR1C3-positive PCa cell 
Dose-response curves for indomethacin, a well-known selective AKR1C3 
inhibitor (positive control) (Liedtke et al, 2013) and for the drug-of-interest, 
dimethoxycurcumin were obtained using MTS cell proliferation assay. This was 
to gain insights on the suitable range of doses of drugs to be used for conducting 
the subsequent experiments to obtain dose-response curves to specifically study 
the drugs’ inhibition effects on AKR1C1 to 3 using LC-MS/MS measurements. 
Dose-Response Curves of Dimethoxycurcumin and
Indomethacin (positive control)
on Inhibition of Cell Proliferation of CWR22Rv1
after 48 hr treatment
































Figure 26. Dose Response Curves on Inhibition of Proliferation on AKR1C3-
postitive CWR22Rv1 when treated with various doses of Dimethoxycurcumin 
and Indomethacin (positive control drug) using MTS Cell Proliferation Assay. 
 
From the curves, the half maximal inhibitory concentration for proliferation, IC50 
of indomethacin was 163.965 µM and IC50 of dimethoxycurcumin was 24.582 
µM. And the saturating doses for maximal inhibition of proliferation were found 
to be 1 mM for indomethacin and 50 µM for dimethoxycurcumin.  
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4.3.3 Investigation of Dimethoxycurcumin using LC-MS/MS as a Potential 
Drug Treatment for CRPC via Multiple Enzymatic Pathways  
4.3.3.1 LC-MS/MS Method Development for Simultaneous Detection of Six 
Key Androgens  
This LC-MS/MS method was developed to simultaneously detect and quantify six 
key androgens, which are involved in the synthesis and metabolism of T and 
DHT. These include the precursors DHEA, A4, the metabolites of DHT namely 
3α- and 3β-Diols, and lastly, T and DHT. These intracellular androgen levels were 
assessed following treatments with the different doses of dimethoxycurcumin and 
compared with another set treated with the positive control drug, indomethacin. 
IC50 values for the inhibition of the enzymes, ARK1C1 to 3 were elicited from the 
dose-response curves using the measured intracellular androgen levels after 
treatment. Given the structural similarities of these six androgens, it was a 
daunting task to develop a method to quantify them simultaneously as it was 
difficult to achieve maximal separation under the liquid chromatographic (LC) 
conditions. This is particularly challenging for the two diols with identical 
chemical structures, except for the chiral centers. Moreover, the two diols also 
shared the same MRM transitions for their fragmentations, which cannot be 
resolved via MS/MS. As such, LC separation of these two compounds has to be 
achieved before MS detection to minimise the interference. Fortunately, though 
they have the exact structures, they are epimers and theoretically would be able to 
demonstrate differences in physical properties. By carefully manipulating of the 
LC mobile phase conditions, the two epimeric diols were successfully separated, 
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similar to the case of the separation of the epimers of testosterone (Bellemare et 
al., 2005). The separation of the diols (Figure 27), together with the other four 
androgens (Figure 28) was achieved within a short runtime of 6 mins. 
Admittedly, there is cross-talk problem for both compounds but as of now this is 
the best achievable detection.  
Among the six androgens, DHEA, A4, T, DHT could be derivatised with 
hydroxylamine as mentioned in Chapter 2 to enhance their signals. As for the 
two diols, they cannot undergo the same derivatisation reaction if all the analytes 
were to be detected simultaneously within the same sample.  
Furthermore, reacting with hydroxylamine at 70 oC for 15 mins, will result in the 
degradation of the diols by approximately 10 % (data not shown here). But when 
the derivatisation reaction was performed at lower temperature of 60 oC for the 
same amount of time, all the signals were much lower. So, reaction was allowed 
to proceed at 70 oC for 15 mins. 
 






Figure 28. Chromatogram of all the Six Androgens. 
 
4.3.3.2 Validation of LC-MS/MS Method 
Linear regressions with 1/y weighting were obtained for DHEA, A4, T and DHT, 
while linear regressions were also obtained without weighting for the other two 
metabolites of DHT, 3α-Diol and 3β-Diol in 1 g/L of PBS/BSA.  
The acceptable ranges for simultaneous measurements of DHEA, A4, T and DHT 
were from 0.05 to 20 nM and for both 3α-Diol and 3β-Diol were from 0.5 to 20 
nM in the matrix. Most of their obtained regression coefficients, r2 for the 
calibration curves were close to 0.99, except for 3α-Diol with slightly lower r2 of 
close to 0.98. For DHEA, the typical calibration curves equations using PBS/BSA 
was y = 3.023400x + 0.004514. For A4, the typical calibration curves equations 
using PBS/BSA was y = 5.951754x + 0.012070. For T, the typical calibration 









typical calibration curves equations using PBS/BSA was y = 0.809512x + 
0.007938. For 3α-Diol, the typical calibration curves equations using PBS/BSA 
was y = 0.253581x + 0.006101. For 3β-Diol, the typical calibration curves 
equations using PBS/BSA was y = 0.140521x + 0.002804. 
Recoveries and matrix effect were determined using the QCs prepared matrix. 
From the chromatograms of the blank matrix, there were small peaks with the 
same retention times for identification of DHEA, A4 and T in the matrix. As for 
DHT, 3α-Diol and 3β-Diol, no peak at the same retention times was observed in 
the matrix (refer to Appendix XV). Despite the peaks observed with the same 
retention times as DHEA, A4 and T respectively in the matrix, the peaks were 
rather insignificant. So, this implied that the method was quite specific for the 
detection of the six androgens. All the validated values for accuracies and 
coefficient of variation (CV%) were within acceptable ranges according to the 
Guidance for Industry Bioanalytical Method Validation ("Guidance for Industry 
Bioanalytical Method Validation," 2001) for the six androgens (Tables 13 to 18). 
The LOQ values of DHEA, A4 and T were experimentally determined to be 0.05 
nM with S/N ratio of at least 10:1. The LLOQ for DHT was experimentally 
determined to be 0.05 nM, whereas LLOQ for both 3α-Diol and 3β-Diol were 0.5 
nM with S/N ratio of at least 5:1. All the data were analyzed with the Agilent 
MassHunter Quantitative Analysis B.05.02 software. Results showed that this 
current method was robust and reproducible for the measurement of the six 








Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.046 0.045 0.045 0.045 0.000 1.00 90.58 
0.1 0.094 0.097 0.098 0.096 0.002 1.94 96.38 
0.5 0.506 0.491 0.476 0.491 0.015 3.02 98.20 
1 0.992 0.957 1.061 1.003 0.053 5.30 100.31 
2 2.085 2.051 2.040 2.059 0.023 1.13 102.93 
5 5.386 5.429 5.127 5.314 0.163 3.08 106.28 
10 10.595 10.774 9.988 10.452 0.412 3.94 104.52 
15 14.918 14.524 14.355 14.599 0.289 1.98 97.33 
20 19.172 19.637 20.781 19.863 0.828 4.17 99.32 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.049 0.055 0.054 0.053 0.004 6.67 105.09 
0.5 0.495 0.518 0.483 0.499 0.017 3.48 99.73 
2 1.940 2.065 2.068 2.024 0.073 3.61 101.22 
10 9.345 10.136 9.287 9.589 0.475 4.95 95.89 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.059 0.058 0.058 0.049 0.049 0.058 0.055 0.005 8.80 110.53 
0.1 0.109 0.095 0.090 0.087 0.087 0.097 0.094 0.009 9.07 93.92 
0.5 0.471 0.511 0.526 0.496 0.533 0.497 0.506 0.022 4.42 101.12 
1 1.055 1.021 1.074 1.059 0.962 0.975 1.024 0.047 4.56 102.40 
2 1.948 1.801 1.897 1.809 1.877 2.148 1.913 0.128 6.67 95.63 
5 5.239 5.194 4.682 4.533 5.117 5.585 5.058 0.387 7.66 101.15 
10 9.937 10.770 9.384 10.614 10.400 11.988 10.516 0.880 8.37 105.12 
15 14.883 16.187 15.238 13.632 14.673 16.755 15.228 1.116 7.33 101.52 
20 19.293 18.899 20.696 18.043 21.496 18.806 19.539 1.297 6.64 97.70 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.052 0.043 0.043 0.043 0.045 0.047 0.046 0.004 7.83 91.12 
0.5 0.460 0.439 0.459 0.471 0.405 0.427 0.444 0.025 5.53 88.68 
2 2.040 2.111 1.765 2.052 1.847 1.815 1.938 0.146 7.54 96.88 










Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.046 0.049 0.049 0.048 0.002 4.09 96.00 
0.1 0.097 0.095 0.098 0.096 0.002 1.60 96.40 
0.5 0.491 0.476 0.454 0.474 0.019 4.00 94.75 
1 0.973 0.935 0.997 0.968 0.031 3.19 96.83 
2 1.879 1.915 1.939 1.911 0.030 1.56 95.54 
5 4.841 5.139 4.799 4.927 0.186 3.77 98.53 
10 10.325 10.593 9.689 10.202 0.464 4.55 102.02 
15 14.573 14.769 14.461 14.601 0.156 1.07 97.34 
20 20.566 19.997 21.440 20.667 0.727 3.52 103.34 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.047 0.053 0.048 0.050 0.003 6.95 99.09 
0.5 0.417 0.466 0.446 0.443 0.025 5.55 88.58 
2 1.772 1.851 1.966 1.863 0.097 5.23 93.14 
10 9.463 10.002 9.425 9.630 0.322 3.35 96.30 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.059 0.059 0.059 0.043 0.059 0.059 0.056 0.006 11.36 112.65 
0.1 0.096 0.086 0.101 0.091 0.092 0.095 0.093 0.005 5.25 93.30 
0.5 0.452 0.436 0.476 0.448 0.488 0.423 0.454 0.025 5.41 90.75 
1 0.881 1.055 0.903 0.886 0.861 0.862 0.908 0.074 8.10 90.77 
2 1.906 1.794 1.875 1.606 1.919 2.106 1.868 0.164 8.79 93.35 
5 5.455 4.977 4.990 4.818 5.000 5.149 5.065 0.218 4.31 101.28 
10 10.019 10.591 9.702 10.563 10.536 11.563 10.496 0.634 6.04 104.93 
15 15.947 17.019 14.785 15.667 14.978 16.087 15.747 0.812 5.16 104.93 
20 19.133 18.502 19.735 17.845 21.211 18.969 19.232 1.158 6.02 96.17 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.052 0.046 0.042 0.047 0.055 0.053 0.049 0.005 10.27 98.35 
0.5 0.469 0.485 0.457 0.462 0.420 0.465 0.460 0.021 4.66 91.92 
2 1.757 1.755 1.804 1.983 1.676 1.747 1.787 0.104 5.83 89.33 










Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.048 0.047 0.049 0.048 0.001 2.09 96.07 
0.1 0.094 0.094 0.096 0.095 0.001 1.19 94.73 
0.5 0.505 0.503 0.483 0.497 0.012 2.49 99.37 
1 0.983 0.990 1.036 1.003 0.028 2.83 100.31 
2 2.008 2.049 2.028 2.028 0.020 1.00 101.41 
5 5.082 5.312 4.916 5.103 0.199 3.90 102.06 
10 10.391 10.281 9.763 10.145 0.335 3.30 101.45 
15 15.007 14.643 14.609 14.753 0.220 1.49 98.35 
20 19.575 19.925 20.972 20.158 0.727 3.61 100.79 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.048 0.048 0.051 0.049 0.002 4.02 97.69 
0.5 0.466 0.518 0.472 0.486 0.028 5.85 97.12 
2 1.924 2.016 2.031 1.991 0.058 2.91 99.53 
10 9.782 10.140 9.518 9.813 0.312 3.18 98.13 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.057 0.057 0.058 0.058 0.058 0.059 0.058 0.001 1.50 115.43 
0.1 0.117 0.093 0.113 0.088 0.089 0.089 0.098 0.013 13.50 97.92 
0.5 0.473 0.508 0.499 0.466 0.476 0.449 0.478 0.022 4.55 95.65 
1 0.979 0.986 0.970 0.981 0.910 0.939 0.961 0.030 3.12 96.05 
2 2.069 1.886 1.943 1.837 1.955 2.150 1.973 0.117 5.91 98.63 
5 5.482 4.979 4.937 4.998 5.364 5.642 5.234 0.301 5.76 104.65 
10 10.006 10.229 9.860 10.575 10.122 11.731 10.420 0.686 6.58 104.18 
15 14.997 15.797 15.197 15.219 14.578 15.773 15.260 0.467 3.06 101.72 
20 19.016 18.803 20.591 17.253 21.796 18.989 19.408 1.577 8.13 97.05 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.059 0.054 0.047 0.046 0.059 0.046 0.052 0.006 11.90 103.65 
0.5 0.500 0.506 0.460 0.519 0.440 0.444 0.478 0.034 7.13 95.58 
2 1.883 1.957 1.922 2.132 1.840 1.921 1.943 0.101 5.21 97.10 










Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.054 0.054 0.056 0.055 0.001 1.99 109.36 
0.1 0.100 0.101 0.105 0.102 0.002 2.43 101.77 
0.5 0.482 0.451 0.461 0.465 0.016 3.48 92.91 
1 0.926 0.906 0.981 0.938 0.039 4.17 93.78 
2 1.942 1.895 1.833 1.890 0.055 2.90 94.51 
5 4.787 4.918 4.518 4.741 0.204 4.30 94.82 
10 9.830 10.519 9.437 9.928 0.548 5.52 99.28 
15 15.226 14.440 15.302 14.989 0.477 3.18 99.93 
20 20.400 20.603 21.349 20.784 0.499 2.40 103.92 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.048 0.045 0.053 0.049 0.004 7.52 97.29 
0.5 0.446 0.514 0.469 0.476 0.035 7.27 95.21 
2 1.813 1.856 1.957 1.875 0.074 3.94 93.77 
10 9.830 10.654 9.712 10.065 0.513 5.10 100.65 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.062 0.062 0.047 0.066 0.064 0.055 0.059 0.007 12.09 118.45 
0.1 0.103 0.092 0.103 0.108 0.095 0.093 0.099 0.007 6.77 98.92 
0.5 0.440 0.433 0.431 0.480 0.476 0.464 0.454 0.022 4.87 90.75 
1 0.988 0.979 0.837 0.869 0.843 0.811 0.888 0.076 8.58 88.77 
2 1.926 1.708 1.721 1.869 1.844 1.934 1.834 0.099 5.38 91.67 
5 4.868 4.577 4.546 4.818 4.674 4.915 4.733 0.156 3.29 94.63 
10 9.477 9.783 9.638 10.686 9.120 11.193 9.983 0.790 7.91 99.80 
15 14.298 15.829 14.451 13.301 12.993 14.693 14.261 1.021 7.16 95.03 
20 19.703 22.292 23.764 20.266 22.581 22.103 21.785 1.520 6.98 108.92 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.058 0.059 0.060 0.049 0.060 0.058 0.057 0.004 7.57 114.33 
0.5 0.432 0.594 0.474 0.545 0.567 0.507 0.520 0.061 11.66 103.93 
2 1.934 2.135 2.216 2.046 1.765 2.129 2.037 0.164 8.06 101.85 









Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.5 0.495 0.507 0.522 0.508 0.013 2.65 101.60 
1 0.962 0.920 1.029 0.970 0.055 5.63 97.04 
2 2.020 1.863 1.997 1.960 0.084 4.31 98.00 
5 4.804 5.106 4.832 4.914 0.167 3.40 98.28 
10 9.710 9.593 9.014 9.439 0.373 3.95 94.39 
15 15.197 15.197 15.244 15.213 0.027 0.18 101.42 
20 20.046 20.047 20.350 20.147 0.175 0.87 100.74 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.5 0.510 0.476 0.497 0.494 0.017 3.46 98.88 
2 1.881 2.191 2.147 2.073 0.168 8.08 103.64 
10 10.433 9.427 10.107 9.989 0.513 5.13 99.89 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.5 0.570 0.562 0.595 0.542 0.562 0.537 0.561 0.021 3.70 112.23 
1 0.989 1.186 1.132 1.015 1.029 1.070 1.070 0.075 7.05 106.97 
2 2.106 1.945 1.872 1.828 2.198 1.947 1.983 0.142 7.15 99.12 
5 4.651 4.558 4.644 4.392 4.563 5.179 4.665 0.269 5.76 93.27 
10 11.455 9.013 10.836 8.955 8.919 11.286 10.077 1.238 12.29 100.73 
15 13.073 12.743 14.083 12.518 14.437 14.650 13.584 0.918 6.76 90.52 
20 19.072 21.791 22.362 20.220 21.846 21.351 21.107 1.231 5.83 105.55 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.5 0.540 0.512 0.452 0.515 0.556 0.578 0.525 0.044 8.30 105.08 
2 2.382 2.226 2.139 1.909 1.800 2.362 2.136 0.238 11.16 106.80 












Estimated Interday Concentration (nM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.5 0.579 0.464 0.415 0.486 0.084 17.31 97.25 
1 1.101 0.938 0.913 0.984 0.102 10.37 98.41 
2 2.225 2.005 2.055 2.095 0.115 5.50 104.76 
5 5.006 4.827 4.766 4.866 0.125 2.57 97.32 
10 10.154 10.609 8.367 9.710 1.185 12.21 97.10 
15 14.592 15.120 15.026 14.912 0.282 1.89 99.42 
20 20.199 19.654 20.849 20.234 0.598 2.96 101.17 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.5 0.520 0.428 0.434 0.461 0.052 11.24 92.13 
2 2.199 1.880 1.955 2.011 0.167 8.30 100.56 
10 9.589 11.287 9.818 10.231 0.921 9.00 102.31 




Estimated Intraday Concentration (nM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.5 0.595 0.487 0.599 0.575 0.527 0.601 0.564 0.047 8.33 112.75 
1 1.026 1.104 1.186 1.071 1.020 1.118 1.087 0.063 5.76 108.73 
2 2.178 2.094 2.346 2.264 2.280 1.887 2.175 0.166 7.63 108.73 
5 4.808 5.248 4.850 4.954 4.777 5.796 5.072 0.394 7.76 101.42 
10 10.564 9.473 9.395 8.749 9.373 9.462 9.503 0.587 6.18 95.00 
15 12.362 13.593 14.793 13.764 15.347 14.010 13.978 1.034 7.40 93.17 
20 17.210 21.189 22.700 19.337 23.331 22.099 20.978 2.311 11.02 104.88 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.5 0.464 0.448 0.473 0.589 0.493 0.495 0.494 0.050 10.12 98.70 
2 2.372 2.081 2.373 2.178 2.274 2.020 2.216 0.149 6.71 110.80 








4.3.3.2 Stabilities of DHEA, A4, T, DHT, 3α-Diol and 3β-Diol in PBS/BSA  
Stabilities of the six androgens in the matrix were studied to understand how fast 
these androgens degrade during storage and sample preparation. Freeze-thaw, 
long term and short term stability tests were performed. Four QC samples were 
prepared for each of the analysis for respective analytes and were termed as 
lowest, low, mid and high QC. However, as the lowest QC sample contained 
concentrations of 3α-Diol and 3β-Diol, which were out of their acceptable 
quantifiable ranges based on the validation data it will not be used for the rest of 
the analysis for the two diols.  
Table 19. Recoveries of Six Androgens at Lowest*, Low, Mid and High 
Concentrations for Freeze-Thaw, Short and Long Term Stability Tests 
Analyte Range of Recoveries (%) 
























































0 to 102.1 0 to 99.3 
3β-Diol 0 to 77.4 0 to 71.5 0 to 90.4  0 to 94.1 0 to 81.6 0 to 139.9 
(* Note: The lowest QC referred here was not used for analysis for 3α-Diol and 
3β-Diol as its concentration fell out of quantifiable ranges of these two 
analytes.) 
 
For the samples prepared in 1g/L of PBS/BSA matrix, the mean recoveries for the 
QCs for the six androgens are shown in Table 19 and Figure 29 when compared 
to the same concentrations of the freshly-spiked samples. 
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% Recovery of DHEA in PBS/BSA matrix



















































% Recovery of A4 in PBS/BSA matrix
























































% Recovery of T in PBS/BSA matrix




















































% Recovery of DHT in PBS/BSA matrix
























































% Recovery of 3-diol in PBS/BSA matrix









































% Recovery of 3-diol in PBS/BSA matrix














































Figures 29. Graphs showing the Recoveries of (a) DHEA, (b) A4, (c) T, (d) 
DHT, (e) 3α-Diol and (f) 3β-Diol in 1g/L of PBS/BSA matrix for the Freeze-





As observed from the average recoveries from the three types of stability tests, the 
four androgens, DHEA, A4, T and DHT remained relatively stable in PBS/BSA 
matrix. DHEA demonstrated insignificant degradation for up to 4 hrs at room 
temperature, and approximately 15 % degradation beyond 4 hrs. DHEA was also 
relatively stable at -80 oC for one month and could withstand three freeze-thaw 
cycles, keeping the degradation to within 12 %.  
As for A4, T and DHT, they showed similar recovery results as reported in 
Chapter 2 for the various stability tests.  
However for 3α- and 3β-Diols, they were not very stable, especially at low 
concentrations. The concentration of these analytes dipped to negligible levels at 
their low concentration samples, after being subjected to the three types of 
stability tests. The mid and high concentrations samples however were more 
stable. In addition, the higher concentration samples containing these two diols 
were more stable when kept under -80 oC or even upon three cycles of freeze-








4.3.3.3 Dimethoxycurcumin as a Selective Inhibitor of AKR1C3 enzyme  
Dose-Response Curves of Dimethoxycurcumin and
Indomethacin (positive control)
on Intracellular Measurements of T in CWR22Rv1
after 48 hr treatment
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Figure 30. Dose Response Curves on Inhibition of AKR1C3 enzyme on 
AKR1C3-postitive CWR22Rv1 when treated with various doses of 
Dimethoxycurcumin and Indomethacin (positive control drug) using intracellular 
measurements of T with LC-MS/MS. 
 
Of the six androgens, T was best quantified by LC-MS/MS. Moreover, since the 
synthesis of T is primarily through conversion of its precursor, A4 via the action 
of AKR1C3 enzyme, the intracellular levels of T following treatment of 
CWR22Rv1 cells with the drugs will reflect upon the AKR1C3 enzyme activity. 
Thus, based on the intracellular T measurements using LC-MS/MS, the calculated 
IC50 of AKR1C3 with indomethacin treatment was 239.0 µM and the IC50 value 
for AKR1C3 with dimethoxycurcumin treatment was 22.3 µM. Therefore, 
dimethoxycurcumin is a more potent inhibitor on AKR1C3 than indomethacin 
with its IC50 of AKR1C3 being approximately ten times smaller than IC50 of 
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AKR1C3 of indomethacin. Furthermore, AKR1C3 is directly responsible in 
catalysing synthesis of T to promote the proliferation of CWR22Rv1 cells. It 
implies that if the drug’s sole mechanism against CRPC cells is through inhibition 
of AKR1C3, it should be expected that the drug’s IC50 of AKR1C3 should be the 
same as its IC50 of proliferation of cells. Hence based on comparison, 
dimethoxycurcumin’s IC50 of AKR1C3 is approximately equal to its IC50 of 
proliferation on CWR22Rv1 cells. In contrast, IC50 of AKR1C3 with 
indomethacin is larger than its own IC50 of proliferation on CWR22Rv1 cells. 
This could suggest that dimethoxycurcumin might function primarily through 
inhibiting AKR1C3 enzyme that leads to decrease in intracrine production of 
potent androgens such as T. With this further reduction of supply of potent 
androgens to activate ARs, it will help to further enhance the AR degradation in 
such AKR1C3 positive-CRPC cells. However, all these would require further 
experimental verifications. 
As for indomethacin, it has a greater IC50 on AKR1C3 than its IC50 on 
proliferation of cells. This means that these CRPC cells have effectively stop 
proliferating at a lower dose before effective inhibition of AKR1C3 occurs. So, 
indomethacin could actually work via other mechanisms (Gurpinar et al., 2013) 
for its anti-proliferative property, besides its selective inhibition on AKR1C3 
enzyme, which will not be discuss further here.  
Besides, the saturating doses for inhibition of production of T via AKR1C3 for 
indomethacin and dimethoxycurcumin were found to be 1 mM and 50 µM 




Figure 31. Dose Response Curves on Inhibition of AKR1C2 enzyme on 
CWR22Rv1 when treated with various doses of Dimethoxycurcumin and 
Indomethacin (positive control drug) using intracellular measurements of 3α-Diol 
with LC-MS/MS. 
 
As mentioned earlier, one of the main concerns to the therapeutic application of 
dimethoxycurcumin as a CRPC drug is its selective inhibition on AKR1C3. 
Hence, in this study an attempt was made to do a simultaneous investigation on 
the dose-response inhibition of dimethoxycurcumin and indomethacin (positive 
control) on AKR1C1 and AKR1C2 enzymes using LC-MS/MS measurements on 
3α-Diol and 3β-Diol. 
Both 3α-Diol and 3β-Diol are metabolites of DHT. 3α-Diol is formed by the 
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action of AKR1C1 on DHT. Thus, similar to the earlier strategy of obtaining the 
dose-response curve of inhibition on AKR1C3 through measurements of 
intracellular T with LC-MS/MS, the dose-responses of inhibition on AKR1C1 and 
AKR1C2 should also be theoretically viable by simultaneous measurements of 
intracellular 3β-Diol and 3α-Diol respectively using LC-MS/MS. Since the 
simultaneous measurements of intracellular T, 3α-Diol and 3β-Diol can be 
performed within the same sample run using LC-MS/MS, a more accurate 
indication of the selectivity of dimethoxycurcumin on AKR1C3 over AKR1C1 
and AKR1C2 can be obtained. 
Intracellular levels of 3β-Diol from CWR22Rv1 after application of the drugs 
were undetectable (data not shown) whereas, intracellular levels of 3α-Diol were 
detectable. As a result, the study of inhibition on AKR1C1 is not possible here, 
while the study of inhibition on AKR1C2 is still achievable. This seems to be a 
reasonable outcome as normally DHT is largely metabolized to 3α-Diol via 
AKR1C2 in prostate, while only a smaller amount is being metabolized via 
AKR1C1 to 3β-Diol (Ji et al., 2007). Since the 3β-Diol is only formed minimally 
in prostate, with addition of these drugs could to some extent further suppress the 
formation of this 3β-Diol. Consequently, this would render the concurrent study 
of both inhibition of AKR1C1 and AKR1C2 to be unattainable.  
From the dose-response curves of dimethoxycurcumin and indomethacin (positive 
control) using measurements of 3α-Diol, both drugs showed similar trends. At 
doses lower than 10 µM, there seemed to be increase in intracellular 3α-Diol. 
However, at doses beyond 10 µM, both drugs exhibited inhibition on AKR1C2, 
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where production of intracellular 3α-Diol decreased steadily. From the latter parts 
of the graphs, the IC50 of AKR1C2 with indomethacin could not be calculated but 
IC50 of AKR1C2 with dimethoxycurcumin was estimated to be approximately 
48.2 µM, which was 2.16-fold higher than its IC50 of AKR1C3. As such, this 
indicated that there is slightly greater selectivity of inhibition on AKR1C3 over 







Figure 32. Comparison of Expression of AKR1C2 and AKR1C3 enzyme among 
T1: 10 % CD-FBS; T2: 10 % CD-FBS with 1 mM Indomethacin and T3: 10 % 
CD-FBS with 50 µM Dimethoxycurcumin. From the diagrams on the right for 
inhibition of AKR1C3 enzyme, when saturating dose of Dimethoxycurcumin was 
added (T3), there was more significant inhibition of AKR1C3 when compared to 
T1. From the diagrams on the left for inhibition of AKR1C2 enzyme, when 
saturating dose of Dimethoxycurcumin was added (T3), there was no apparent 
differences in inhibition of AKR1C2 when compared to T1. This shows that 
Dimethoxycurcumin has greater selectivity of inhibition of AKR1C3 over 
AKR1C2 enzyme. 
 
AKR1C2 and AKR1C3 protein expression in CWR22Rv1 were also analysed via 
western blot analysis after being subjected to saturating doses of 1 mM of 
indomethacin and 50 µM of dimethoxycurcumin. This was done to verify the 
Control,      T1           T2           T3 
MCF-7 
Control,      T1             T2            T3 
HepG2 
Control,      T1             T2            T3 
HepG2 




earlier conclusion derived from the LC-MS/MS results, where these doses of 
indomethacin and dimethoxycurcumin inhibited both AKR1C2 and AKR1C3, 
with a greater inhibition on AKR1C3.  
For AKR1C2, breast cancer cell line, MCF-7 was used as the positive control and 
for AKR1C3, liver cancer cell line, HepG2 was used as the positive control. 
Treatment of CWR22Rv1 with the various doses of indomethacin and 
dimethoxycurcumin decreased both AKR1C2 and AKR1C3 protein expression. 
This is in accordance to the conclusion drawn from LC-MS/MS results. 
 
4.3.3.4 Changes to Intracellular Androgen Levels under Different 
Treatments using Dimethoxycurcumin and Known AKR1C3 
Inhibitor 
Six different culture conditions were used by applying the saturating doses of 
drugs, where the media used across were all supplemented with CD-FBS. The 
treatment conditions were stated in Figure 33 and cell structures before and after 
treatment were also captured. 
  
Type of Treatment Before Treatment After Treatment for 48 hrs 
T1: 10 % CD-FBS  
(Negative control) 
  












T5: 10 % CD-FBS + 




T6: 10 % CD-FBS + 




Figure 33. Diagrams of CWR22Rv1 Cells Condition Before and After 48 hrs of 
treatment with Saturating Doses of 50 µM of Dimethoxycurcumin and 1 mM of 




Two observations were made from the different culture conditions with the 
saturating doses of indomethacin and dimethoxycurcumin.  
The first observation was the significant reduction in the intracellular T, most 
clearly observed between Treatments 4 and 5 (p-value < 0.05) and between 
Treatments 4 and 6 (p-value < 0.05), when the saturating doses of indomethacin 
and dimethoxycurcumin were added, despite the additional A4 added to the media 
(Figures 34 a & b). This implied that dimethoxycurcumin could inhibit AKR1C3 
enzyme, which directly helps to reduce the production of intracellular T. This is a 
highly desired outcome as significant reduction of intracellular T, can greatly aid 
in impeding such CRPC cells from proliferation.  
Intracelluar T in pmole/million cells in CWR22Rv1
under Different Treatments with
Saturating Doses of Indomethacin (positive control) and
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Figures 34. Intracellular levels of T measured in pmole/ million cells under (a) 
Six Different Treatments. Using one-way Annova with Bonferoni post-test 
corrections, significant differences in intracellular T were observed between T4 
and T5 (with 1 mM Indomethcin added) (p-value < 0.05) and T4 and T6 (with 50 
µM Dimethoxycurcumin added) (p < 0.05). 
 (b) Enlarged portion of diagram of Intracellular levels of T detected in 
Treatments 1 to 3  
 
Upon adding saturating doses of either indomethacin or dimethoxycurcumin, 
there were minimal or negligible levels of intracellular 3α-Diol (data not shown), 
while there were relatively higher levels of 3β-Diol (Figure 35). This is very 
different from the normal circumstances where DHT is mainly metabolised to 3α-
Diol via AKR1C2 in prostate and only a small amount is converted to 3β-Diol (Ji 




Intracelluar 3-Diol in pmole/million cells in CWR22Rv1
under Different Treatments with
Saturating  Doses of Indomethacin (positive control) and
Dimethoxycurcumin_Repeated Expts









Round 1_Conc. of intracellular 3-diol
Round 2_Conc. of intracellular 3-diol
T1:10 % CD-FBS
T2:10 % CD-FBS w
           1 mM Indomethacin
T4:10 % CD-FBS w 0.1M A4
T5:10 % CD-FBS w 0.1M A4
w 1mM Indomethacin
T6:10 % CD-FBS w 0.1M A4
           w 50 M Dimethoxycurcumin
T3:10 % CD-FBS w
                     50M Dimethoxycurcumin






























Figure 35. Intracellular 3β-Diol measured in pmole/million cells under Six 
Different Treatment Conditions. Using one-way Annova with Bonferoni post-test 
corrections, significant differences in intracellular 3β-Diol were observed between 
T4 and T6 (p-value < 0.05) and T5 and T6 (p-value < 0.05), where under T6, 
which contains 50 µM Dimethoxycurcumin can induce a significant increase in 
intracellular 3β-Diol, a selective ERβ ligand. 
 
This could be another desirable outcome as by lowering the chances of 
accumulation of this weak androgen, 3α-Diol, it can prevent it from acting as 
potential ligand to activate AR that could lead to CRPC (Yang et al., 2008). 
Furthermore, 3α-Diol was reportedly able to go through the “backdoor” pathway 
(Yang, et al., 2008; Mohler et al., 2011; Ishizaki et al., 2013), where it can be 
directly converted back into DHT again. Therefore, accumulation of 3α-Diol 





In contrast, with the addition of saturating doses of indomethacin and 
dimethoxycurcumin here, 3β-Diol was preferentially formed from DHT. In fact, 
this is most significant upon addition of saturating dose of dimethoxycurucmin, 
where highest intracellular 3β-Diol was detected (under Treatments 4 and 6 with p 
< 0.05 and Treatments 5 and 6 with p < 0.05). This could be beneficial as 
deactivation of DHT is still maintained through catabolism to 3β-Diol instead. 
Moreover, this ligand has been associated with anti-proliferative effect on PCa as 
3β-Diol is reputed to be a selective agonist to ERβ receptors (Guerini et al., 2005; 
Dondi et al., 2010). And upon activation of ERβ, it is often associated with 
beneficial effects such as anti-invasive and anti-proliferative for the PCa cells 
(Guerini et al., 2005; Dondi et al., 2010).  
 
4.4 Summary of Results 
Among the PCa cell lines tested, only CWR22Rv1, a CRPC cell endogenously 
contains high expression of AKR1C3 enzyme. MTS cell proliferation assay was 
used as a preliminary study to find out the suitable range of doses of drugs to be 
use for subsequent dose-response curves for study of IC50 on AKR1C1 to 3 and 
also to find out the respective IC50 values of the drugs on proliferation of 
CWR22Rv1 cells. Subsequently, LC-MS/MS was used as well to specifically find 
out the IC50 of the drugs and their inhibition effects on AKR1C3 enzyme through 
measurements of intracellular T upon subjected to different doses of the drugs on 




simultaneously obtain the IC50 of inhibition of AKR1C2 via measurements of 
intracellular 3α-Diol. However, simultaneous study of inhibition of AKR1C1 is 
impossible as there might be further suppression to formation of the inherently 
minute levels of intracellular 3β-Diol with the drugs.  
IC50 of AKR1C3 for indomethacin and dimethoxycurcumin were estimated, to be 
239.0 µM and 22.3 µM respectively. Furthermore, the saturating doses for 
inhibition of AKR1C3 for indomethacin and dimethoxycurcumin were found to 
be 1 mM and 50 µM respectively. As observed, the IC50 for inhibition of 
AKR1C3 for dimethoxycurcumin was about ten times lower as compared to 
indomethacin, indicating its higher potency than indomethacin as an AKR1C3 
inhibitor.  
From the LC-MS/MS results, at doses below 10 µM, both drugs showed an 
increase in activities on the AKR1C2 enzyme, where the production of 
intracellular 3α-Diol increased. However at doses above 10 µM, they started to 
show inhibitory effects on AKR1C2 enzyme instead, where intracellular levels of 
3α-Diol decreased. From the inhibitory part of the curve, IC50 of 
dimethoxycurcumin was estimated to be approximately 48.2 µM. This is 2.16-
fold higher as compared to the IC50 of AKR1C3 for dimethoxycurcumin and 
indicated a slightly greater selectivity of inhibition by dimethoxycurcumin on 
AKR1C3 over AKR1C2.  
Comparison was made on treating CWR22Rv1 with just CD-FBS media and CD-




doses of drugs for both indomethacin and dimethoxycurcumin, there was a 
significant decrease in the intracellular T levels (p-values < 0.05). This finding 
suggested that like the known AKR1C3 inhibitor, indomethacin, 
dimethoxycurcumin could also effectively inhibit AKR1C3 enzyme. This directly 
reduces the production of T as observed here (p-value < 0.05), which is a 
desirable effect for treatment of CRPC.  
In addition, it was observed that upon treatment with saturating doses of either 
indomethacin or dimethoxycurcumin, formation of intracellular 3β-Diol was 
preferred over 3α-Diol instead. This is very different from the normal 
circumstances, where DHT is mainly catabolised to 3α-Diol via AKR1C2 in 
prostate. With lesser 3α-Diol was produced upon treatment of the saturating doses 
of dimethoxycurcumin and indomethacin, it reduced the chances of accumulation 
of sufficient 3α-Diol that might be able to activate ARs to sustain PCa progression 
even after androgen ablation. Moreover, with lesser 3α-Diol, it also reduces the 
chances of DHT synthesis via the“backdoor” pathway. On the other hand, 3β-Diol 
has been reputed to be a selective agonist towards ERβ receptors, which have 
been associated with anti-proliferative effect on PCa. Hence these results might 
indicate that with appropriate dose of dimethoxycurcumin used, DHT deactivation 
is still maintained by conversion to 3β-Diol instead. Moreover, this metabolite is 






Investigation of Pharmacokinetics and Pharmacodistribution of 
Dimethoxycurcumin in Mice Sera and Organs using LC-MS/MS 
5.  Introduction 
Curcumin is a major component of the rhizome of turmeric (Curcuma Longa 
Linn) (Anand et al., 2007; Anand et al., 2008; Vareed et al., 2008). It is a bis-α,β-
unsaturated β-diketone. In the acidic or neutral conditions, it exists predominantly 
in keto form but becomes an enol when in the alkaline condition (Adams et al., 
2004; Anand et al., 2007; Anand et al., 2008). Curcumin showed potential as an 
anti-cancer drug through perturbation of several molecular targets (Saradhi et al., 
2010). No detrimental effect was observed for applications of high doses 
curcumin during clinical trials (Vareed et al., 2008; Singh & Jain, 2010; Li et al., 
2011). However, with its low oral bioavailability and fast in vivo metabolic rate, 
its actual use as a drug is limited (Anand et al., 2007; Vareed et al., 2008; Saradhi 
et al., 2010; Singh & Jain, 2010; Wei et al., 2012). One of the ways to avert this 
problem is through structural modifications of curcumin (Adams et al., 2004; 
Anand et al., 2007; Tamvakopoulos et al., 2007; Saradhi et al., 2010; Wei et al., 
2012). In fact, several curcumin derivatives and analogues were able to impede 
proliferation and invasion of tumor cells (Adams et al., 2004; Tamvakopoulos et 
al., 2007). 
In this study, a curcumin derivative, dimethoxycurcumin or 5-hydroxy-1,7-




AR degradation enhancer (Yamashita et al., 2012; Lai et al., 2013). It was able to 
suppress AR function through selective interruption of the interactions between 
AR and its co-activators (ARA55 or ARA70) that are expressed mainly in 
prostate stromal or epithelial luminal cells (Lai et al., 2013). As a result, it can 
lead to suppression of AR-mediated diseases, including PCa (Yamashita et al., 
2012; Lai et al., 2013), liver cancer (Wu et al., 2010), bladder cancer (Miyamoto 
et al., 2007) and spinal and bulbar muscular atrophy (SBMA) (Yang et al., 2007). 
Unlike some of the presently used anti-androgens for ADT, which may initiate 
development of CRPC, dimethoxycurcumin could continually suppress PCa even 
at CRPC stage (Lai et al., 2013; Lin, Izumi, et al., 2013; Lin, Lee, et al., 2013; 
Yamashita et al., 2012). Another advantage is the minimal side effects associated 
with it since the sexual libido of the tested mice seemed unaffected (Yang et al., 
2007). Thus, this suggested that it could be a better option to treat PCa or other 
AR-related diseases. Therefore, it is important to determine dimethoxycurcumin 
in the various biological samples. 
An LC-MS/MS method of detection and quantification was developed and 
validated for quantification of dimethoxycurcumin in mice sera and organ 
samples. The pharmacokinetic and distribution of dimethoxycurcumin in mice 








Dimethoxycurcumin (ASC-J9®) was a gift from AndroScience Corporation (San 
Diego, CA, USA). Curcumin and bovine serum albumin (BSA) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). HPLC-grade solvents, ethyl acetate, 
acetonitrile and formic acid were obtained from Merck (Darmstadt, Germany). 
Commercial mouse serum was purchased from Innovative Research Inc. (Peary 
court Novi, MI, USA). Phosphate buffer saline (PBS) was purchased from 
Vivantis Technologies Sdn Bhd (Selangor Darul Ehsan, Malaysia). Ultrapure 
water was from a Milli-Q (Millipore, Bedford, MA, USA) water purification 
system.   
 
5.2 Experimental 
5.2.1 Preparation and Extraction of Calibration Standards and Quality 
Controls  
All the stock and standard solutions of dimethoxycurcumin and curcumin were 
stored at -20 oC and wrapped with foil. Two sets of calibration curves were set up 
using mouse sera and 1g/L of PBS/BSA. Calibration standards were prepared by 
spiking 20 µL of each of the standard solution of dimethoxycurcumin in 
acetonitrile into either 80 µL of blank mouse serum or PBS/BSA to a total of 100 
µL of sample. The final calibration standards ranged from 0.005 to 5 µM in 
mouse sera and 0.005 to 10 µM in 1g/L of PBS/BSA. 10 µL of 2.5 µM curcumin 




controls (QCs) with concentrations 0.025 µM, 0.25 µM and 1 µM respectively 
were prepared in both matrices. 0.5 mL of ethyl acetate was used during each 
liquid-liquid extraction and vortexed vigorously for 2 mins. Samples were 
centrifuged at 13,000 rpm for 3 mins at room temperature. Supernatants were 
transferred into clean eppendorf tubes. Extraction was repeated thrice and extracts 
were combined and dried under nitrogen gas at 40 oC. The dried residue was 
reconstituted with 100 µL of 60 % aqueous acetonitrile and 10 µL of the 
reconstituted solution was injected for the analysis. 
 
5.2.2 Preparation of Stability Tests Samples  
A 10 µL of 2.5 µM curcumin was spiked into each of the triplicates of the 3 QCs 
as mentioned in section 5.2.1 as internal standard. For freeze-thaw stability 
determination of dimethoxycurcumin, one set of triplicates of the 3 QCs were 
subjected to three freeze-thaw cycles over 3 days and were stored at -80 oC till 
analysis. For short term stability determination of dimethoxycurcumin, another set 
was left at room temperature of 24 oC for 6, 8 and 24 hrs respectively in mouse 
serum and PBS/BSA. The responses for the 2 sets of stability samples were 
compared against responses from triplicates of a reference set with the same 







5.2.3 Sample preparation for Mice Sera and Organ samples   
5.2.3.1 Mice Sera Samples 
C57BL/6 or B6 mice purchased from The Jackson Laboratories, USA were 
chosen and administered with 75 mg/kg of dimethoxycurcumin through 
intraperitoneal (i.p.) injection. Three sera samples were collected from three mice 
per timepoint at various timepoints. Afterwhich, the blood samples were allowed 
to stand for 20 to 30 mins before centrifuging at 1,500 rpm for 10 mins. 
Supernatant was transferred to a clean tube and stored immediately at -80 ºC 
before extraction and LC-MS/MS analysis.  
 
5.2.3.2 Mice Organ Samples 
Triplicates of organs were collected from six mice after single i.p. injection of 
dimethoxycurcumin at 8 hrs and 24 hrs respectively. The collected organs were 
immediately stored at -80 oC. Before extraction, they were thawed at room 
temperature and rinsed with saline buffer and dried before weighing. Each organ 
sample was placed in a 2 ml eppendorf tube and homogenised. A 10 µL of 2.5 
µM curcumin was spiked as internal standard into the sample. Similar extraction 
procedure as mentioned in section 5.2.1 was followed except that these samples 
were ultrasonicated for 10 mins after each addition of extraction solvent. And 
samples were centrifuged at 6,000 rpm for 10 mins before transferring the 





5.2.4 LC-MS/MS Analysis  
Agilent Technologies (Palo Alto, CA, USA) Model 1200 liquid chromatography 
system with a binary pump and autosampler was used for the chromatographic 
separation. Analyst software version 1.4.2 (ABI-Sciex, Foster City, CA) was used 
to record and process the chromatographic data. A Phenomenex (Torrance, CA) 
Luna C18 (50 mm × 2.00 mm, 100Å) column attached to a guard column with 
C18 (4 mm × 2.0 mm) filter cartridge was used for the LC separation. The 
separated analytes were detected and analyzed using an API 3200 triple 
quadrupole mass spectrometer (ABI-Sciex, Toronto, Ontario, Canada) equipped 
with a turbo ion spray source operated under positive multiple reaction 
monitoring (MRM) mode.  
The mobile phase consisted of solvent A (ultrapure water with 0.1 % formic acid) 
and solvent B (acetonitrile), delivered at a flow rate of 0.35 mL/min. The analyte 
was separated under isocratic mode of 40 % solvent A and 60 % solvent B. The 





Figure 36. Chromatogram of the Keto-Enol Isomers of Dimethoxycurcumin. 
 
Figure 36 is the typical chromatogram of dimethoxycurcumin where the pair of 
peaks represented the keto-enol isomers from the analyte. Internal standard, 
curcumin also displayed similar observations. (Tamvakopoulos et al., 2007; 
Saradhi et al., 2010). Peaks that were eluted later were the predominant peaks for 
both analytes. For dimethoxycurcumin, the peak ratio was about 1:22 and for 
curcumin, it was about 1:11. Since the second peak for each compound was the 
predominant peak and the ratios of the two peaks were consistent, the latter peak 
was used for quantitation.  
XIC of +MRM (2 pairs): 397.0/191.0 amu from Sample 1 (Std5.1) of DataSET1_Std5.1.wiff (Turbo Spray) Max. 2.2e4 cps.










































Positive ESI-MRM mode was used to determine both dimethoxycurcumin and 
curcumin. Similar fragmentation pattern was observed for both. MRM transitions 
for dimethoxycurcumin was at m/z 397 → 191 and for internal standard, curcumin 
was at m/z 369 → 177. Flow injection analysis was used to optimise the source 
and instrument parameters. The optimized conditions for dimethoxycurcumin 
were declustering potential at 30 V, entrance potential at 8 V, collisional entrance 
potential at 18.7 V, collisional energy at 40 V, collisional cell exit potential at 4 
V, curtain gas at 10, and collisional gas at 4. The ionspray voltage was set at 5500 
V with the turbo ion spray interface at 600 oC. Ion source drying gases 1 and 2 
were set at 60 and 65 respectively. An eight-point calibration curve of peak area 
ratio against the concentration ratio of the analyte to internal standard was used to 
quantify the concentration of dimethoxycurcumin.   
 
5.2.5 Method Validation 
Each set of calibration standards in mouse serum and in PBS/BSA was validated 
through interday (n = 9) and intraday (n= 6) assays to determine the accuracy and 
the coefficient of variation (CV %) of the method. Limit of quantification (LOQ) 
was based on signal-to-noise (S/N) ratio of 10:1. Matrix effects were investigated 







5.3 Results and Discussions 
5.3.1 Validation of LC-MS/MS Method 
Linear regression with 1/y2 weighting and regression coefficient, r2 of 0.99 was 
obtained for dimethoxycurcumin in mouse serum from range of 0.005 to 5 µM. A 
typical calibration curve equation of y = 17 x + 0.0584 was obtained. Quadratic 
regression with 1/y2 weighting was obtained instead for dimethoxycurcumin in 
PBS/BSA over the range of 0.005 to 10 µM, having regression coefficient, r2 of 
0.99. A typical calibration equation of y = -0.58 x2 + 15.1 x – 0.00286 was 
obtained. Recoveries and matrix effects were investigated using the QCs of 
dimethoxycurcumin prepared in both matrices. No peaks with the same retention 
times as dimethoxycurcumin at m/z 397 →  191 was found from the 
chromatograms of both types of blank matrices. This implied the method was 
selective and specific for detection of this compound. All accuracies and 
coefficient of variation (CV%) were shown in Tables 20 to 21 and met the 
requirements of the Guidance for Industry Bioanalytical Method Validation 
("Guidance for Industry Bioanalytical Method Validation," 2001). The LOQ of 
dimethoxycurcumin was experimentally determined to be 0.005 µM in both 
matrices with S/N ratio of at least 10 :1 as analysed by the Analyst version 1.4.2 
software. From our results, it indicated that this new method was more sensitive, 
robust and reproducible for the measurement of dimethoxycurcumin in mouse 




al., 2007). This also implied that the method could be easily be extended to other 
types of biological matrices  




Estimated Interday Concentration (µM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(µM) 
Stdev CV % Accuracy % 
0.005 0.005 0.005 0.005 0.005 0.000 3.44 100.22 
0.025 0.026 0.024 0.027 0.026 0.001 5.73 104.24 
0.05 0.051 0.050 0.049 0.050 0.001 2.07 99.84 
0.25 0.272 0.285 0.254 0.270 0.016 5.82 108.08 
0.5 0.523 0.524 0.501 0.516 0.013 2.46 103.19 
1 1.091 0.991 1.092 1.058 0.058 5.50 105.77 
2.5 2.491 2.436 2.352 2.427 0.070 2.88 97.06 
5 4.241 4.769 5.141 4.717 0.452 9.59 94.34 




Estimated Interday Concentration (µM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(µM) 
Stdev CV % Accuracy % 
0.025 0.022 0.030 0.022 0.025 0.004 17.22 99.67 
0.25 0.224 0.283 0.257 0.254 0.029 11.55 101.79 
1 0.971 1.219 0.887 1.025 0.173 16.86 102.54 




Estimated Intraday Concentration (µM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(µM) 
Stdev CV % Accuracy 
% 
0.005 0.006 0.006 0.004 0.004 0.005 0.004 0.005 0.001 19.50 101.49 
0.025 0.031 0.030 0.028 0.029 0.029 0.028 0.029 0.001 4.38 116.79 
0.05 0.054 0.050 0.048 0.048 0.043 0.054 0.049 0.004 8.84 98.70 
0.25 0.236 0.243 0.273 0.254 0.247 0.235 0.248 0.014 5.74 99.16 
0.5 0.496 0.462 0.528 0.619 0.582 0.570 0.543 0.058 10.72 108.58 
1 0.890 1.090 0.812 0.909 1.100 0.960 0.960 0.114 11.91 95.97 
2.5 2.920 2.640 2.520 2.660 2.650 2.780 2.694 0.140 5.18 107.76 
5 4.950 4.540 4.140 5.470 4.210 4.630 4.657 0.493 10.59 93.15 




Estimated Intraday Concentration (µM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(µM) 
Stdev CV % Accuracy 
% 
0.025 0.029 0.027 0.030 0.022 0.023 0.024 0.026 0.003 13.36 103.02 
0.25 0.254 0.244 0.296 0.213 0.228 0.247 0.247 0.028 11.45 98.83 










Estimated Interday Concentration (µM)                          Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(µM) 
Stdev CV % Accuracy % 
0.005 0.005 0.005 0.005 0.005 0.000 2.18 100.37 
0.025 0.027 0.029 0.025 0.027 0.002 7.84 108.73 
0.05 0.055 0.044 0.045 0.048 0.006 13.23 95.96 
0.25 0.275 0.232 0.240 0.249 0.023 9.17 99.62 
0.5 0.494 0.565 0.542 0.533 0.036 6.77 106.69 
1 0.977 0.931 1.154 1.021 0.118 11.55 102.06 
2.5 2.263 2.680 2.699 2.547 0.247 9.68 101.90 
5 4.632 5.753 4.984 5.123 0.573 11.19 102.46 
10 10.891 9.284 9.713 9.963 0.832 8.35 99.63 




Estimated Interday Concentration (µM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(µM) 
Stdev CV % Accuracy % 
0.025 0.024 0.021 0.027 0.024 0.003 12.74 95.01 
0.25 0.251 0.235 0.277 0.254 0.021 8.37 101.60 
1 0.931 0.933 0.869 0.911 0.036 3.99 91.10 




Estimated Intraday Concentration (µM)                       Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th 
Run 
5th Run 6th Run Mean 
Conc. 
(µM) 
Stdev CV % Accuracy 
% 
0.005 0.005 0.005 0.005 0.005 0.004 0.005 0.005 0.000 7.80 103.06 
0.025 0.026 0.026 0.025 0.024 0.024 0.024 0.025 0.001 3.71 98.66 
0.05 0.043 0.043 0.052 0.052 0.040 0.040 0.045 0.006 12.79 89.83 
0.25 0.232 0.229 0.252 0.248 0.241 0.235 0.239 0.009 3.73 95.78 
0.5 0.444 0.442 0.617 0.603 0.608 0.606 0.553 0.086 15.50 110.64 
1 1.170 1.160 1.160 1.170 1.140 1.150 1.158 0.010 0.86 115.80 
2.5 2.700 2.670 2.720 2.760 2.710 2.690 2.708 0.029 1.05 108.32 
5 4.950 5.050 4.920 4.980 5.080 5.070 5.009 0.067 1.33 100.18 
10 9.570 9.650 9.530 9.860 9.750 9.720 9.679 0.121 1.25 96.79 




Estimated Intraday Concentration (µM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(µM) 
Stdev CV % Accuracy 
% 
0.025 0.028 0.025 0.025 0.027 0.028 0.025 0.026 0.002 6.07 104.84 
0.25 0.324 0.229 0.248 0.244 0.262 0.251 0.260 0.033 12.88 103.90 







5.3.2 Stability of Dimethoxycurcumin in Serum and PBS/BSA matrix 
Studying the stability of dimethoxycurcumin spiked in the different matrices is to 
gain information so as to ensure that the drug does not undergo degradation 
during storage and sample preparation. It could also give indications on the 
metabolism rate of dimethoxycurcumin. Here, freeze-thaw and short term stability 
studies were done. For the samples in serum matrix, the mean recoveries were 90 
to 105 % for dimethoxycurcumin samples subjected to three freeze-thaw cycles 
(Figure 37). As for the short-term stability test samples, much lower recoveries 
for dimethoxycurcumin were obtained. Recoveries were found to be 42 to 48 % 
for 6 hrs, 30 to 42 % for 8 hrs, and 13 to 22 % for 24 hrs (Figure 37). Thus, there 
was significant degradation of dimethoxycurcumin in serum when left under room 
temperature.  
% Recovery of Dimethoxycurcumin in Mouse Serum







































Figure 37. Graphs showing the Recoveries of Dimethoxycurcumin in Mice Sera 




% Recovery of Dimethoxycurcumin in 1 g/L of PBS/BSA









































Figure 38. Graph showing the Recoveries of Dimethoxycurcumin in 1g/L of 
PBS/BSA matrix from Freeze-Thaw and Short term Stability Samples 
 
However, there was a lesser extent of degradation for dimethoxycurcumin in 
PBS/BSA matrix than in serum for both the freeze thaw and short-term stability 
samples, where the recoveries were 93% to 98 % and 92 to 97 % for 6 hrs, 93 to 
95 % for 8 hrs, and 87 to 90 % for 24 hrs respectively (Figure 38). 
Comparatively, curcumin degraded much faster than dimethoxycurcumin in 
serum or in PBS/BSA under the exact conditions for both the freeze-thaw and 
short-term stability samples (data not shown). Thus, to ensure that curcumin can 
act reliably as internal standard for quantification, it has to be freshly prepared 







5.3.3 Pharmacokinetic Study of Dimethoxycurcumin in Mice Sera  
Concentration of dimethoxycurcumin in mice sera samples collected at different 
time-points was determined using this validated LC–MS/MS method. This was 
done to enable investigation of pharmacokinetic profile of drug after i.p. injection 
at 75 mg/kg. A two-compartment model with the Phoenix WinNonlin software 
version 6.0 was used to analyse the pharmacokinetic values of 
dimethoxycurcumin. Maximum concentration of dimethoxycurcumin after 
administration, Cmax was found to be 2.91 µmol/L at 0.34 hr. The concentration of 
dimethoxycurcumin in serum decreased but remained detectable till 8 hrs (Figure 
39).  






Note: Log plot was used in this case. And negligible dimethoxycurcumin was



































Figure 39. Pharmacokinetic Profile of Dimethoxycurcumin in Mice Sera taken at 
Different Time Points measured using LC-MS/MS. The peak of the profile 
showed Cmax, maximum concentration of Dimethoxycurcumin after 




The absorption half-life, k01_t ½ is the rate that the drug enters the systemic 
circulation after i.p. injection was estimated to be 0.19 hrs. Distribution half-life, 
α_ t ½ was estimated to be 0.24 hrs which indicated how rapidly the drug can be 
distributed in the tissues. This explained why there was a steep reduction in drug 
concentration in serum. Besides, the elimination rate constant, β was estimated to 
be 0.13 hr-1 and the elimination half-life, β_t 1/2 was 5.45 hrs. This is about 13 
times larger than the elimination half-life reported for curcumin which is 0.4 hrs 
(Saradhi et al., 2010). Therefore, dimethoxycurcumin could have higher 
bioavailability in vivo than curcumin which would require further investigation.  
 
5.3.4 Distribution of Dimethoxycurcumin in Mice Organs at 8 and 24 hrs 
after Single Dose Injection  
High concentrations of dimethoxycurcumin were found in the prostate and liver 
after 8 hrs after a single injection. This goes in accordance to the pharmacokinetic 
results, where dimethoxycurcumin in serum decreased rapidly but was actually 
rapidly distributed in the organs as indicated by the short distribution half-life, α_ 
t ½. Notably, minimal or negligible dimethoxycurcumin was left in most of the 
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Dimethoxycurcumin seemed more likely to accumulate in the liver, testes and 
prostate. Nevertheless, further investigations have to be conducted to see whether 
the accumulation of this drug in these organs from prolonged treatment could 
have beneficial or detrimental effects as there is no toxicology information of this 









5.4 Summary of Results  
A simple, fast, robust and more sensitive LC-MS/MS method has been developed 
and validated to accurately quantify the dimethoxycurcumin in mouse serum and 
tissue samples. This method was applied to study the pharmacokinetics of 
dimethoxycurcumin in mouse serum and the distribution of the drug in various 
mice organs. This drug can be quickly absorbed in vivo and had a relatively slow 
elimination half-life of 5.45 hrs when compared to curcumin. The 
dimethoxycurcumin has a higher likelihood to accumulate in liver, testes and 
prostate. However, more work has to be done to explore the potential of this 






Conclusions and Limitations & Future Works 
6.1 Conclusions  
A series of sensitive LC-MS/MS methods were successfully developed to 
determine trace amounts of sex hormone receptor active compounds in this study. 
Firstly, a highly selective LC-MS/MS method was developed for the first time to 
simultaneously detect and quantify the six androgens, including the pair of 
metabolites from DHT, 3α- and 3β-Diols. The two diols are epimers of each 
other, which increased the difficulty for accurate detection and quantitation. With 
the LC-MS/MS method, it enabled the study of the effects of dimethoxycurcumin 
on the AKR1C family of enzymes in the CRPC cells.  
Another convenient LC-MS/MS method was developed for the detection and 
quantitation of dimethoxycurcumin that enabled the study of its pharmacokinetic 
and distribution profile in vivo. This new method was of better sensitivity as 
compared to an existing reported method.  
These newly developed LC-MS/MS methods enabled the analysis of the 
intracellular levels of androgens and estrogens in the prostate cells. The PCa cells 
from the same lineage, regardless of androgen sensitive, LNCap or CRPC cells, 
C4-2 and C4-2B shared similar mechanisms where they displayed enhanced 




they can take in the androgens more readily from the external sources even when 
cultured under CD-FBS supplemented media only. 
On the other hand, CWR22Rv1 showed a different behavior to the rest of the 
CRPC cells studied here. Cell extracts from CWR22Rv1 can induce faster 
proliferation than other PCa cells. Furthermore, from the combined data of LC-
MS/MS and AR-transfected HeLa luciferase assay, CWR22Rv1 was able to 
sustain approximately similar levels of the potent androgens with or without 
excess DHT added to culture media. This indicated that CWR22Rv1 depended on 
intracrine synthesis of potent androgens. 
Further studies conducted among the PCa cell lines studied here, showed that 
CRPC cells such as C4-2 and C4-2B did not express AKR1C3 enzyme whereas 
only CWR22Rv1 endogenously expressed high levels of this enzyme. This further 
affirms the earlier observations of this cell line’s innate ability to synthesise the 
potent androgens which explains its exceptional resilience to survive and 
proliferate even after ablation. Concurrent study on the inhibition of AKR1C1 
was not possible due to possible further suppression of the inherently minimal 
intracellular levels of 3β-Diol in prostate with the drugs. IC50 values of 
dimethoxycurcumin inhibitory effect on AKR1C3 and AKR1C2 were calculated 
when measurements of intracellular T and 3α-Diol were taken simultaneously 
using LC-MS/MS. IC50 of AKR1C3 for dimethoxycurcumin was estimated, to be 
22.33 µM and the saturating dose for AKR1C3 was found to be 50 µM. However, 




only started to show inhibitory effect on AKR1C2 enzyme at doses above 10 µM. 
From the inhibitory part of the curve, IC50 of AKR1C2 for dimethoxycurcumin 
was estimated to be 48.2 µM. This IC50 of AKR1C2 for the drug was about 2.16-
fold higher as compared to its IC50 of AKR1C3, which implied a slightly greater 
selectivity of inhibition by dimethoxycurcumin on AKR1C3 over AKR1C2.  
Upon treatment of saturating dose of dimethoxycurcumin, there was a significant 
reduction in the intracellular T levels (p-values < 0.05), which indicated this 
drug’s efficacy on inhibition of AKR1C3. Apart from this, it was found that with 
treatment of the saturating dose of dimethoxycurcumin produced negligible 
intracellular 3α-Diol and relatively high levels of 3β-Diol. By convention, it 
seemed undesirable that lesser 3α-Diol was produced after treatment with 
saturating dose of dimethoxycurcumin as it may imply that DHT was not 
effectively deactivated. However, from the results obtained here, this consequence 
after treatment is acceptable as DHT levels became negligible and was 
preferentially deactivated and converted to its other metabolite, 3β-Diol instead. 
Furthermore, recent studies have shown that 3α-Diol upon sufficient 
accumulation may potentially be able to activate AR even though it was 
considered as a weak androgenic ligand previously. With lesser 3α-Diol, it also 
reduces the likelihood of “backdoor” pathway occurring, where it can be 
converted back into its precursor, DHT.  
On the other hand, 3β-Diol which was preferentially formed after treated with 




receptors. Since it can selectively activate ERβ, which upon its activation is 
normally associated with desirable effects such as anti-invasive and anti-
proliferation on PCa and ER-related cancers or diseases. This will in turn be an 
added bonus towards a better treatment for CRPC condition.  
A separate in vivo study on the pharmacokinetics and distribution of 
dimethoxycurcumin was conducted. Dimethoxycurcumin was able to be quickly 
absorbed in vivo with a slow elimination half-life of 5.45 hrs as compared to 
curcumin. Dimethoxycurcumin also has higher tendency to accumulate in liver, 
testes and prostate.  
Though based on the studies conducted thus far, it seemed to indicate that 
dimethoxycurcumin shows promises as a potential dual mechanistic drug, where 
it not only has been reported to be an AR degradation enhancer but also seemed to 
be also exhibiting AKR1C3 inhibition effects too. However, further studies must 























 C4-2 and C4-2B deduced to have overexpressd ARs and enhanced sensitivity of 
ARs. 
 CWR22Rv1 deduced to be able to do intracrine synthesis of potent androgens 
such as T and DHT.  
Chapter 3 
 All PCa might contain promiscuous ARs that enabled them to take in more E2 
from the excess E2 added than the normal and benign hyperplasia prostate cells.  
 
Chapter 4 
 Newly developed and validated LC-MS/MS method to simultaneously quantify 
six key androgens involved in the steroidogenesis path.  
 CWR22Rv1 verified to endogenously express high levels of AKR1C3. 
 Devised LC-MS/MS to simultaneously measure intracellular T and 3α-Diol to 
obtain dose-response curves for study of the inhibition ability of 
dimethoxycurcumin on AKR1C3 and AKR1C2 respectively. 
 For dimethoxycurcumin, IC50 of proliferation of AKR1C3-positive cells ≈ IC50 of 
AKR1C3. So, it could imply that this drug function mainly through inhibiting 
AKR1C3, which can in turn enhance the degradation of AR through prolonged 
shortage of androgens for activation. 
 IC50 of AKR1C3 with dimethoxycurcumin = 22.3 µM and IC50 of AKR1C2 with 
dimethoxycurcumin = 48.6 µM, so dimethoxycurcumin has slightly greater 
selectivity of inhibition of AKR1C3 over AKR1C2. 
 Upon application of saturating doses of dimethoxycurcumin, significant reduction 
of intracellular T and DHT becomes negligible.  
 Consequently, 3α-Diol becomes negligible too and 3β-Diol was preferentially 
formed instead. 
 3β-Diol, a selective ERβ agonist, is often associated with beneficial effects such 




 New LC-MS/MS method of quantification for dimethoxycurcumin was 
developed and validated. 
 Dimethoxycurcumin was able to be quickly absorbed in vivo with a slow 
elimination half-life of 5.45 hrs as compared to curcumin.  





6.2 Limitations & Future Works 
There are several other areas that can be further explored for this current study. 
However, due to time contraints and other limitations, these areas could not be 
explored during the course of my program. Firstly, it would be better to quantify 
the intratumoural androgens and estrogen from matched human prostate tissue 
samples such as the benign, primary PCa and CRPC prostate tissue samples. This 
would enable a comparison between the intracellular levels of androgens and 
estrogens detected in the in vitro experiments with the human prostate tissues 
samples and determined if there is correlation between them for a more reliable 
deduction of the plausible mechanisms behind CRPC conditions. However, this 
could be a daunting task as based on information obtained from local urologists 
and histo-pathologists, it is very challenging to obtain PCa tissues of high 
homogeneity of the cancerous cells. Special surgical techniques have to be used to 
select the cancerous sections for dissection as otherwise the measurements would 
be highly unreliable. In addition, surgical treatment is not part of the standard care 
for patients in Singapore who are already at the CRPC stage. Hence, it is 
extremely challenging to obtain CRPC tissue samples for the study due to the 
ethical issues involved.  
PCa tumour is heterogeneous and contains different types of PCa cells of varying 
nature. From the current results of this study, these cancerous cells, especially the 
androgen insensitive or CRPC type used different mechanisms for sustainability, 




will be good if this study could be further extended to test on a wider variety of 
CRPC cells with at least a couple more CRPC cell lines that endogenously 
expressed the AKR1C3 enzyme. This will enable us to compare if these cells 
shared similar characteristics as CWR22Rv1 for intracrine synthesis of potent 
androgens. Furthermore, more of these AKR1C3-positive CRPC cells types can 
be used for testing the therapeutic properties of dimethoxycurcumin as an 
AKR1C3 inhibitor on CRPC conditions.  
Besides the current methods used in this study to compare the AKR1C3 inhibition 
effects of dimethoxycurcumin to indomethacin, methods such as X-ray 
crystallography can also be explored so as to further ascertain that 
dimethoxycurcumin can bind to AKR1C3 enzyme to act as its inhibitor. The 
dimethoxycurcumin-AKR1C3 structure can be obtained and study the interactions 
of this drug with the AKR1C3 enzyme. These data will be useful in making 
informed structural modifications to dimethoxycurcumin, so as to enable 
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 Descriptions of Various Stages of Prostate Cancers ("Prostate cancer," 
2012; Compton et al., 2012) 




(“National Cancer Institute: Prostate Cancer 
Treatment (PDQ®) Stages of Prostate Cancer”, 
2014) 
 Tumour cannot be felt with digital rectal 
exam (DRE) or seen with an imaging test 
such as transrectal ultrasound (TRUS) 
(found during a transurethral resection or 
diagnosed by needle biopsy) [T1].  
 Cancer is localised within the prostate. 
Has not spread to nearby lymph nodes 
[N0] or elsewhere in the body [M0].  
 Gleason score is less than or equal to 6 
and the PSA is less than 10. 
OR 
 Tumor can be felt during DRE or seen 
with imaging such as TRUS and is in one 
half or less of only one side (left or right) 
of prostate [T2a].  
 Cancer is localised within the prostate 
and has not spread to nearby lymph nodes 
[N0] or elsewhere in the body [M0].  
 Gleason score is less than or equal to 6 




(“National Cancer Institute: Prostate Cancer 
Treatment (PDQ®) Stages of Prostate Cancer”, 
2014) 
 Tumor cannot be felt or seen with 
imaging such as TRUS [T1].  
 Cancer has not spread to nearby lymph 
nodes [N0] or elsewhere in the body 
[M0].  
 Gleason score of 7 and PSA is less than 
20 or Gleason score of less than or equal 
to 6 and PSA is from 10 to 20. 
OR 
 Tumor can be felt by DRE or seen with 
TRUS and is in only one side of the 
prostate [T2a or T2b].  
 Cancer has not spread to nearby lymph 
nodes [N0] or elsewhere in the body 
[M0].  
 Gleason score of less than or equal to 7 







(“National Cancer Institute: Prostate Cancer 
Treatment (PDQ®) Stages of Prostate Cancer”, 
2014) 
 Tumor can be felt by DRE or seen with 
imaging such as TRUS and is in both 
sides of the prostate [T2c].  
 Cancer has not spread to nearby lymph 
nodes [N0] or elsewhere in the body 
[M0].  
 Any Gleason score and any PSA value. 
OR 
 Cancer has not spread to outside the 
prostate. It may (or may not) be felt by 
DRE or seen with imaging such as TRUS 
[T1 or T2].  
 Cancer has not spread to nearby lymph 
nodes [N0] or elsewhere in the body 
[M0].  
 Any Gleason score and PSA level is at 
least 20 or Gleason score is 8 or higher 




(“National Cancer Institute: Prostate Cancer 














 Cancer has spread to outside the prostate 
and may have spread to the seminal 
vesicles [T3]. 
 Has not spread to nearby lymph nodes 
[N0] or elsewhere in the body [M0].  








(“National Cancer Institute: Prostate Cancer 
Treatment (PDQ®) Stages of Prostate Cancer”, 
2014) 
 Cancer has spread to tissues next to the 
prostate such as the urethral sphincter 
(muscle that helps control urination), 
rectum, bladder, and/or the wall of the 
pelvis [T4].  
 Cancer has not spread to nearby lymph 
nodes [N0] or elsewhere in the body 
[M0].  
 Any Gleason score and the PSA can be 
any value. 
OR  
 Tumor may or may not be growing into 
tissues near the prostate [any T].  
 Cancer has spread to nearby lymph nodes 
(N1) but has not spread elsewhere in the 
body [M0].  
 Any Gleason score and the PSA can be 
any value. 
OR 
 Cancer may or may not be growing into 
tissues near the prostate [any T] and may 
or may not have spread to nearby lymph 
nodes [any N].  
 Has spread to other, more distant sites in 
the body [M1].  









Summary Table for Treatments Available for Different Stages of Prostate 
Cancers  ("Prostate cancer," 2012) 
Stage Description of 
Stage of Cancer 
Suitable Treatments 
Available 
Possible Side effects 
I:  Tumour cannot be 
felt with DRE or 
seen with an 
imaging test such as 
TRUS [T1] and 
gleason score is less 
than or equal to 6 
and the PSA is less 
than 10.  
 Or Tumor can be 
felt during DRE or 
seen with TRUS in 
one half or less of 
only one side (left 
or right) of prostate 
[T2a] and gleason 
score is less than or 
equal to 6 and the 
PSA is less than 10. 
 Cancer is localised 
within the prostate. 
Has not spread to 
nearby lymph nodes 
[N0] or elsewhere 




 Surgery (or called 
Radical 
Prostatectomy) 
 Urinary incontinence  
 Impotence or erectile 
dysfunction  
 Loss of fertility  
 Changes in orgasm,  
 Lymphedema (rare)  
 Change in penis length 
 Inguinal hernia. 
 Radiation therapy Associated side effects of 
External beam radiation 
therapy include  
 bowel and bladder 
problems,  
 urinary incontinence  
 impotence  
 fatigue,  
 lymphedema  
 urethral stricture  




 May affect people such as 
partners, pregnant ladies 
and young children 
though radiation may not 
travel far.  
 Bowel and urinary 
problems  




 Blood in urine after 
procedure for 1 or 2 days 
and soreness in area 
where needles are 
inserted.  
 Freezing may also affect 
the bladder and intestines 
which will cause pain and 
burning feeling.  
 Urinary incontinence 





IIA  Tumor cannot be 
felt or seen with 
imaging such as 
TRUS [T1] and 
gleason score of 
less than 7 and PSA 
is from 10 to 20.  
 Tumor can be felt 
by DRE or seen 
with imaging such 
as TRUS and is in 
only one side of the 
prostate [T2a or 
T2b] and gleason 
score of less than or 
equal to 7 and PSA 
is less than 20. 
 Cancer has not 
spread to nearby 
lymph nodes [N0] 
or elsewhere in the 




 Surgery (or called 
Radical 
Prostatectomy) 
 Urinary incontinence  
 Impotence or erectile 
dysfunction  
 Loss of fertility  
 Changes in orgasm,  
 Lymphedema (rare)  
 Change in penis length 
 Inguinal hernia. 
 Radiation therapy Associated side effects of 
External beam radiation 
therapy include  
 bowel and bladder 
problems,  
 urinary incontinence  
 impotence  
 fatigue,  
 lymphedema  
 urethral stricture  
 




 May affect people such as 
partners, pregnant ladies 
and young children 
though radiation may not 
travel far.  
 Bowel and urinary 
problems  
 Erection problems  
 Cryosurgery 
(cryotherapy) 
 Blood in urine after 
procedure for 1 or 2 days 
and soreness in area 
where needles are 
inserted.  
 Freezing may also affect 
the bladder and intestines 
which will cause pain and 
burning feeling.  
 Urinary incontinence 
 Impotence  
IIB  Tumor can be felt 
by DRE or seen 
with imaging such 
as TRUS and is in 
both sides of the 




 Surgery (or called 
Radical 
Prostatectomy) 
 Urinary incontinence  
 Impotence or erectile 
dysfunction  




any gleason score 
and any PSA value. 
 Or cancer has not 
yet begun to spread 
outside the prostate. 
It may (or may not) 
be felt by DRE or 
seen with imaging 
such as TRUS [T1 
or T2] and any 
gleason score and 
PSA level is at least 
20 or gleason score 
is 8 or higher and 
PSA can be any 
value. 
 Cancer has not 
spread to nearby 
lymph nodes [N0] 
or elsewhere in the 
body [M0].  
 Changes in orgasm,  
 Lymphedema (rare)  
 Change in penis length 
 Inguinal hernia. 
 Radiation therapy Associated side effects of 
External beam radiation 
therapy include  
 bowel and bladder 
problems,  
 urinary incontinence  
 impotence  
 fatigue,  
 lymphedema  
 urethral stricture  
 




 May affect people such as 
partners, pregnant ladies 
and young children 
though radiation may not 
travel far.  
 Bowel and urinary 
problems  
 Erection problems  
 Cryosurgery 
(cryotherapy) 
 Blood in urine after 
procedure for 1 or 2 days 
and soreness in area 
where needles are 
inserted.  
 Freezing may also affect 
the bladder and intestines 
which will cause pain and 
burning feeling.  
 Urinary incontinence 
 Impotence  
III  Cancer has begun to 
spread outside the 
prostate and may 
have spread to the 
seminal vesicles 
[T3]. 
 Has not spread to 
nearby lymph nodes 
[N0] or elsewhere 
in the body [M0].  
 Any Gleason score 
and the PSA can be 
any value. 
 Hormone therapy The side effects are for 
orchiectomy, LHRH agonists 
and antagonists, are similar 
due to changes in the 
hormone levels. These 
include 
 decrease or no sexual 
libido 
 Impotence 
 Hot flashes, which might 
get better 
 Breast tenderness and 




 Osteoporosis which can 
lead to fragility of bones 
 Anemia 
 Reduction in mental 
sharpness 
 Loss of muscle mass 
 Gain in weight 
 Fatigue 
 Increased in Cholesterol 
levels 
 Depression 
 increase in risk of getting 
hypertension, diabetes, 
strokes, heart attacks and 
even death from 
cardiovascular diseases. 
 Chemotherapy  Hair loss 
 Mouth sores 
 Loss of appetite 
 Nausea and vomiting 
 Diarrhea 
 Lowered resistance to 
infections (due to lower 
white blood cell counts) 
 Easy bruising or bleeding 
(due to lower blood 
platelets) 
 Fatigue (due to lower red 
blood cell counts) 
 Immunotherapy 
 
 Fever, chills, fatigue, 
back and joint pain, 
nausea and headache 
which normally lasts for a 
couple of days after 
infusions.  
 More severe symptoms 
includes breathing and 
high blood pressure 
which will improve after 
treatment. 
IV  Cancer has spread 
to tissues next to 
the prostate, other 
than the seminal 
vesicles [T4] and 
any gleason score 
and the PSA can be 
any value.  
 Or Tumor may or 
may not be growing 
into tissues near the 
prostate [any T] but 
 Hormone therapy The side effects are for 
orchiectomy, LHRH agonists 
and antagonists, are similar 
due to changes in the 
hormone levels. These 
include 
 decrease or no sexual 
libido 
 Impotence 
 Hot flashes, which might 
get better 




has spread to 
nearby lymph nodes 
(N1) and any 
gleason score and 
the PSA can be any 
value. 
 Or Cancer may or 
may not be growing 
into tissues near the 
prostate [any T] and 
may or may not 
have spread to 
nearby lymph nodes 
[any N] but has 
spread to other, 
more distant sites in 
the body [M1] and 
any Gleason score 
and the PSA can be 
any value. 
growth of breast tissue 
 Osteoporosis which can 
lead to fragility of bones 
 Anemia 
 Reduction in mental 
sharpness 
 Loss of muscle mass 
 Gain in weight 
 Fatigue 
 Increased in Cholesterol 
levels 
 Depression 
 increase in risk of getting 
hypertension, diabetes, 
strokes, heart attacks and 
even death from 
cardiovascular diseases. 
 Chemotherapy  Hair loss 
 Mouth sores 
 Loss of appetite 
 Nausea and vomiting 
 Diarrhea 
 Lowered resistance to 
infections (due to lower 
white blood cell counts) 
 Easy bruising or bleeding 
(due to lower blood 
platelets) 
 Fatigue (due to lower red 
blood cell counts) 
 Immunotherapy 
 
 Fever, chills, fatigue, 
back and joint pain, 
nausea and headache 
which normally lasts for a 
couple of days after 
infusions.  
 More severe symptoms 
include breathing and 
high blood pressure 








Chromatograms of Blank matrices detecting A4, T and DHT in 



































Partial Validation Data for Detection of A4, T and DHT in  
(a) RPMI-1640 media matrix 
 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.202 0.175 0.183 0.187 0.014 7.5 93.3 
2 1.958 1.884 1.768 1.870 0.096 5.1 93.5 
10 9.982 9.269 9.539 9.597 0.360 3.8 96.0 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.191 0.186 0.171 0.194 0.193 0.201 0.189 0.010 5.5 94.7 
2 1.760 1.724 1.820 1.889 1.869 1.760 1.804 0.066 3.7 90.2 








Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.201 0.200 0.198 0.200 0.002 0.8 99.8 
2 2.008 2.077 1.707 1.931 0.197 10.2 96.5 
10 9.999 9.784 9.683 9.822 0.161 1.6 98.2 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.200 0.193 0.202 0.187 0.186 0.201 0.195 0.007 3.8 97.3 
2 1.692 1.675 1.756 1.854 1.826 1.834 1.772 0.077 4.3 88.6 









Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 2.082 2.162 2.181 2.142 0.052 2.4 107.1 
2 19.786 22.327 23.373 21.828 1.845 8.5 109.1 
10 102.896 107.389 115.961 108.749 6.638 6.1 108.7 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 2.000 2.245 2.297 2.337 2.247 2.300 2.238 0.122 5.4 111.9 
2 22.899 23.686 23.533 22.944 23.750 23.749 23.427 0.400 1.7 117.1 
10 116.606 114.537 116.740 108.221 110.418 112.039 113.094 3.456 3.1 113.1 
 
 
(b) DMEM media matrix 
 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.177 0.189 0.176 0.181 0.007 4.1 90.3 
2 1.946 1.793 1.906 1.882 0.079 4.2 94.1 
10 10.609 8.555 9.422 9.529 1.031 10.8 95.3 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.195 0.169 0.165 0.202 0.160 0.187 0.179 0.017 9.7 89.7 
2 1.811 2.161 1.746 1.766 1.676 1.934 1.849 0.175 9.5 92.5 










Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.193 0.209 0.178 0.193 0.016 8.1 96.6 
2 2.145 1.838 1.950 1.977 0.155 7.9 98.9 
10 11.204 8.915 9.616 9.912 1.173 11.8 99.1 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.189 0.177 0.167 0.199 0.170 0.200 0.184 0.014 7.8 91.8 
2 1.794 2.192 1.864 1.652 1.702 1.963 1.861 0.197 10.6 93.1 








Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 2.096 2.146 2.139 2.127 0.027 1.3 106.3 
2 22.189 20.399 22.694 21.761 1.206 5.5 108.8 
10 113.184 97.288 108.367 106.280 8.151 7.7 106.3 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 2.168 2.165 2.084 2.285 2.258 2.128 2.181 0.077 3.5 109.1 
2 22.963 23.182 21.938 20.543 17.294 21.907 21.305 2.177 10.2 106.5 






(c) KSFM media matrix 
 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.2 0.183 0.191 0.186 0.186 0.004 2.1 
2 2 1.702 2.104 1.910 1.905 0.201 10.6 
10 10 9.152 9.991 9.525 9.556 0.420 4.4 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.195 0.195 0.167 0.166 0.168 0.191 0.186 0.014 7.8 90.2 
2 1.760 1.908 2.062 1.730 2.071 1.973 1.910 0.147 7.7 95.9 








Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 0.210 0.202 0.192 0.201 0.009 4.5 100.7 
2 1.867 2.121 1.793 1.927 0.172 8.9 96.4 
10 9.649 10.520 9.919 10.030 0.446 4.4 100.3 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 0.191 0.203 0.182 0.180 0.176 0.197 0.188 0.011 5.6 94.1 
2 1.651 1.931 1.799 1.707 1.740 1.719 1.758 0.097 5.5 87.9 










Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.2 2.152 2.266 2.285 2.234 0.072 3.2 111.7 
2 19.245 21.783 22.669 21.232 1.777 8.4 106.2 
10 100.233 112.313 110.252 107.599 6.462 6.0 107.6 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.2 2.297 2.286 2.273 2.070 2.256 2.273 2.242 0.086 3.8 112.1 
2 22.279 23.049 22.678 21.015 20.024 21.730 21.796 1.126 5.2 109.0 









Table showing the Intracellular Androgens Ratios 
Cell Line 
  
Type of Cell 
Line 
  
Average Ratio btw 2 passages 










+ 1 nM 
DHT 































































































































































 Basal Concentrations of the Respective Androgens of Interest in 
Media  
Types of Media 
Used for Cell 
Lines 










































































Type of Cell 
Line 




  (1) 
10 % FBS 
(2) 
10 % FBS + 1 nM 
DHT 
(3) 
10 % CD-FBS 
(4)  
10 % CD-FBS + 1 
nM DHT 
RWPE-1 


















































































































































































































Chromatograms of Blank matrices detecting E1 and E2 in 
(e) PBS/BSA Blank Matrix 
 
 






















Partial Validation Data for Detection of E1 and E2 in  
(a) RPMI-1640 media matrix 
 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.049 0.048 0.053 0.050 0.003 5.1 100.0 
0.2 0.465 0.428 0.463 0.452 0.021 4.6 90.4 
5 4.990 4.847 4.708 4.848 0.141 2.9 97.0 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.052 0.055 0.052 0.053 0.060 0.053 0.054 0.003 5.7 108.0 
0.2 0.488 0.430 0.472 0.523 0.458 0.449 0.470 0.033 7.0 94.0 








Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.052 0.051 0.046 0.049 0.003 6.5 98.5 
0.2 0.504 0.458 0.440 0.467 0.033 7.1 93.5 
5 5.120 4.933 4.573 4.875 0.278 5.7 97.5 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.041 0.052 0.044 0.054 0.049 0.052 0.049 0.005 10.5 97.0 
0.2 0.442 0.452 0.425 0.464 0.475 0.457 0.453 0.018 3.9 90.6 





(b) DMEM media matrix 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.052 0.044 0.052 0.049 0.005 9.4 98.8 
0.2 0.556 0.471 0.522 0.516 0.042 8.2 103.3 
5 5.552 5.200 4.536 5.096 0.516 10.1 101.9 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.050 0.046 0.060 0.056 0.048 0.055 0.052 0.005 10.0 104.8 
0.2 0.474 0.554 0.540 0.428 0.432 0.545 0.495 0.058 11.7 99.1 








Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.056 0.049 0.053 0.053 0.004 7.5 105.5 
0.2 0.513 0.520 0.494 0.509 0.013 2.6 101.8 
5 5.685 5.210 5.070 5.322 0.322 6.1 106.4 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.052 0.051 0.056 0.046 0.055 0.050 0.052 0.004 7.4 103.6 
0.2 0.501 0.491 0.490 0.452 0.469 0.487 0.482 0.018 3.7 96.3 








(c) KSFM media matrix 




Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.047 0.050 0.048 0.048 0.002 3.8 96.7 
0.2 0.540 0.532 0.507 0.526 0.017 3.3 105.3 
5 5.394 5.122 5.603 5.373 0.241 4.5 107.5 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.043 0.053 0.046 0.050 0.042 0.054 0.048 0.005 10.7 96.6 
0.2 0.521 0.539 0.461 0.543 0.555 0.573 0.532 0.039 7.4 106.4 








Estimated Interday Concentration (nM)                         Interday Validation Summary 
Day 1 Day 2 Day 3 Mean Conc. 
(nM) 
Stdev CV % Accuracy % 
0.05 0.048 0.050 0.045 0.048 0.003 5.3 95.6 
0.2 0.561 0.554 0.503 0.539 0.031 5.8 107.8 
5 5.398 5.345 5.220 5.321 0.091 1.7 106.4 




Estimated Intraday Concentration (nM)                    Intraday Validation Summary 
1st Run 2nd Run 3rd Run 4th Run 5th Run 6th Run Mean 
Conc. 
(nM) 
Stdev CV % Accuracy 
% 
0.05 0.047 0.048 0.040 0.044 0.042 0.047 0.045 0.003 6.9 89.2 
0.2 0.556 0.548 0.405 0.546 0.540 0.546 0.524 0.058 11.1 104.7 









Table showing the Intracellular Estrogens Ratios 
Cell Line 
  
Type of Cell 
Line 
  
Average Ratio btw 2 passages 










+ 10 nM 
E2* 









































































































































Basal Concentrations of the Respective Estrogens of 
Interest in Media  
Types of Media 
Used for Cell 
Lines 
Av. Basal Conc. Of Estrogens in 














































Type of Cell 
Line 




  (1) 
10 % FBS 
(2) 
10 % FBS + 1 nM 
DHT 
(3) 
10 % CD-FBS 
(4)  
10 % CD-FBS + 1 
nM DHT 
RWPE-1 



























































































































































Solutions for Tris/Glycine SDS-Polyacrylamide Gel Electrophoresis 
6% 5 mL 10 mL 15 mL 20 mL 25 mL 30 mL 40 mL 50 mL 
H2O 2.7 5.3 8 10.6 13.2 15.9 21.1 26.5 
30% Acrylamide Mixa 1 2 3 4 5 6 8 10 
1.5 M Tris (pH 8.8)b 1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% SDSc 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
TEMEDd 0.004 0.008 0.012 0.016 0.02 0.024 0.032 0.04 
8% 5 mL 10 mL 15 mL 20 mL 25 mL 30 mL 40 mL 50 mL 
H2O 2.3 4.6 7 9.3 11.6 13.9 18.6 23.2 
30% Acrylamide Mixa 1.3 2.7 4 5.3 6.7 8 10.7 13.4 
1.5 M Tris (pH 8.8)b 1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% SDSc 0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
TEMEDd 0.003 0.006 0.009 0.012 0.015 0.018 0.024 0.03 
10% 5 mL 10 mL 15 mL 20 mL 25 mL 30 mL 40 mL 50 mL 
H2O 2 4 5.9 7.9 9.9 11.9 15.8 20 
30% Acrylamide Mixa 1.7 3.3 5 6.7 8.3 10 13.3 16.6 
1.5 M Tris (pH 8.8)b 1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% SDSc 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
TEMEDd 0.002 0.004 0.006 0.008 0.01 0.012 0.016 0.02 
12% 5 mL 10 mL 15 mL 20 mL 25 mL 30 mL 40 mL 50 mL 
H2O 1.7 3.3 5 6.6 8.3 9.9 13.2 16.4 
30% Acrylamide Mixa 2 4 6 8 10 12 14 20 
1.5 M Tris (pH 8.8)b 1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% SDSc 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
TEMEDd 0.002 0.004 0.006 0.008 0.01 0.012 0.016 0.02 
15% 5 mL 10 mL 15 mL 20 mL 25 mL 30 mL 40 mL 50 mL 
H2O 1.2 2.3 3.5 4.6 5.7 6.9 9.2 11.4 
30% Acrylamide Mixa 2.5 5 7.5 10 12.5 15 20 25 
1.5 M Tris (pH 8.8)b 1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% SDSc 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 0.005 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
TEMEDd 0.002 0.004 0.006 0.008 0.01 0.012 0.016 0.02 
STACK 5% 5 mL 10 mL 15 mL 20 mL 25 mL 30 mL 40 mL 50 mL 
H2O 0.68 1.4 2.1 2.7 3.4 4.1 5.5 6.8 
30% Acrylamide Mixa 0.17 0.33 0.5 0.67 0.83 1 1.3 1.7 
1.0 M Tris (pH 6.8)b 0.13 0.25 0.38 0.5 0.63 0.75 1 1.25 
10% SDSc 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 
10% APS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1 






Formulation for 4x SDS Loading buffer 
For 10 ml of loading buffer: 
 4 ml 100% glycerol 
 2.4 ml 1M Tris/HCl pH 6.8 
 0.8 g SDS 
 4 mg bromophenol blue 
 0.5 ml beta-mercaptoethanol 






Chromatograms of Blank matrices detecting DHEA, A4, T, DHT, 3α-Diol 
and 3β-Diol in 
(d) PBS/BSA Blank Matrix 
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